Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2018/001948
Kind Code:
A1
Abstract:
The present invention relates to compounds of formula (I): (I) or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Inventors:
CUMMING JOHN G (CH)
LIN XIANFENG (CN)
LIU HAIXIA (CN)
NAJERA ISABEL (CH)
QIU ZONGXING (CN)
SANDRIN VIRGINIE (CH)
TANG GUOZHI (CN)
WU GUOLONG (CN)
Application Number:
PCT/EP2017/065682
Publication Date:
January 04, 2018
Filing Date:
June 26, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HOFFMANN LA ROCHE (US)
HOFFMANN LA ROCHE (US)
International Classes:
C07D401/14; A61K31/502; A61P31/16; C07D401/12; C07D403/12; C07D405/12; C07D471/04; C07D491/052
Domestic Patent References:
WO2010077947A12010-07-08
WO2011000566A22011-01-06
Foreign References:
US20140038990A12014-02-06
US201161550045P2011-10-21
US201261650713P2012-05-23
US201261650725P2012-05-23
US201261679968P2012-08-06
US201161550057P2011-10-21
Other References:
MAGDEN J. ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 66, 2005, pages 612 - 621
ERIKSSON, B. ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 11, 1977, pages 946 - 951
FURUTA ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 49, no. 3, 2005, pages 981 - 986
NUKIWA ET AL., CLIN INFECT DIS, vol. 51, no. 6, 2010, pages 725 - 731
CHAN ET AL., J INFECT DIS, vol. 206, 2012, pages 1359 - 1366
HU ET AL., LANCET, vol. 381, 2013, pages 2271 - 2277
S. P. PARKER: "McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY
ELIEL, E.; WILEN, S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC.
CAHN ET AL., ANGEW. CHEM. INTER. EDIT., vol. 5, 1966, pages 385
A. D. MCNAUGHT & A. WILKINSON: "IUPAC - Compendium of Chemical Terminology, 2nd ed.", 1997, BLACKWELL SCIENTIFIC PUBLICATIONS
BIOCHEM. PHARMACOL., vol. 22, 1973, pages 3099
ANSEL H.C. ET AL.: "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, LIPPINCOTT, WILLIAMS & WILKINS
GENNARO A.R. ET AL.: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS
ROWE R.C: "Handbook of Pharmaceutical Excipients", 2005, PHARMACEUTICAL PRESS
CHANG ET AL., ANTIVIRAL RESEARCH, vol. 89, 2011, pages 26 - 34
TRAN V. ET AL., J. VIROL, vol. 87, no. 24, 2013, pages 13321 - 13329
Attorney, Agent or Firm:
HALBIG, Dirk (CH)
Download PDF:
Claims:
A compound of formula (I)

wherein

X 1S-CH2-CH2-CH2-, -CH=CH-CH=CH-, -CH2-CH2-CH2-CH2-,

-CH2-O-CH2-CH2-, CH2-CH2-O-CH2-, -CH2-NR2-CH2-CH2-, or -CH2-CH2-NR2- CH2-; n is 0, 1 or 2; each R1 is independently selected from halo, Ci_7 alkyl, C2-7 alkenyl, hydroxy, Ci_7 alkoxy, NR10Rn, and CONR10Rn;

wherein Ci_7 alkyl and Ci_7 alkoxy are optionally substituted by one or more Ci_7 alkyl, hydroxy, Ci_7 alkoxy, NR10Rn or COR9;

with the proviso that if X is -CH=CH-CH=CH- then an optional R1 in position 8 of the phthalazin-l-onyl is fluoro;

R2 is H, Ci_7 alkyl, hydroxy-Ci_7 alkyl, COR9, CONR10Rn, or S02-Ci_7 alkyl;

Y1 is N, CH or CCH3,

Y2 is N or CR3;

with the proviso that not both of Y1 and Y2 are N;

R3 is H, halogen, Ci_7 alkyl, halo-Ci_7 alkyl, CONR10Rn or CO-Ci_7 alkoxy;

R4 is H or Ci_7 alkyl, wherein Ci_7 alkyl is optionally substituted with one or more R5; each R5 is independently selected from hydroxy, Ci_7 alkoxy, NR12R13, COR9,

CONR10Rn, S02-Ci_7 alkyl, SO2-NR10Rn, heterocycloalkyl and heteroaryl; wherein Ci_7 alkoxy is optionally substituted by COR9 or CONR10Rn ;

wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from halo, Ci_7 alkyl, halo-Ci_7 alkyl, hydroxy, Ci_7 alkoxy, oxo, COR9, Ci_7 alkyl-COR9 or NR10Rn;

Z1 is N, CH or CO-CH3;

Z2 is N or CH;

R6 is Ci_7 alkyl, hydroxy-Ci_7 alkyl, halo-Ci_7 alkyl, Ci_7 alkoxy-Ci_7 alkyl, Ci_7

alkoxy, halo-Ci_7 alkoxy, Ci_7 alkoxy-Ci_7 alkoxy, S-halo-Ci_7 alkyl, SF5, C3_7 cycloalkyl, heterocycloalkyl or heterocycloalkyl substituted by Ci_7 alkyl;

R7 is H, halogen or Ci_7 alkyl;

R8 is H, halogen or Ci_7 alkyl;

R9 is H, Ci_7 alkyl, hydroxy, or Ci_7 alkoxy;

R10 is H or Ci_7 alkyl;

wherein Ci_7 alkyl is optionally substituted with one or more hydroxy, Ci_7 alkoxy, COOH, or CO-Ci_7 alkoxy;

R11 is H, Ci_7 alkyl, CO-Ci_7 alkoxy or heterocycloalkyl;

wherein Ci_7 alkyl is optionally substituted with one or more hydroxy, Ci_7 alkoxy, NH2, N(Ci_7 alkyl)2, COOH, or CO-Ci_7 alkoxy; or R10 and R11 together with the interconnecting nitrogen form a heterocycloalkyl which is optionally substituted with one ore more halo, Ci_7 alkyl, halo-Ci_7 alkyl, hydroxy, Ci_7 alkoxy, oxo, COOH, CO-Ci_7 alkoxy or NH2;

R12 is H or Ci_7 alkyl;

wherein Ci_7 alkyl is optionally substituted with one or more hydroxy, Ci_7 alkoxy, COOH, or CO-Ci_7 alkoxy;

R13 is H, Ci_7 alkyl, CO-Ci_7 alkoxy or heterocycloalkyl,

wherein Ci_7 alkyl is optionally substituted with one or more hydroxy, Ci_7 alkoxy, NH2, N(Ci_7 alkyl)2, COOH, or CO-Ci_7 alkoxy; or a pharmaceutically acceptable salt thereof. The compound of claim 1 having formula (IA)

wherein Y1, Y2, Z1, Z2, n, R1, R4 and R6 to R8 are as described in claim 1 , or a pharmaceutically acceptable salt thereof.

The compound of claim 1 having formula (IB)

wherein Y1, Y2, Z1, Z2, n, R1, R4 and R6 to R8 are as described in claim 1 , or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 having formula (IC)

wherein Y1, Y2, Z1 , Z2, n, R1, R4 and R6 to R8 are as described in claim 1 , or a pharmaceutically acceptable salt thereof.

The compound of claim 1 having formula (ID)

wherein Y1, Y2, Z1, Z2, n, R1, R4 and R6 to R8 are as described herein, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 having formula (IE)

(IE) wherein Y1, Y2, Z1, Z2, n, R1, R4 and R6 to R8 are as described herein, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 having formula (IF)

wherein Y 1 , R4 and R 6" to R 8° are as described in claim 1 , or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 having formula (IG)

wherein Y 1 , R4 and R 6" to R 8° are as described in claim 1 , or a pharmaceutically acceptable salt thereof.

9. The compound according to any of claims 1 to 8, wherein n is 0 or 1.

10. The compound according to any of claims 1 to 9, wherein each R1 is independently selected from Ci_7 alkyl, hydroxy, Ci_7 alkoxy, and NR10Rn; wherein Ci_7 alkyl is optionally substituted by one hydroxy.

11. The compound according to any of claims 1 to 10, wherein each R1 is independently selected from fluoro, methyl, ethyl, ethenyl, hydroxy, methoxy, ethoxy, NH2 and CONH2; wherein methyl, ethyl, methoxy, and ethoxy are optionally substituted by one methyl, hydroxy, methoxy, NH2 or N(CH3)2.

12. The compound according to any of claims 1 to 11, wherein R2 is COR9.

13. The compound according to any of claims 1 to 12, wherein R2 is H, methyl, ethyl,

isopropyl, propyl, isobutyl, hydroxy-methyl, hydroxy-ethyl, hydroxy-isopropyl, hydroxy- propyl, hydroxy-isobutyl, COH, COCH3, COOCH3, CONHCH3, or S02-CH3.

14. The compound according to any of claims 1 to 13, wherein Y1 is N or CH, with the proviso that not both of Y1 and Y2 are N.

15. The compound according to any of claims 1 to 14, wherein Y2 is CR3.

16. The compound according to any of claims 1 to 15, wherein R3 is H, halogen, or Ci_7 alkyl.

17. The compound according to any of claims 1 to 16, wherein R3 is H, fluoro, chloro, methyl, ethyl, isopropyl, trifiuoromethyl, CONHCH3 or COOCH3.

18. The compound according to any of claims 1 to 17, wherein R4 is H or Ci_7 alkyl, wherein Ci_7 alkyl is optionally substituted with one R5.

19. The compound according to any of claims 1 to 18, wherein R4 is H, methyl, ethyl, propyl or isobutyl, wherein methyl, ethyl, propyl and isobutyl are optionally substituted with one or two R5.

20. The compound according to any of claims 1 to 19, wherein each R5 is independently

selected from hydroxy, Ci_7 alkoxy, NR12R13, COR9, CONR10Rn, S02-Ci_7 alkyl, S02- NR10Rn, heterocycloalkyl and heteroaryl;

wherein Ci_7 alkoxy is optionally substituted by COR9 or CONR10Rn;

wherein heterocycloalkyl and heteroaryl are optionally substituted with one or two substituents selected from halo, Ci_7 alkyl, halo-Ci_7 alkyl, hydroxy, Ci_7 alkoxy, oxo, COR9, Ci_7 alkyl-COR9 and NR10Rn.

21. The compound according to any of claims 1 to 20, wherein each R5 is independently

selected from hydroxy, methoxy, NH2, NHCH3, N(CH3), N(CH2CH3)2, NH(CH2COOH), NH(COO-tert-butyl), N(CH3)(CH2COOH), N(CH2COOH)(COO-tert-butyl),

NH(oxetanyl), COOH, COOCH3, CONH2, CONH(CH3), CONH(CH2CH2N(CH3)2, CONH(CH2CH2OH), CONH(CH2CH2CH2OCH3), CONH(CH(CH3)2), CON(CH3)2, S02- methyl, S02-NH2, azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and imidazolyl; wherein methoxy is optionally substituted by COOH, COOCH2CH3, CONH(CH3), or CON(CH3)2;

wherein azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and imidazolyl are optionally substituted with one or two substituents selected from methyl, trifluoromethyl, hydroxy, methoxy, COOH, COOCH3, and COOCH2CH3.

22. The compound according to any of claims 1 to 21, wherein Z1 is N or CH.

23. The compound according to any of claims 1 to 22, wherein Z2 is CH.

24. The compound according to any of claims 1 to 23, wherein R6 is Ci_7 alkyl, halo-Ci_7 alkyl, or halo-Ci_7 alkoxy.

25. The compound according to any of claims 1 to 24, wherein R6 is tert-butyl, hydroxy- isopropyl, trifluoromethyl, methoxy, ethoxy, methoxy-ethoxy, difluoromethoxy, trifluoromethoxy, cyclopropyl, oxetanyl or methyl-oxetanyl.

26. The compound according to any of claims 1 to 25, wherein R7 is H.

27. The compound according to any of claims 1 to 26, wherein R8 is H, fluoro or methyl.

28. The compound according to any of claims 1 to 27, wherein R9 is H, Ci_7 alkyl or Ci_7

alkoxy.

29. The compound according to any of claims 1 to 28, wherein R9 is H, methyl, hydroxy, methoxy or ethoxy.

30. The compound according to any of claims 1 to 29, wherein R10 is H, Ci_7 alkyl or Ci_7 alkyl substituted with one COOH.

31. The compound according to any of claims 1 to 30, wherein R10 is H, methyl, ethyl or CH2- COOH.

32. The compound according to any of claims 1 to 31, wherein R11 is is H, Ci_7 alkyl, Ci_7 alkyl substituted with one hydroxy, Ci_7 alkyl substituted with one Ci_7 alkoxy, Ci_7 alkyl substituted with one N(CH3)2, Ci_7 alkyl substituted with one COOH, CO-Ci_7 alkoxy or heterocycloalkyl.

33. The compound according to any of claims 1 to 32, wherein R11 is is H, methyl, ethyl,

isopropyl, hydroxy-ethyl, methoxy-propyl, ethyl substituted with one N(CH3)2, CH2- COOH, CO-tert-butoxy or oxetanyl.

34. The compound according to any of claims 1 to 29, wherein R10 and R11 together with the interconnecting nitrogen form azetidinyl, piperazinyl, morpholinyl, imidazolyl or pyrrolidinyl, each optionally substituted with one ore two halo, Ci_7 alkyl, halo-Ci_7 alkyl, hydroxy, Ci_7 alkoxy, oxo, COOH, CO-Ci_7 alkoxy or NH2.

35. The compound according to any of claims 1 to 29, wherein R10 and R11 together with the interconnecting nitrogen form azetidinyl, piperazinyl, morpholinyl, imidazolyl or pyrrolidinyl, each optionally substituted with one ore two methyl, trifluoromethyl, hydroxy, methoxy, COOH, CO-methoxy or CO-ethoxy.

36. The compound according to any of claims 1 to 35, wherein R12 is H, Ci_7 alkyl or alkyl substituted by one COOH.

37. The compound according to any of claims 1 to 36, wherein H, Ci_7 alkyl, Ci_7 alkyl

substituted with one COOH, CO-Ci_7 alkoxy or heterocycloalkyl.

38. The compound according to any of claims 1 to 37, selected from the group consisting of:

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin-l -one; 4-[(2-oxo- 1 H-pyridin-3 -yl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl] acetate;

methyl 2,2-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 - yl]amino]-l-pyridyl]propanoate;

ethyl 2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l -yljamino]- 1- pyridyl] ethoxy] acetate;

methyl (2R)- 1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 -pyridyl] ethyl]pyrrolidine-2-carboxylate;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[2-methyl-4-(trifluoromethoxy )phenyl]phthalazin-

1- one;

2- (6-tert-butyl-3-pyridyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]phthalazin-l -one;

2-(2-tert-butylpyrimidin-5-yl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]phthalazin-l-one; 2-[4-(3-methyloxetan-3-yl)phenyl]-4-[(l-methyl-2-oxo-3-pyridyl)amino]phthalazin-l-one; 4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(oxetan-3-yl)phenyl]phthalazin-l -one;

2-(4-cyclopropylphenyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]phthalazin-l-one;

2-[4-(2-methoxyethoxy)phenyl]-4-[(l-methyl-2-oxo-3-pyridyl)amino]phthalazin-l-one; 2-(4-tert-butylphenyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]phthalazin-l-one;

2-(4-tert-butylphenyl)-4-[(2-oxo- 1 H-pyridin-3-yl)amino]phthalazin- 1 -one;

7- methoxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

8- fluoro-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin- 1-one;

5 -fluoro-4-[( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin-

1- one;

5 -methoxy-4-[( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

2- (4-tert-butylphenyl)-7-ethyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]phthalazin- 1-one; 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-5, 6,7,8- tetrahydrophthalazin- 1 -one;

4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

methyl l-methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -yl] amino]pyridine-3 -carboxylate;

methyl 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin-l- yl]amino]-l-pyridyl]acetate;

4-[ [ 1 - [2-(dimethylamino)ethyl] -6-oxo-pyrimidin-5 -yljamino] -2- [4- (trifluoromethoxy)pheny 1] -5,6,7,8 -tetrahy drophthalazin- 1 -one;

2-(6-tert-butyl-3-pyridyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-5,6,7,8- tetrahydrophthalazin- 1 -one;

2-[4-(difluoromethoxy)phenyl]-4-[(l-methyl-2-oxo-3-pyridyl)amino]-5,6,7,8- tetrahydrophthalazin- 1 -one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(2,6-dimethyl-3-oxo-pyridazin-4-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

1 -[(5 -fluoro- 1 -methyl-2-oxo-3 -pyridyl)amino] -3 - [4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[(l,5-dimethyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(5-chloro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[ [ 1 -methyl-2-oxo-5 -(trifluoromethyl)-3 -pyridyl] amino] -3 -[4-(trifluoromethoxy)phenyl] - 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[(5-ethyl-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

l-[(5-isopropyl-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one; methyl 4-[5-chloro-2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanoate;

methyl 4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanoate;

ethyl 2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]-l -pyridyl]ethoxy]acetate;

1 -[[ 1 -(2-imidazol- 1 -ylethyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

ethyl 4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-l-yl]amino]-l-pyridyl]ethyl]morpholine-2-carboxylate;

1 -[[ 1 -[2-(3-methoxypyrrolidin- 1 -yl)ethyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

2- [tert-butoxycarbonyl-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyljethyljaminojacetic acid;

l-[[l-(3-morpholinopropyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

tert-butyl N-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]-l -pyridyl]ethyl]carbamate;

1 -[[ 1 -[2-(3-hydroxyazetidin- 1 -yl)ethyl]-2-oxo-3-pyridyl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[l-(2-hydroxyethyl)-6-oxo-pyrimidin-5-yl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[3-(4-methylpiperazin- 1 -yl)propyl]-2-oxo-3-pyridyl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[ [ 1 -(3 -hydroxypropyl)-2-oxo-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(dimethylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(diethylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[6-oxo-l-(2-pyrrolidin-l-ylethyl)pyrimidin-5-yl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

3- (4-tert-butyl-2-fluoro-phenyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-[2-fluoro-4-(trifluoromethyl)phenyl]-l-[(l -methyl -2-oxo-3-pyridyl)amino]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

3-(6-ethoxy-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one; 3-(6-methoxy-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

1 -[(5-fluoro- 1 -methyl-2-oxo-3-pyridyl)amino]-3-(6-methoxy-3-pyridyl)-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-(6-tert-butyl-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3- [4-(difluoromethoxy)phenyl]-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7-dih^

cyclopenta[d]pyridazin-4-one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

6,6-dimethyl- 1 -[( 1 -methyl-2-oxo-3 -pyridyl)amino] -3 - [4-(trifluoromethoxy)phenyl] -5 ,7- dihydrocyclopenta[d]pyridazin-4-one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H- pyrano[3,4-d]pyridazin-4-one;

4- [(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy )phenyl]-7, 8-dihydro-5H- pyrano[3,4-d]pyridazin-l -one;

4-[(l,6-dimethyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin-l-one;

4-[(2-methyl-6-oxo-lH-pyrimidin-5-yl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin-

1-one;

4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin-l- one;

4-[(5-ethyl-l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin-l- one;

4-[(6-methyl-2-oxo-lH-pyridin-3-yl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin-l- one;

methyl 3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl]propanoate;

4-[[ 1 -[2-(dimethylamino)ethyl] -2-0X0-3 -pyridyl] amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

4-[[l-(2-methoxyethyl)-2-oxo-3-pyridyl]amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin- 1-one;

4-[[ 1 -(2-methylsulfonylethyl)-2-oxo-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl 4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl]butanoate;

3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl]propane- 1 -sulfonamide;

N,N-dimethyl-3 - [2-0X0-3 -[ [4-0X0-3 -[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino] - 1 -pyridyl]propane- 1 -sulfonamide;

4-[[ 1 -(2-morpholinoethyl)-2-oxo-3-pyridyl]amino]-2-[4-

(trifluoromethoxy)phenyl]phthalazin- 1 -one;

4-[ [ 1 - [2-[3 -hydroxy-3 -(trifluoromethyl)azetidin- 1 -yljethyl] -2-oxo-3 -pyridyl] amino] -2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

4-[ [ 1 - [2-(3 -hydroxypyrrolidin- 1 -yl)ethyl] -2-oxo-3 -pyridyl] amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl (2S)-l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]- 1 -pyridyl] ethyl]pyrrolidine-2-carboxylate;

4-[ [ 1 - [2-(dimethylamino)ethyl] -6-oxo-pyrimidin-5 -yl]amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

6- ethyl-4-[( 1 -methyl-2-oxo-3-pyridyl)amino] -2-[4-(trifluoromethoxy)phenyl]phthalazin- 1 - one;

7- ethyl-4-[( 1 -methyl-2-oxo-3-pyridyl)amino] -2-[4-(trifluoromethoxy)phenyl]phthalazin- 1 - one;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy )phenyl]-6-vinyl -phthalazin- 1-one;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy )phenyl]-7-vinyl -phthalazin- 1-one;

6-acetyl- l-[(l-ethyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-7, 8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl- 1 -[(6-oxo- 1 -propyl -pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-7, 8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl- 1 - [(5-fluoro- 1 -methyl-2-oxo-3 -pyridyl)amino] -3 - [4-(trifluoromethoxy)phenyl] -

7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

4-[[ 1 -(2-morpholino-2-oxo-ethyl)-2-oxo-3-pyridyl]amino]-2-[4-

(trifluoromethoxy)phenyl]phthalazin- 1 -one;

N,N-dimethyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]- 1 -pyridyl] acetamide;

N-isopropyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl] acetamide;

N-methyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl] acetamide;

N-(2-hydroxyethyl)-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl]amino]-l-pyridyl]acetamide;

N-[2-(dimethylamino)ethyl] -2-[2-oxo-3 - [ [4-oxo-3 - [4-

(trifluoromethoxy)phenyl]phthalazin- 1 -yl] amino] - 1 -pyridyl] acetamide;

N-(3 -methoxypropyl)-2- [2-0X0-3 - [ [4-oxo-3 -[4-(trifluoromethoxy)phenyl]phthalazin- 1 - yl]amino]-l-pyridyl]acetamide;

N-methyl-3 -[2-0X0-3 -[ [4-0X0-3 - [4-(trifluorom

pyridyl]propanamide;

N,N-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amm^ 1 -pyridyl]propanamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl]butanamide;

N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amm^ 1 -pyridyl]butanamide;

N,2,2-trimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl]amino]-l-pyridyl]propanamide;

N,N,2,2-tetramethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl]amino]-l-pyridyl]propanamide;

2,2-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amn^^ pyridyl]propanamide;

N-methyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amm^ pyridyl] ethoxy] acetamide;

N,N-dimethyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yljamino] - 1 -pyridyl] ethoxy] acetamide;

N-methyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -yl]amino] - 1 -pyridyl] acetamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanamide;

N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanamide;

N-methyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethoxy] acetamide;

N,N-dimethyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethoxy] acetamide;

3- [2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl]propanoic acid;

4- [2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl]butanoic acid;

2,2-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl]propanoic acid;

2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl] ethoxy] acetic acid;

2-[methyl-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl]ethyl]amino]acetic acid;

1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l -yljamino]- 1 - pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

(2S)-l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l- pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

(2R)- 1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l -yljamino]- 1 - pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

4-[5-chloro-2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanoic acid;

4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanoic acid;

2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]-l -pyridyl]ethoxy]acetic acid;

l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethyl]pyrrolidine-3 -carboxylic acid;

1- [2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-l-yl]amino]-l-pyridyl]ethyl]morpholine-2-carboxylic acid;

4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethyl]morpholine-3 -carboxylic acid;

4-[6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]pyrimidin- 1 -yl]butanoic acid;

7-hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

6-hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

1 -[[ 1 -(morpholin-3-ylmethyl)-6-oxo-pyrimidin-5-yl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(methylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

2- [2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]-l -pyridyl]ethylamino]acetic acid;

1 -[[ 1 -(2-aminoethyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

1 -[ [2-oxo- 1 -(pyrrolidin-2-ylmethyl)-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

6-methyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-methyl-4-[(l-methyl-2-oxo-3-pyridyl)am

dihydro-5H-pyrido [3 ,4-d]pyridazin- 1 -one;

l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydropyrido [3 ,4-d]pyridazin-4-one;

1 -[ [ 1 - [ [(2S)-Morpholin-2-yl]methyl] -2-oxo-3 -pyridyl] amino] -3 - [4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

6- (2-methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7- (2-methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

5- (2-methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazine-6- carboxamide;

7-(l-hydroxyethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-(hydroxymethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-amino-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin- 1-one;

7-(aminomethyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-[(dimethylamino)methyl] -4- [( 1 -methyl -2-0X0-3 -pyridyl)amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

6- (2-hydroxypropyl)- 1 -[(1 -methyl-2-oxo-3-pyridyl)amino]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-(2-hydroxy-2-methyl-propyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-(2-hydroxyethyl)-l-[(l -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]- 7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3 ,4-d]pyridazin- 1 -one;

6-acetyl-l-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl-4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3 ,4-d]pyridazin- 1 -one;

methyl 4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazine-6-carboxylate;

methyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazine-6-carboxylate;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-l-oxo-2-[4-(trifluoromethoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazine-6-carbaldehyde;

1- [(1 -methyl -2 -oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromethoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazine-6-carbaldehyde;

1 -[( 1 -methyl -2 -oxo-3-pyridyl)amino]-6-methylsulfonyl-3 -[4-(trifluoromethoxy)phenyl] - 7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-6-methylsulfonyl-2-[4-(trifluoromethoxy)phenyl]- 7,8-dihydro-5H-pyrido[3,4-d]pyridazin-l-one;

6-ethyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazin-4-one;

6- isopropyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

N-methyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-(trifluoromethoxy)phenyl]- 7,8-dihydro-5H-pyrido[3,4-d]pyridazine-6-carboxamide;

N-methyl- 1 -[( 1 -methyl-2-oxo-3 -pyridyl)amino] -4-oxo-3 -[4-(trifluoromethoxy)phenyl] - 7,8-dihydro-5H-pyrido[3,4-d]pyridazine-6-carboxamide;

2- [4-( 1 -hydroxy- 1 -methyl-ethyl)phenyl] -4- [( 1 -methyl -2-oxo-3 -pyridyl)amino]phthalazin- 1-one;

4-[[l-(2-hydroxyethyl)-2-oxo-3-pyridyl]amino]-2-[4-(trifluoromethoxy)phenyl]phthalazin- 1-one;

7- hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

6-hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

1 -[[ 1 -(3-amino-2-hydroxy-2-methyl-propyl)-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[2-Oxo-l -(2-oxo-2-piperazin- 1 -yl-ethyl)-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[l-[2-(Oxetan-3-ylamino)ethyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(3-Hydroxyazetidin- 1 -yl)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

trans- 1 - [ [ 1 -[(5 -Amino- 1 ,3 -dioxan-2-yl)methyl] -2-oxo-3 -pyridyl] amino] -3 - [4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[( 1 -Methyl-2-oxo-3 -pyridyl)amino] -3 - [2-methyl-4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

3-(3,4-Dimethoxyphenyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3- [3-Methoxy-4-(trifluoromethyl)phenyl]-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6,7^ dihydro-5H-cyclopenta[d]pyridazin-4-one;

N,l-Dimethyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -yl] amino]pyridine-3 -carboxamide;

N, 1 -Dimethyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l - yl]amino]pyridine-3-carboxamide;

4- [[l-methyl-2-oxo-5-(trifiuoromethyl)-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

and pharmaceutically acceptable salts thereof.

A process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof according to any of claims 1 to 38, comprising a palladium- mediated amination reaction of a compound of formula (IV)

A process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof according to any of claims 1 to 38, comprising a palladium- mediated animation reaction of a compound of formula (VII)

(VII) (I)

41. A compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically

obtainable salt thereof obtainable by the process of claim 39 or 40.

42. A pharmaceutical composition comprising a c compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically obtainable salt thereof and at least one

pharmaceutically acceptable excipient.

43. A compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically

obtainable salt thereof for use as therapeutically active substances.

44. A compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically

obtainable salt thereof for use in the treatment or prevention of viral diseases.

45. A method for the treatment or prevention of viral diseases, which method comprises

administering a compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically obtainable salt thereof to a human being or animal.

46. Use of a compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically obtainable salt thereof for the treatment or prevention of viral diseases.

47. Use of a compound of formula (I) according to any of claims 1 to 38 or a pharmaceutically obtainable salt thereof for the preparation of medicaments useful for the treatment or prevention of viral diseases.

48. The invention as hereinbefore described.

Description:
Pyridazinone-based broad spectrum anti-influenza inhibitors

The present invention relates to a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein X, Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R4 and R 6 to R 8 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Background of the invention

Influenza viruses infect humans and animals and have incurred great financial and societal cost for decades. The most common flu viruses infecting humans are the type A and type B viruses. Influenza A viruses are responsible for sporadic pandemics that usually cause higher mortality rates than seasonal influenza epidemics. The most severe pandemic ("the Spanish flu") occurred in 1918, with approximately 50 million deaths worldwide (1% of the world's population, 2.5% case:fatality rate). Most recently, the serious threat posed by influenza viruses to worldwide public health has been highlighted by, (i) firstly, the transmission to humans of the highly pathogenic avian influenza A viruses such as the recurrent H5N1 (53% mortality in infected humans; WHO/GIP data in HQ as of 09 May 2016,

http://www.who.int/influenza/human_animal_interface/EN_GI P_20160509cumulativenumberH 5Nlcases.pdf?ua=l ), H7N9 (2 waves in China in 2013 and 2014 with high rates of severe illness and death) and H10N8 (first case reported in China in 2013), and (ii) secondly, the unexpected emergence in 2009 of a novel pandemic influenza virus strain, the swineA/HlNl, that has rapidly spread around the world (http://www.who.int/csr/disease/swinefiu/en/).

Fortunately, these strains were respectively highly pathogenic but poorly human-to-human

HD / 08.06.2017 transmissible, and highly transmissible but causing only mild illness. A catastrophic, yet plausible, scenario would be the generation by genetic mutation(s) of strains highly pathogenic and contagious and requires constant monitoring.

Besides pandemics, seasonal epidemics occur mainly during the winter months in temperate climates or throughout the year in tropical regions. WHO estimates that annual epidemics cause 3 to 5 million cases of severe illness and 250,000-500,000 deaths worldwide per year {http://www.who.int/mediacentre/factsheets/fs211/en/). Hospitalization and death occur mainly in high-risk populations, the very young, elderly, chronically ill, pregnant woman and immunocompromised patients. On the general population, flu epidemics can result in substantial absenteeism and productivity losses.

Convential prophylactic and therapeutic treatments are the seasonal vaccine and direct acting antivirals. The vaccine is, however, poorly effective in the elderly and children under the age of two, and some years poorly or totally ineffective due to failed prediction of the epidemic strains. Also, it should be noted that the delay in generating a vaccine (~6 motnhs in the relatively favorable case of A/H1N1) and the lack of vaccinal coverage against highly pathogenic strains highlight the need for therapeutic options.

Two classes of licenced pathogen-targeting antivirals exist: the M2 ion channel blockers (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir). They respectively block the virus life cycle at the entry and release stages. The M2 blockers have not been extensively used due to their side effects and the rapid development of resistant virus mutants (Magden J. et al., Appl. Microbiol. Biotechnol. (2005) 66:612-621). In addition, rather unspecific viral drugs, such as ribavirin, can be used to treat influenza and other virus infections {Eriksson, B. et al, Antimicrob. Agents Chemother. (1977) 11:946-951) but Ribavirin has been approved only in a few countries due to its severe side effects (Furuta et al., Antimicrobial Agents and Chemotherapy (2005) 49 (3) :981-986). The Standard of Care has been Oseltamivir for years, despite its significant limitations; 1) a rather limited treatment window as it has to be administred within 48h of the onset of symptoms; 2) a partial efficacy in high-risk and hospitalized patients and the failure to prevent complications in some patients; 3) the existence of resistance by many influenza strains, as reported by IRIS (http://apps.who.int/iris/handle/10665/205523); and 4) a low potency against flu B and the fact that Oseltamivir monotherapy has not prevented death in patients with severe pandemic H1N1 (Nukiwa et al, Clin Infect Dis (2010) 51(6):725-731), H5N1 (Chan et al, J Infect Dis (2012) 206:1359-1366) or H7N9 (Hu et al, Lancet (2013) 381: 2271-2277). An obvious strategy to improve on the standard of care would be to combine drugs with different modes of action ("MO A") or develop drugs with new MOAs that could be used as stand-alone. It is an object of the present invention to identify such new compounds with new MO A which are effective against viral diseases, particularly influenza, and which have improved pharmacological properties.

Detailed description of the invention

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below.

All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

The nomenclature used in this Application is based on IUPAC systematic nomenclature, unless indicated otherwise. Any open valency appearing on a carbon, oxygen, sulfur or nitrogen atom in the structures herein indicates the presence of a hydrogen, unless indicated otherwise.

The definitions described herein apply irrespective of whether the terms in question appear alone or in combination. It is contemplated that the definitions described herein can be appended to form chemically-relevant combinations, such as e.g. "heterocycloalkylaryl",

"haloalkylheteroaryl", "arylalkylheterocycloalkyl", or "alkoxyalkyl". The last member of the combination is the radical which is binding to the rest of the molecule. The other members of the combination are attached to the binding radical in reversed order in respect of the literal sequence, e.g. the combination arylalkylheterocycloalkyl refers to a heterocycloalkyl-radical which is substituted by an alkyl which is substituted by an aryl. When indicating the number of substituents, the term "one or more" refers to the range from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents.

The term "optional" or "optionally" denotes that a subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.

The term "substituent" denotes an atom or a group of atoms replacing a hydrogen atom on the parent molecule. "The term "compound(s) of this invention" and "compound(s) of the present invention" refers to compounds as disclosed herein and stereoisomers, tautomers, solvates, and salts (e.g., pharmaceutically acceptable salts) thereof.

When the compounds of the invention are solids, it is understood by those skilled in the art that these compounds, and their solvates and salts, may exist in different solid forms, particularly different crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.

The term "pharmaceutically acceptable salts" denotes salts which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts.

The term "pharmaceutically acceptable acid addition salt" denotes those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid. The term "pharmaceutically acceptable base addition salt" denotes those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, and polyamine resins.

Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al. Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511). The prefixes D and L or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or L designating that the compound is

levorotatory. A compound prefixed with (+) or D is dextrorotatory.

Compounds of present invention can have one or more chiral centers and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. Whenever a chiral center is present in a chemical structure, it is intended that all stereoisomers associated with that chiral center are encompassed by the present invention.

The term "halo", "halogen", and "halide" are used interchangeably herein and denote fluoro, chloro, bromo, or iodo. Particular examples of halo are fluoro and chloro.

The term "hydrogen" and "hydro" are used interchangeably to denote a hydrogen radical (- H).

The term "alkyl" denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms. In particular embodiments, alkyl has 1 to 7 carbon atoms, and in more particular embodiments 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, or tert-butyl. Particular examples of alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, and tert-butyl.

The term "alkenyl" denotes a monovalent linear or branched hydrocarbon group of 2 to 7 carbon atoms with at least one double bond. In particular embodimets, alkenyl has 2 to 4 carbon atoms with at least one double bond. Examples of alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl, and iso-butenyl. Particular example of alkenyl is ethenyl. The term "alkoxy" denotes a group of the formula -O-R', wherein R' is an alkyl group.

Examples of alkoxy moieties include methoxy, ethoxy, isopropoxy, and tert-butoxy. Particular examples of alkoxy include methoxy, ethoxy and tert-butoxy.

The term "haloalkyl" denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloalkyl include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, or

tnfluorom ethyl. The term "perhaloalkyl" denotes an alkyl group where all hydrogen atoms of the alkyl group have been replaced by the same or different halogen atoms. Particular examples of haloalkyl include trifluoromethyl and difluoromethyl. The term "haloalkoxy" denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloalkoxyl include monofluoro-, difluoro- or trifluoro-methoxy, - ethoxy or -propoxy, for example 3,3,3-trifluoropropoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, fluoromethoxy, or tnfluoromethoxy. The term "perhaloalkoxy" denotes an alkoxy group where all hydrogen atoms of the alkoxy group have been replaced by the same or different halogen atoms. Particular examples of haloalkoxy include trifluoromethoxy and difluoromethoxy.

The term "hydroxyalkyl" denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a hydroxy group. Examples of hydroxyalky include hydroxymethyl, 2 -hydroxy ethyl, 2-fiydroxypropyl, 3 -fiydroxypropyl, 1-

(hydroxymethyl)-2-methylpropyl, 2-fiydroxybutyl, 3-fiydroxybutyl, 4-fiydroxybutyl, 2,3 " dihydroxypropyl, 2-hydroxy-l-hydroxymethylethyl, 2,3 -dihydroxybutyl, 3,4-dihydroxybutyl or 2-(hydroxymethyl)-3 -fiydroxypropyl. Particular example of hydroxyalkyl include

hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl and hydroxyisobutyl. The term "alkoxyalkyl" denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by an alkoxy group. Exemplary alkoxyalkyl groups include 2-methoxyethyl, 3-methoxypropyl, l-methyl-2-methoxyethyl, l-(2-methoxyethyl)-3- methoxypropyl, and l-(2-methoxyethyl)-3-methoxypropyl.

The term "bicyclic ring system" denotes two rings which are fused to each other via a common single or double bond (annelated bicyclic ring system), via a sequence of three or more common atoms (bridged bicyclic ring system) or via a common single atom (spiro bicyclic ring system). Bicyclic ring systems can be saturated, partially unsaturated, unsaturated or aromatic. Bicyclic ring systems can comprise heteroatoms selected from N, O and S.

The term "cycloalkyl" denotes a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms. In particular embodiments cycloalkyl denotes a monovalent saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms. Bicyclic means consisting of two saturated carbocycles having one or more carbon atoms in common. Particular cycloalkyl groups are monocyclic. Examples for monocyclic cycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl. Examples for bicyclic cycloalkyl are

bicyclo[2.2.1]heptanyl, or bicyclo[2.2.2]octanyl. Particular example of cycloalkyl is cyclopropyl.

The term "cycloalkylalkyl" denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group is replaced by a cycloalkyl group. Examples of cycloalkylalkyl include cyclopropylmethyl, cyclopropylethyl, cyclobutylpropyl and cyclopentylbutyl. The term "heterocycloalkyl" denotes a monovalent saturated or partly unsaturated mono- or bicyclic ring system of 3 to 9 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In particular embodiments, heterocycloalkyl is a monovalent saturated monocyclic ring system of 4 to 7 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples for monocyclic saturated heterocycloalkyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, l,l-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Examples for bicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza- bicyclo[3.3.1]nonyl, or 3-thia-9-aza-bicyclo[3.3.1]nonyl. Examples for partly unsaturated heterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or dihydropyranyl. Particular examples of heterocycloalkyl are azetidinyl, oxetanyl, pyrrolidinyl, piperazinyl, and morpholinyl.

The term "aromatic" denotes the conventional idea of aromaticity as defined in the literature, in particular in IUPAC - Compendium of Chemical Terminology, 2nd, A. D.

McNaught & A. Wilkinson (Eds). Blackwell Scientific Publications, Oxford (1997).

The term "aryl" denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms. Examples of aryl moieties include phenyl and naphthyl.

The term "aryloxy" denotes a group of the formula -O-R', wherein R' is aryl. An example of aryloxy is phenoxy.

The term "heteroaryl" denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples of heteroaryl moieties include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or

quinoxalinyl. Particular example of heteroaryl is imidazolyl.

The term "amino" denotes a group of the formula -NR'R" wherein R' and R" are independently hydrogen, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

Alternatively, R' and R", together with the nitrogen to which they are attached, can form a heterocycloalkyl. The term "primary amino" denotes a group wherein both R' and R" are hydrogen. The term "secondary amino" denotes a group wherein R' is hydrogen and R" is not. The term "tertiary amino" denotes a group wherein both R' and R" are not hydrogen. Particular secondary and tertiary amines are methylamine, ethylamine, propylamine, isopropylamine, phenylamine, benzylamine dimethylamine, diethylamine, dipropylamine and diisopropylamine. The term "alkylamino" denotes a group -NR'R", wherein R' is hydrogen and R" is a alkyl.

The term "dialkylamino" as used herein denotes a group -NR'R", wherein R' and R" are both alkyl. Examples of alkylamino groups include methylamino and ethylamino. Examples of alkylamino groups include dimethylamino, methylethylamino, diethylamino and di(l - methy lethy l)amino . The terms "pharmaceutical composition" and "pharmaceutical formulation" (or

"formulation") are used interchangeably and denote a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with

pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need thereof. The term "pharmaceutically acceptable" denotes an attribute of a material which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and is acceptable for veterinary as well as human pharmaceutical use.

The terms "pharmaceutically acceptable excipient", "pharmaceutically acceptable carrier" and "therapeutically inert excipient" can be used interchangeably and denote any

pharmaceutically acceptable ingredient in a pharmaceutical composition having no therapeutic activity and being non-toxic to the subject administered, such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants, carriers, diluents or lubricants used in formulating pharmaceutical products. An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non- human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

The term "half maximal inhibitory concentration" (IC50) denotes the concentration of a particular compound or molecule required for obtaining 50% inhibition of a biological process in vitro. IC50 values can be converted logarithmically to pIC50 values (-log IC50), in which higher values indicate exponentially greater potency. The IC50 value is not an absolute value but depends on experimental conditions e.g. concentrations employed. The IC50 value can be converted to an absolute inhibition constant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol. (1973) 22:3099).

The term "therapeutically effective amount" denotes an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.

An "effective amount" of an agent, e.g., a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

The term "treating" or "treatment" of a disease state includes inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms, or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.

The term "preventing" or "prevention" of a disease state denotes causing the clinical symptoms of the disease state not to develop in a subject that can be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state.

8-Fluoro-2H-phthalazin-l-one, i.e. a phthalazin-l-onyl with a fluoro-substituent in position 8, has the structure as follows:

In detail, the present invention relates to a compound of formula (I)

wherein

X 1S-CH 2 -CH 2 -CH 2 -, -CH=CH-CH=CH-, -CH 2 -CH 2 -CH 2 -CH 2 -,

-CH2-O-CH2-CH2-, CH2-CH2-O-CH2-, -CH 2 -NR 2 -CH 2 -CH 2 -, or -CH 2 -CH 2 -NR 2 -CH 2 -; n is 0, 1 or 2; each R 1 is independently selected from halo, Ci_ 7 alkyl, C 2-7 alkenyl, hydroxy, Ci_ 7 alkoxy, NR 10 R n , and CONR 10 R n ;

wherein Ci_ 7 alkyl and Ci_ 7 alkoxy are optionally substituted by one or more Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, NR 10 R n or COR 9 ;

R 2 is H, Ci_ 7 alkyl, hydroxy-Ci_ 7 alkyl, COR 9 , CONR 10 R n , or S0 2 -Ci_ 7 alkyl;

Y 1 is N, CH or CCH 3 ,

Y 2 is N or CR 3 ;

with the proviso that not both of Y 1 and Y 2 are N; R 3 is H, halogen, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, CONR 10 R n or CO-Ci_ 7 alkoxy;

R 4 is H or Ci_ 7 alkyl, wherein Ci_ 7 alkyl is optionally substituted with one or more R 5 ; each R 5 is independently selected from hydroxy, Ci_ 7 alkoxy, NR 12 R 13 , COR 9 , CONR 10 R n , S0 2 - Ci_ 7 alkyl, SO 2 -NR 10 R n , heterocycloalkyl and heteroaryl;

wherein Ci_ 7 alkoxy is optionally substituted by COR 9 or CONR 10 R n ;

wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COR 9 , Ci_ 7 alkyl-COR 9 or NR 10 R n ; is N, CH or CO-CH 3 ;

Z 2 is N or CH;

R 6 is Ci_7 alkyl, hydroxy-Ci_7 alkyl, halo-Ci_7 alkyl, Ci_ 7 alkoxy-Ci_ 7 alkyl, Ci_ 7 alkoxy, halo-Ci_ 7 alkoxy, Ci_ 7 alkoxy-Ci_ 7 alkoxy, S-halo-Ci_ 7 alkyl, SF 5 , C 3 _ 7 cycloalkyl, heterocycloalkyl or heterocycloalkyl substituted by Ci_ 7 alkyl;

R 7 is H, halogen or Ci_ 7 alkyl;

R 8 is H, halogen or Ci_ 7 alkyl;

R 9 is H, Ci_ 7 alkyl, hydroxy, or Ci_ 7 alkoxy;

R 10 is H or Ci_ 7 alkyl;

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy,

COOH, or CO-Ci_ 7 alkoxy;

R 11 is H, Ci_ 7 alkyl, CO-Ci_ 7 alkoxy or heterocycloalkyl,

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy, NH 2 , N(Ci_ 7 alkyl) 2 , COOH, or CO-Ci_ 7 alkoxy; or R 10 and R 11 together with the interconnecting nitrogen form a heterocycloalkyl which is

optionally substituted with one ore more halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COOH, CO-Ci_ 7 alkoxy or NH 2 ;

R 12 is H or Ci_ 7 alkyl;

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy, COOH, or CO-Ci_ 7 alkoxy;

R 13 is H, Ci_ 7 alkyl, CO-Ci_ 7 alkoxy or heterocycloalkyl,

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy, NH 2 , N(Ci_ 7 alkyl) 2 , COOH, or CO-Ci_ 7 alkoxy; or a pharmaceutically acceptable salt thereof. Further, it is to be understood that every embodiment relating to a specific X, Y 1 , Y 2 , Z 1 ,

Z 2 , n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , or R 13 as disclosed herein may be

1 2 1 2 1 2 3 4 5 combined with any other embodiment relating to another X, Υ , Υ , Ζ , Ζ , η, R , R , R , R , R , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , or R 13 as disclosed herein. a particular embodiment, the present invention relates to a compound of formula (I)

wherein

X 1S-CH 2 -CH 2 -CH 2 -, -CH=CH-CH=CH-, -CH 2 -CH 2 -CH 2 -CH 2 -,

-CH2-O-CH2-CH2-, CH2-CH2-O-CH2-, -CH 2 -NR 2 -CH 2 -CH 2 -, or -CH 2 -CH 2 -NR 2 -CH 2 -; n is 0, 1 or 2; each R 1 is independently selected from halo, Ci_ 7 alkyl, C 2-7 alkenyl, hydroxy, Ci_ 7 alkoxy, NR 10 R n , and CONR 10 R n ;

wherein Ci_ 7 alkyl and Ci_ 7 alkoxy are optionally substituted by one or more Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, NR 10 R n or COR 9 ;

with the proviso that if X is -CH=CH-CH=CH- then an optional R 1 in position 8 of the phthalazin-l-onyl is fluoro;

R 2 is H, Ci_ 7 alkyl, hydroxy-Ci_ 7 alkyl, COR 9 , CONR 10 R n , or S0 2 -Ci_ 7 alkyl;

Y 1 is N, CH or CCH 3 , Y 2 is N or CR 3 ;

with the proviso that not both of Y 1 and Y 2 are N;

R 3 is H, halogen, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, CONR 10 R n or CO-Ci_ 7 alkoxy;

R 4 is H or Ci_ 7 alkyl, wherein Ci_ 7 alkyl is optionally substituted with one or more R 5 ; each R 5 is independently selected from hydroxy, Ci_ 7 alkoxy, NR 12 R 13 , COR 9 , CONR 10 R n , S0 2 - Ci_ 7 alkyl, SO 2 -NR 10 R n , heterocycloalkyl and heteroaryl;

wherein Ci_ 7 alkoxy is optionally substituted by COR 9 or CONR 10 R n ;

wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COR 9 , Ci_ 7 alkyl-COR 9 or NR 10 R n ;

Z 1 is N, CH or CO-CH 3 ;

Z 2 is N or CH; R 6 is Ci_ 7 alkyl, hydroxy-Ci_ 7 alkyl, halo-Ci_ 7 alkyl, Ci_ 7 alkoxy-Ci_ 7 alkyl, Ci_ 7 alkoxy, halo-Ci_ 7 alkoxy, Ci_ 7 alkoxy-Ci_ 7 alkoxy, S-halo-Ci_ 7 alkyl, SF 5 , C 3 _ 7 cycloalkyl, heterocycloalkyl or heterocycloalkyl substituted by Ci_ 7 alkyl;

R 7 is H, halogen or Ci_ 7 alkyl;

R 8 is H, halogen or Ci_ 7 alkyl; R 9 is H, Ci_ 7 alkyl, hydroxy, or Ci_ 7 alkoxy;

R 10 is H or Ci_ 7 alkyl;

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy, COOH, or CO-Ci_ 7 alkoxy;

R 11 is H, Ci_ 7 alkyl, CO-Ci_ 7 alkoxy or heterocycloalkyl;

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy,

NH 2 , N(Ci_ 7 alkyl) 2 , COOH, or CO-Ci_ 7 alkoxy; or R 10 and R 11 together with the interconnecting nitrogen form a heterocycloalkyl which is optionally substituted with one ore more halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COOH, CO-Ci_ 7 alkoxy or NH 2 ; R 12 is H or Ci_ 7 alkyl;

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy, COOH, or CO-Ci_ 7 alkoxy;

R 13 is H, Ci_ 7 alkyl, CO-Ci_ 7 alkoxy or heterocycloalkyl,

wherein Ci_ 7 alkyl is optionally substituted with one or more hydroxy, Ci_ 7 alkoxy, NH 2 , N(Ci_ 7 alkyl) 2 , COOH, or CO-Ci_ 7 alkoxy; or a pharmaceutically acceptable salt thereof. A particular embodiment of the invention relates to a compound of formula (IA)

wherein Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein, or a pharmaceutically acceptable salt thereof.

A particular embodiment of the invention relates to a compound of formula (IB)

wherein Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein, or a pharmaceutically acceptable salt thereof. A particular embodiment of the invention relates to a compound of formula (IC)

wherein Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein, or a

pharmaceutically acceptable salt thereof.

A particular embodiment of the invention relates to a compound of formula (ID)

wherein Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein, or a

pharmaceutically acceptable salt thereof A particular embodiment of the invention relates to a compound of formula (IE)

wherein Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein, or a

pharmaceutically acceptable salt thereof.

A particular embodiment of the invention relates to a compound of formula (IF)

wherein Y 1 , R4 and R 6" to R 8° are as described herein, or a pharmaceutically acceptable salt thereof. A particular embodiment of the invention relates to a compound of formula (IG)

wherein Y 1 , R4 and R 6" to R 8° are as described herein, or a

pharmaceutically acceptable salt thereof.

A particular embodiment of the present invention relates to compounds of formula (I), wherein X is -CH 2 -CH 2 -CH 2 -, -CH=CH-CH=CH-, -CH 2 -CH 2 -CH 2 -CH 2 -, -CH 2 -NR 2 -CH 2 -CH 2 -, or -CH 2 -CH 2 -NR 2 -CH 2 -.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein n is 0 or 1.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 1 is independently selected from Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, and NR 10 R n ; wherein Ci_ 7 alkyl is optionally substituted by one hydroxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 1 is independently selected from Ci_ 7 alkyl and Ci_ 7 alkoxy; wherein Ci_ 7 alkyl is optionally substituted by one hydroxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 1 is independently selected from fluoro, methyl, ethyl, ethenyl, hydroxy, methoxy, ethoxy, NH 2 and CONH 2 ; wherein methyl, ethyl, methoxy, and ethoxy are optionally substituted by one methyl, hydroxy, methoxy, NH 2 or N(CH 3 ) 2 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 1 is independently selected from methyl, ethyl, hydroxy, methoxy, ethoxy, and NH 2 ; wherein methyl is optionally substituted by one hydroxy. A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 1 is independently selected from methyl, ethyl, and methoxy; wherein methyl is optionally substituted by one hydroxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 2 is COR 9 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 2 is H, methyl, ethyl, isopropyl, propyl, isobutyl, hydroxy-methyl, hydroxy-ethyl, hydroxy-isopropyl, hydroxy-propyl, hydroxy-isobutyl, COH, COCH 3 , COOCH3, CONHCH3, or SO 2 -CH3. A particular embodiment of the present invention relates to compounds of formula (I), (IA),

(IB), (IC), (ID), (IE), (IF) or (IG), wherein R 2 is COCH 3 or COOCH 3 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 2 is COCH 3 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Y 1 is N or CH, with the proviso that not both of Y 1 and Y 2 are N.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Y 1 is CH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Y 2 is N with the proviso that not both of Y 1 and Y 2 are N.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Y 2 is CR 3 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 3 is H, halogen, or Ci_ 7 alkyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 3 is H, fluoro, chloro, methyl, ethyl, isopropyl, trifluoromethyl, CONHCH 3 or COOCH 3 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 3 is H, fluoro, chloro, or methyl. A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 4 is H or Ci_ 7 alkyl, wherein Ci_ 7 alkyl is optionally substituted with one R 5 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 4 is Ci_ 7 alkyl optionally substituted with one or two R 5 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 4 is Ci_ 7 alkyl optionally substituted with one R 5 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 4 is H, methyl, ethyl, propyl or isobutyl, wherein methyl, ethyl, propyl and isobutyl are optionally substituted with one or two R 5 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 4 is methyl, ethyl, propyl or isobutyl, each

optionally substituted with one R 5 . A particular embodiment of the present invention relates to compounds of formula (I), (IA),

(IB), (IC), (ID), (IE), (IF) or (IG), wherein R 4 is methyl, ethyl, or propyl, each optionally substituted with one R 5 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, Ci_ 7 alkoxy, NR 12 R 13 , COR 9 , CONR 10 R n , S0 2 -Ci_ 7 alkyl, SO 2 -NR 10 R n , heterocycloalkyl and heteroaryl;

wherein Ci_ 7 alkoxy is optionally substituted by COR 9 or CONR 10 R n ;

wherein heterocycloalkyl and heteroaryl are optionally substituted with one or two substituents selected from halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COR 9 , Ci_ 7 alkyl-COR 9 and NR 10 R n .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, Ci_ 7 alkoxy, NR 12 R 13 , COR 9 , CONR 10 R n , S0 2 -Ci_ 7 alkyl, SO 2 -NR 10 R n , and heterocycloalkyl;

wherein Ci_ 7 alkoxy is optionally substituted by COR 9 or CONR 10 R n ;

wherein heterocycloalkyl is optionally substituted with one substituent selected from Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, and COR 9 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, NR 12 R 13 , CONR 10 R n , and heterocycloalkyl;

wherein heterocycloalkyl is optionally substituted with one Ci_ 7 alkyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, methoxy, NR 12 R 13 , COR 9 , CONR^R 11 , S0 2 -methyl, S0 2 -NH 2 , azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and imidazolyl;

wherein methoxy is optionally substituted by COR 9 or CONR 10 R n ;

wherein azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and imidazolyl are optionally substituted with one or two substituents selected from methyl, trifluoromethyl, hydroxy, methoxy, COR 9 , and NR 1( 1 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, methoxy, NH 2 , NHCH 3 , N(CH 3 ), N(CH 2 CH 3 ) 2 , NH(CH 2 COOH), NH(COO-tert-butyl),

N(CH 3 )(CH 2 COOH), N(CH 2 COOH)(COO-tert-butyl), NH(oxetanyl), COOH, COOCH 3 ,

CONH 2 , CONH(CH 3 ), CONH(CH 2 CH 2 N(CH 3 ) 2 , CONH(CH 2 CH 2 OH),

CONH(CH 2 CH 2 CH 2 OCH 3 ), CONH(CH(CH 3 ) 2 ), CON(CH 3 ) 2 , S0 2 -methyl, S0 2 -NH 2 , azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and imidazolyl;

wherein methoxy is optionally substituted by COOH, COOCH 2 CH 3 , CONH(CH 3 ), or

CON(CH 3 ) 2 ;

wherein azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and imidazolyl are optionally substituted with one or two substituents selected from methyl, trifluoromethyl, hydroxy, methoxy, COOH, COOCH 3 , and COOCH 2 CH 3 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, methoxy, NR 12 R 13 , COR 9 , CONR^R 11 , S0 2 -methyl, SO 2 -NR 10 R 11 , azetidinyl, pyrrolidinyl, piperazinyl, and morpholinyl;

wherein methoxy is optionally substituted by COR 9 or CONR 10 R n ;

wherein azetidinyl, pyrrolidinyl, piperazinyl, and morpholinyl is optionally substituted with one substituent selected from methyl, hydroxy, methoxy, or COR 9 . A particular embodiment of the present invention relates to compounds of formula (I), (IA),

(IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, methoxy, N(CH 3 ), N(CH 2 CH 3 ) 2 , NH(oxetanyl), COOCH 3 , CONH(CH 3 ),

CONH(CH 2 CH 2 CH 2 OCH 3 ), CON(CH 3 ) 2 , S0 2 -methyl, S0 2 -NH 2 , azetidinyl, pyrrolidinyl, piperazinyl, and morpholinyl;

wherein methoxy is optionally substituted by CONH(CH ), or CON(CH ) 2 ; wherein azetidinyl, pyrrolidinyl, piperazinyl, and morpholinyl is optionally substituted with one substituent selected from methyl, hydroxy, methoxy, and COOCH 3 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein each R 5 is independently selected from hydroxy, N(CH 3 ), CONH(CH 3 ), CON(CH 3 ) 2 , piperazinyl, and piperazinyl substituted with one methyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Z 1 is N or CH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Z 1 is N. A particular embodiment of the present invention relates to compounds of formula (I), (IA),

(IB), (IC), (ID), (IE), (IF) or (IG), wherein Z 1 is CH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Z 2 is N.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein Z 2 is CH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 6 is Ci_7 alkyl, halo-Ci_ 7 alkyl, or halo-Ci_ 7 alkoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 6 is tert-butyl, hydroxy-isopropyl,

trifluoromethyl, methoxy, ethoxy, methoxy-ethoxy, difluoromethoxy, trifluoromethoxy, cyclopropyl, oxetanyl or methyl-oxetanyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 6 is tert-butyl, trifluoromethyl,

difluoromethoxy or trifluoromethoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 6 is tert-butyl, trifluoromethyl, or

trifluoromethoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 7 is H. A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 8 is H, fluoro or methyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 8 is H. A particular embodiment of the present invention relates to compounds of formula (I),

(IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 9 is H, Ci_ 7 alkyl or Ci_ 7 alkoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 9 is H, methyl, hydroxy, methoxy or ethoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 9 is methyl or methoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 is H, Ci_ 7 alkyl or Ci_ 7 alkyl substituted with one COOH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 is H, methyl, ethyl or CH 2 -COOH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 is H, methyl or ethyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 is H or methyl. A particular embodiment of the present invention relates to compounds of formula (I),

(IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 11 is is H, Ci_ 7 alkyl, Ci_ 7 alkyl substituted with one hydroxy, Ci_ 7 alkyl substituted with one Ci_ 7 alkoxy, Ci_ 7 alkyl substituted with one N(CH 3 ) 2 , Ci_ 7 alkyl substituted with one COOH, CO-Ci_ 7 alkoxy or heterocycloalkyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 11 is is H, Ci_ 7 alkyl, or Ci_ 7 alkyl substituted with one Ci_ 7 alkoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 11 is is H, methyl, ethyl, isopropyl, hydroxy- ethyl, methoxy-propyl, ethyl substituted with one N(CH 3 ) 2 , CH 2 -COOH, CO-tert-butoxy or oxetanyl. A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 11 is is H, methyl, ethyl, or methoxy-propyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 11 is is methyl. A particular embodiment of the present invention relates to compounds of formula (I),

(IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 and R 11 together with the interconnecting nitrogen form a heterocycloalkyl which is optionally substituted with one ore more halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COOH, CO-Ci_ 7 alkoxy or NH 2 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 and R 11 together with the interconnecting nitrogen form azetidinyl, piperazinyl, morpholinyl, imidazolyl or pyrrolidinyl, each optionally substituted with one ore two halo, Ci_ 7 alkyl, halo-Ci_ 7 alkyl, hydroxy, Ci_ 7 alkoxy, oxo, COOH, CO-Ci_ 7 alkoxy or NH 2 .

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 10 and R 11 together with the interconnecting nitrogen form azetidinyl, piperazinyl, morpholinyl, imidazolyl or pyrrolidinyl, each optionally substituted with one ore two methyl, trifluoromethyl, hydroxy, methoxy, COOH, CO-methoxy or CO-ethoxy.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 12 is H, Ci_ 7 alkyl or alkyl substituted by one COOH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 12 is H, methyl, ethyl or CH 2 -COOH.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 13 is H, Ci_ 7 alkyl, Ci_ 7 alkyl substituted with one COOH, CO-Ci_ 7 alkoxy or heterocycloalkyl.

A particular embodiment of the present invention relates to compounds of formula (I), (IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 13 is H, Ci_ 7 alkyl, Ci_ 7 alkyl substituted with one COOH, CO-Ci_ 7 alkoxy or oxetanyl. A particular embodiment of the present invention relates to compounds of formula (I),

(IA), (IB), (IC), (ID), (IE), (IF) or (IG), wherein R 13 is H, methyl, ethyl, CH 2 -COOH, CO-tert butoxy or oxetanyl. Particular compounds of formula (I) of the present invention are those selected from the group consisting of:

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalaz in-l -one;

4-[(2-oxo-lH-pyridin-3-yl)amino]-2-[4-(trifluoromethoxy)p henyl]phthalazin-l-one;

methyl 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl] acetate;

methyl 2,2-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin- 1 -yljamino]- 1 -pyridyl]propanoate;

ethyl 2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalaz in-l -yljamino]- 1- pyridyl] ethoxy] acetate;

methyl (2R)- 1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazi n- 1 -yl]amino]-l - pyridyl]ethyl]pyrrolidine-2-carboxylate;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[2-methyl-4-(trifluoromethoxy)phenyl ]phthalazin-l -one; 2-(6-tert-butyl-3-pyridyl)-4-[(l-methyl-2-oxo-3-pyridyl)amin o]phthalazin-l-one;

2-(2-tert-butylpyrimidin-5-yl)-4-[(l-methyl-2-oxo-3-pyrid yl)amino]phthalazin-l-one;

2-[4-(3-methyloxetan-3-yl)phenyl]-4-[(l-methyl-2-oxo-3-pyrid yl)amino]phthalazin-l-one;

4- [(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(oxetan-3-yl)phenyl]phthalazin-l -one;

2-(4-cyclopropylphenyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]phthalazin-l -one;

2-[4-(2-methoxyethoxy)phenyl]-4-[(l-methyl-2-oxo-3-pyridy l)amino]phthalazin-l-one;

2-(4-tert-butylphenyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino ]phthalazin-l-one;

2-(4-tert-butylphenyl)-4-[(2-oxo- lH-pyridin-3-yl)amino]phthalazin- 1 -one;

7- methoxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorom ethoxy)phenyl]phthalazin-l- one;

8- fluoro-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorome thoxy)phenyl]phthalazin-l-one; 5-fluoro-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoro methoxy)phenyl]phthalazin-l-one;

5- methoxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorom ethoxy)phenyl]phthalazin-l- one;

2-(4-tert-butylphenyl)-7-ethyl-4-[(l-methyl-2-oxo-3-pyridyl) amino]phthalazin-l-one;

4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethox y)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluorometh oxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

methyl l-methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6, 7,8-tetrahydrophthalazin- 1 -yl]amino]pyridine-3 -carboxylate;

methyl 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-te trahydrophthalazin-l- yl]amino]-l-pyridyl]acetate;

4-[ [ 1 - [2-(dimethylamino)ethyl] -6-oxo-pyrimidin-5 -yl]amino] -2- [4-(trifluoromethoxy)phenyl] - 5 ,6,7,8-tetrahydrophthalazin- 1 -one; 2-(6-tert-butyl-3-pyridyl)-4-[(l-methyl-2-oxo-3-pyridyl)amin o]-5,6,7,8-tetrahydrophthal^ one;

2-[4-(difluoromethoxy)phenyl]-4-[(l-methyl-2-oxo-3-pyridyl)a mino]-5,6,7,8- tetrahydrophthalazin- 1 -one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(2,6-dimethyl-3-oxo-pyridazin-4-yl)amino]^^

cyclopenta[d]pyridazin-4-one;

l-[(l-methyl-6-oxo-pyrimidin-5-yl)amm^

cyclopenta[d]pyridazin-4-one;

l-[(5-fluoro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(triflu oromethoxy)phenyl]-6,7-dihy cyclopenta[d]pyridazin-4-one;

l-[(l,5-dimethyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluorome thoxy)phenyl]-6,7-dihydro-5H cyclopenta[d]pyridazin-4-one;

l-[(5-chloro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(triflu oromethoxy)phenyl]-6,7-dihydra cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -methyl-2-oxo-5-(trifluoromethyl)-3-pyridyl]am

dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[(5 -ethyl- 1 -methyl-2-oxo-3 -pyridyl)amino] -3 - [4-(trifluoromethoxy)phenyl] -6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(5-isopropyl-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(tri fluoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

methyl 4-[5-chloro-2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6 ,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanoate;

methyl 4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydr o-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanoate;

ethyl 2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyljethoxyjacetate;

1 -[[ 1 -(2-imidazol- 1 -ylethyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluoromethoxy)phen yl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

ethyl 4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]ethyl]morpholine-2-carboxylate;

1 -[[ 1 -[2-(3-methoxypyrrolidin- 1 -yl)ethyl]-2-oxo-3-pyridyl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyr idazin-4-one;

2-[tert-butoxycarbonyl-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluor omethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]ethyl]amino]acetic acid;

1 -[[ 1 -(3-morpholinopropyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluoro methoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one; tert-butyl N-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]ethyl]carbamate;

1 -[ [ 1 - [2-(3 -hydroxyazetidin- 1 -yl)ethyl] -2-oxo-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] - 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[l-(2-hydroxyethyl)-6-oxo-pyrimidin-5-yl]amino]-3-[4-( trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[3-(4-methylpiperazin- 1 -yl)propyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one;

l-[[l-(3-hydroxypropyl)-2-oxo-3-pyridyl]amino]-3-[4-(trif luoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(dimethylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4-( trifluoromethoxy)phenyl]- 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[l-[2-(diethylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino] -3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[6-oxo-l-(2-pyrrolidin-l-ylethyl)pyrimidin-5-yl]amino] -3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

3-(4-tert-butyl-2-fluoro-phenyl)-l-[(l-methyl-2-oxo-3-pyridy l)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-[2-fluoro-4-(trifluoromethyl)phenyl]-l-[(l-methyl-2-oxo-3- pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-(6-ethoxy-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-6 ,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-(6-methoxy-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]- 6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

1 -[(5-fluoro- 1 -methyl-2-oxo-3-pyridyl)amino]-3-(6-methoxy-3-pyridyl)-6,7-d ihydro-5H- cyclopenta[d]pyridazin-4-one;

3-(6-tert-butyl-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)amin o]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3- [4-(difluoromethoxy)phenyl]-l-[(l-methyl-2-oxo-3-pyridyl)ami no]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethyl)phenyl]-6,7-dihy dro-5H- cyclopenta[d]pyridazin-4-one;

6,6-dimethyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifl uoromethoxy)phenyl]-5,7- dihydrocyclopenta[d]pyridazin-4-one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-dih ydro-5H- pyrano[3,4-d]pyridazin-4-one;

4- [(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy )phenyl]-7, 8-dihydro-5H- pyrano[3,4-d]pyridazin-l -one; 4-[(l,6-dimethyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorometho xy)phenyl]phth

4-[(2-methyl-6-oxo- 1 H-pyrimidin-5-yl)am

4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino

4-[(5 -ethyl- 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin-l-one; 4-[(6-methyl-2-oxo-lH-pyridin-3-yl)amino]-2-[4-(M

methyl 3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl]propanoate;

4-[[ 1 -[2-(dimethylamino)ethyl]-2-oxo-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

4-[[ 1 -(2-methoxyethyl)-2-oxo-3-pyridyl]amino]-2-[4-(trifluorometh oxy)phenyl]phthalazin-l -one; 4-[[ 1 -(2-methylsulfonylethyl)-2-oxo-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl 4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl]butanoate;

3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalaz in-l-yl]amino]-l-pyridyl]propane-l- sulfonamide;

N,N-dimethyl-3 - [2-0X0-3 -[ [4-0X0-3 -[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino] - 1 - pyridyljpropane- 1 -sulfonamide;

4-[[l-(2-morpholinoethyl)-2-oxo-3-pyridyl]amino]-2-[4-(trifl uoromethoxy)phenyl]phthalazin-l- one;

4-[[ 1 -[2-[3-hydroxy-3-(trifluoromethyl)azetidin- 1 -yl]ethyl]-2-oxo-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

4-[ [ 1 - [2-(3 -hydroxypyrrolidin- 1 -yl)ethyl] -2-oxo-3 -pyridyl] amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl (2S)-l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]pht halazin-l-yl]amino]-l- pyridyl]ethyl]pyrrolidine-2-carboxylate;

4-[ [ 1 - [2-(dimethylamino)ethyl] -6-oxo-pyrimidin-5 -yl]amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

6-ethyl-4-[( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin- 1 -one; 7-ethyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorom ethoxy)phenyl]phthalazin-l-one;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-6-vinyl -phthalazin-l -one;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-7-vinyl -phthalazin-l -one;

6-acetyl- l-[(l-ethyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluorometho xy)phenyl]-7,8-dihydro-

5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl- 1 -[(6-oxo- 1 -propyl -pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-di hydro-

5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl- l-[(5-fluoro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoro methoxy)phenyl]-7, 8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one; 4-[[l-(2-morpholino-2-oxo-ethyl)-2-oxo-3-pyridyl]amino]-2-[4 - (trifluoromethoxy)phenyl]phthalazin- 1 -one;

N,N-dimethyl -2- [2-0X0-3 -[ [4-0X0-3 -[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino] - 1 - pyridyl] acetamide;

N-isopropyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phe nyl]phthalazin-l-yl]amino]-l- pyridyl] acetamide;

N-methyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazin-l-yl]amino]-l- pyridyl] acetamide;

N-(2-hydroxyethyl)-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy )phenyl]phthalazin-l -yljamino]- 1 -pyridyl] acetamide;

N-[2-(dimethylamino)ethyl]-2-[2-oxo-3-[[4-oxo-3-[4-(trifluor omethoxy)phenyl]phthalazin-l- yl]amino]-l-pyridyl]acetamide;

N-(3 -methoxypropyl)-2- [2-0X0-3 - [ [4-oxo-3 - [4-(trifluoromethoxy)phenyl]phthalazin- 1 - yl]amino]-l-pyridyl]acetamide;

N-methyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl ]phthalazin-l-yl]amino]-l- pyridyl]propanamide;

N,N-dimethyl-3 - [2-0X0-3 -[ [4-0X0-3 -[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yl]amino] - 1 - pyridyl]propanamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazin-l-yl]amino]-l- pyridyl]butanamide;

N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin-l-yl]amino]-l- pyridyl]butanamide;

N,2,2-trimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)ph enyl]phthalazin-l-yl]amino]-l- pyridyl]propanamide;

N,N,2,2-tetramethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromet hoxy)phenyl]phthalazin-l-yl]amino]- 1 -pyridyl]propanamide;

2,2-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin-l-yl]amino]-l- pyridyl]propanamide;

N-methyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl ]phthalazin-l-yl]amino]-l- pyridyl] ethoxy] acetamide;

N,N-dimethyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)ph enyl]phthalazin-l-yl]amino]-l- pyridyl] ethoxy] acetamide;

N-methyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5 ,6,7,8-tetrahydrophthalazin-l- yl]amino]-l-pyridyl]acetamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl ]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanamide;

N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanamide; N-methyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl ]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]ethoxy]acetamide;

N,N-dimethyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy )phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]ethoxy]acetamide;

3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalaz in-l-yl]amino]-l-pyridyl]propanoic acid;

4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl]amino]-l-pyridyl]butanoic acid;

2,2-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin-l -yljamino]- 1- pyridyljpropanoic acid;

2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalaz in-l -yljamino]- 1 - pyridyl]ethoxy] acetic acid;

2-[methyl-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl] phthalazin-l -yljamino]- 1- pyridyl]ethyl]amino]acetic acid;

1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazi n-l -yljamino]- 1 - pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

(2S)-l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]pht halazin-l-yl]amino]-l- pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

(2R)- 1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazi n-l -yl]amino]- 1 - pyridyl] ethyl]pyrrolidine-2-carboxylic acid;

4-[5-chloro-2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6 ,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanoic acid;

4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydr o-5H-cyclopenta[d]pyridazin-l- yl]amino]-l-pyridyl]butanoic acid;

2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin- 1 -yl]amino]-l -pyridyl]ethoxy]acetic acid;

l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethyl]pyrrolidine-3 -carboxylic acid;

l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin- l-yl]amino]-l-pyridyl]ethyl]pyrrolidine-2-carboxylic acid;

4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H-cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethyl]morpholine-2-carboxylic acid;

4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H-cyclopenta[d]pyridazin- 1 -yl]amino] - 1 -pyridyl] ethyl]morpholine-3 -carboxylic acid;

4-[6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H-cyclopenta[d]pyridazin-l- yl]amino]pyrimidin- 1 -yl]butanoic acid;

7-hydroxy-4- [( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin- 1 - one; 6-hydroxy-4- [( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin- 1 - one;

1 -[[ 1 -(morpholin-3-ylmethyl)-6-oxo-pyrim

dihydro-5H-cyclopenta[d]pyridazin-4-one;

l-[[l-[2-(methylamino)ethyl]-6-oxo-pyrim

dihydro-5H-cyclopenta[d]pyridazin-4-one;

2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H-cyclopenta[d]pyridazin- l-yl]amino]-l-pyridyl]ethylamino]acetic acid;

l-[[l-(2-aminoethyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluo romethoxy)phenyl]-6,7-dihydro- cyclopenta[d]pyridazin-4-one;

1 -[ [2-oxo- 1 -(pyrrolidin-2-ylmethyl)-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

6-methyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoro methoxy)phenyl]-7,8-dihydro-5H- pyrido[3,4-d]pyridazin-4-one;

6-methyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(triflu oromethoxy)phenyl]-7,8-dihydro-5H- pyrido [3 ,4-d]pyridazin- 1 -one;

l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethox y)phenyl]-5,6,7,8- tetrahydropyrido [3 ,4-d]pyridazin-4-one;

1 -[[ 1 -[ [(2S)-Morpholin-2-yl]methyl] -2-0X0-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] - 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

6- (2-methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7- (2-methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

5-(2-methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2 -[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazine-6- carboxamide;

7-(l-hydroxyethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-(hydroxymethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-amino-4-[( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin- 1 -one; 7-(aminomethyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-[(dimethylamino)methyl] -4- [( 1 -methyl -2 -oxo-3 -pyridyl)amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

6-(2-hydroxypropyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4 -(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-(2-hydroxy-2-methyl-propyl)-l-[(l-methyl-2-oxo-3-pyridyl)a mino]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-4-one;

6-(2-hydroxyethyl)-l-[(l -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoro methoxy)phenyl]-7,8-dih^ pyrido[3,4-d]pyridazin-4-one;

6-acetyl-4-[(l-methyl-2-oxo-3-pyridyl)amm^

pyrido [3 ,4-d]pyridazin- 1 -one;

6-acetyl- 1 - [( 1 -methyl-6-oxo-pyrimidin-5 -yl)amino] -3 -[4-(trifluoromethoxy)phenyl] -7, 8-dihydro- 5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl-4-[(l-methyl-6-oxo-pyrimidin-5-yl)amm^

5H-pyrido[3 ,4-d]pyridazin- 1 -one;

methyl 4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-(trifluoromet hoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazine-6-carboxylate;

methyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromet hoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazine-6-carboxylate;

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-l -oxo-2-[4-(trifluoromethoxy )phenyl]-7, 8-dihydro-5H- pyrido[3,4-d]pyridazine-6-carbaldehyde;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromethoxy )phenyl]-7, 8-dihydro-5H- pyrido[3,4-d]pyridazine-6-carbaldehyde;

1- [(l-methyl-2-oxo-3-pyridyl)amino]-6-methylsulfonyl-3-[4-(tri fluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

4-[(l-methyl-2-oxo-3-pyridyl)amino]-6-methylsulfonyl-2-[4-(t rifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-l-one;

6-ethyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluorom ethoxy)phenyl]-7,8-dihydro-5H- pyrido [3, 4-d]pyridazin-4-one;

6- isopropyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluor omethoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazin-4-one;

N-methyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-( trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazine-6-carboxamide;

N-methyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(tri fluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazine-6-carboxamide;

2- [4-(l -hydroxy- 1 -methyl-ethyl)phenyl] -4-[( 1 -methyl-2-oxo-3-pyridyl)amino]phthalazin- 1 -one; 4-[ [ 1 -(2-hydroxyethyl)-2-oxo-3 -pyridyl] amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin- 1 -one;

7- hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorom ethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

6-hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluor omethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

1 -[[ 1 -(3-amino-2-hydroxy-2-methyl-propyl)-2-oxo-3-pyridyl]amino]- 3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one;

1 -[ [2-Oxo- 1 -(2-oxo-2-piperazin- 1 -yl-ethyl)-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] - 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(Oxetan-3-ylamino)ethyl]-2-oxo-3-pyridyl]amino]-3-[4-(tr ifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(3-Hydroxyazetidin- 1 -yl)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one;

trans- 1 - [[ 1 -[(5 -Amino- 1 ,3-dioxan-2-yl)methyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one;

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-3-[2-methyl-4-(triflu oromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-(3,4-Dimethoxyphenyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]- 6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-[3-Methoxy-4-(trifluoromethyl)phenyl]-l-[(l-methyl-2-oxo-3 -pyridyl)amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

N,l-Dimethyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]- 5,6,7,8-tetrahydrophthalazin-l- yl]amino]pyridine-3-carboxamide;

N,l-Dimethyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin-l-yl]amino]pyridine-

3- carboxamide;

4- [[ 1 -methyl-2-oxo-5-(trifluoromethyl)-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

and pharmaceutically acceptable salts thereof.

Even more particular compounds of formula (I) of the present invention are those selected from the group consisting of:

4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]phthalaz in-l -one;

methyl 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl] acetate;

methyl (2R)- 1 -[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazi n- 1 -yl]amino]-l - pyridyl]ethyl]pyrrolidine-2-carboxylate;

7-methoxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluor omethoxy)phenyl]phthalazin-l- one;

2-(4-tert-butylphenyl)-7-ethyl-4-[(l-methyl-2-oxo-3-pyrid yl)amino]phthalazin-l-one;

4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethox y)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one; 4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluorometh oxy)phenyl]-5,6,7 tetrahydrophthalazin- 1 -one;

methyl 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-te trahydrophthalazin-l- yl]amino]-l-pyridyl]acetate;

4-[[ 1 -[2-(dimethylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]-2-[4-( trifluoromethoxy)phenyl]- 5 ,6,7,8-tetrahydrophthalazin- 1 -one;

2-(6-tert-butyl-3-pyridyl)-4-[(l-methyl-2-oxo-3-pyridyl)amin o]-5,6,7,8-tetrahydrophthalazin-l- one;

2-[4-(difluoromethoxy)phenyl]-4-[(l-methyl-2-oxo-3-pyridyl)a mino]-5,6,7,8- tetrahydrophthalazin- 1 -one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(2,6-dimethyl-3-oxo-pyridazin-4-yl)amino]-3-[4-(triflu oromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluorom ethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(5-fluoro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(triflu oromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(l,5-dimethyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluorome thoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(5-chloro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(triflu oromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

methyl 4-[5-chloro-2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6 ,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanoate;

methyl 4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydr o-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanoate;

1 -[[ 1 -[2-(3-methoxypyrrolidin- 1 -yl)ethyl]-2-oxo-3-pyridyl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyr idazin-4-one;

1 -[[ 1 -(3-morpholinopropyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluoro methoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[ [ 1 - [2-(3 -hydroxyazetidin- 1 -yl)ethyl] -2-oxo-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] -

6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[3-(4-methylpiperazin- 1 -yl)propyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one;

l-[[l-(3-hydroxypropyl)-2-oxo-3-pyridyl]amino]-3-[4-(trif luoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[2-(dimethylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]-3-[4-( trifluoromethoxy)phenyl]- 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one; 1 -[[ 1 -[2-(diethylamino)ethyl]-6-oxo-pyrim

dihydro-5H-cyclopenta[d]pyridazin-4-one;

3- (4-tert-butyl-2-fluoro-phenyl)-l-[(l-methyl-2-oxo-3-pyridyl) amino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

3-(6-tert-butyl-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)a mino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethyl)phenyl]-6,7-dihy dro-5H- cyclopenta[d]pyridazin-4-one;

4- [(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-7,8-dih ydro-5H- pyrano[3,4-d]pyridazin-l-one;

4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluorometh oxy)phenyl]phthalazin-l-one; 4-[[ 1 -[2-(dimethylamino)ethyl]-2-oxo-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

4-[[ 1 -(2-methylsulfonylethyl)-2-oxo-3-pyridyl]amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl 4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -yljamino]- 1 - pyridyl]butanoate;

3- [2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl]amino]-l-pyridyl]propane-l- sulfonamide;

N,N-dimethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)ph enyl]phthalazin-l-yl]amino]-l- pyridyl]propane- 1 -sulfonamide;

4- [[l-(2-morpholinoethyl)-2-oxo-3-pyridyl]amino]-2-[4-(trifluo romethoxy)phenyl]phthalazin-l- one;

4-[ [ 1 - [2-(3 -hydroxypyrrolidin- 1 -yl)ethyl] -2-oxo-3 -pyridyl] amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

methyl (2S)-l-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]pht halazin-l -yljamino]- 1- pyridyl]ethyl]pyrrolidine-2-carboxylate;

6-acetyl- 1 -[(6-oxo- 1 -propyl -pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-di hydro- 5H-pyrido[3,4-d]pyridazin-4-one;

6-acetyl- l-[(5-fluoro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoro methoxy)phenyl]-7, 8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

4-[[l-(2-morpholino-2-oxo-ethyl)-2-oxo-3-pyridyl]amino]-2 -[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

N,N-dimethyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin-l-yl]amino]-l- pyridyl] acetamide;

N-methyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazin-l-yl]amino]-l- pyridyl]acetamide;

N-(3 -methoxypropyl)-2- [2-0X0-3 - [ [4-oxo-3 - [4-(trifluoromethoxy)phenyl]phthalazin- 1 - yl]amino]-l-pyridyl]acetamide;

N,N-dimethyl-3 - [2-0X0-3 -[ [4-0X0-3 -[4-(M

pyridyl]propanamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazin-l-yl]amino]-l^ pyridyl]butanamide;

N,N-dimethyl -4- [2-0X0-3 -[ [4-0X0-3 -[4-(trifl

pyridyl]butanamide;

N,N,2,2-tetramethyl-3-[2-oxo-3-[[4-oxo-3-[4-(trif^

1 -pyridyl]propanamide;

N-methyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phe nyl]phthalazin-l -yljamino]- 1 - pyridyl] ethoxy] acetamide;

N,N-dimethyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)ph enyl]phthalazin- pyridyl] ethoxy] acetamide;

N-methyl-2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5 ,6,7,8-tetrahydrophthalazin-l- yl]amino]- 1 -pyridyl]acetamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6 ,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanamide;

N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl]butanamide;

N-methyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phe nyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl] ethoxy] acetamide;

N,N-dimethyl-2-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy )phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yl]amino]- 1 -pyridyl] ethoxy] acetamide;

1 -[[ 1 -(morpholin-3-ylmethyl)-6-oxo-pyrimidin-5-yl]amino]-3-[4-(tr ifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

1 -[ [2-oxo- 1 -(pyrrolidin-2-ylmethyl)-3 -pyridyl] amino] -3 - [4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one;

7-(l-hydroxyethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-

(trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-(hydroxymethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4-

(trifluoromethoxy)phenyl]phthalazin- 1 -one;

7-amino-4-[( 1 -methyl-2-oxo-3 -pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl]phthalazin- 1 -one;

6- acetyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluorome thoxy)phenyl]-7,8-dihydro-5H- pyrido[3,4-d]pyridazin-4-one;

methyl 4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-(trifluoromet hoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazine-6-carboxylate;

7- hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorom ethoxy)phenyl]-5,6,7,8;

tetrahydrophthalazin- 1 -one; 6-hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluor omethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

1 -[[ 1 -[2-(Oxetan-3-ylamino)ethyl]-2-oxo-3-pyridyl]amino]-3-[4-(tr ifluoromethoxy)phenyl] dihydro-5H-cyclopenta[d]pyridazin-4-one;

and pharmaceutically acceptable salts thereof.

Most particular compounds of formula (I) of the present invention are those selected from the group consisting of:

7-methoxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluor omethoxy)phenyl]phthalazin-l- one;

2-(4-tert-butylphenyl)-7-ethyl-4-[(l-methyl-2-oxo-3-pyridyl) amino]phthalazin-l-one;

4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethox y)phenyl]-5,6,7,8- tetrahydrophthalazin- 1 -one;

4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluorometh oxy)phenyl]-5,6,7,8- tetrahydrophthalazin-l-one;

4-[ [ 1 - [2-(dimethylamino)ethyl] -6-oxo-pyrimidin-5 -yljamino] -2- [4-(trifluoromethoxy)phenyl] - 5 ,6,7,8-tetrahydrophthalazin- 1 -one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin-4-one;

1 -[(5-fluoro- l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)pheny l]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(l,5-dimethyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluorome thoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

l-[(5-chloro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(triflu oromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

1 -[[ 1 -[3-(4-methylpiperazin- 1 -yl)propyl]-2-oxo-3-pyridyl]amino]-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyr idazin-4-one;

l-[[l-(3-hydroxypropyl)-2-oxo-3-pyridyl]amino]-3-[4-(trif luoromethoxy)phenyl]-6,7-dihydro-

5H-cyclopenta[d]pyridazin-4-one;

3-(6-tert-butyl-3-pyridyl)-l-[(l-methyl-2-oxo-3-pyridyl)a mino]-6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one;

1-[(1 -methyl -2 -oxo-3-pyridyl)amino]-3-[4-(trifluoromethyl)phenyl]-6,7-dihy dro-5H- cyclopenta[d]pyridazin-4-one;

6-acetyl- l-[(5-fluoro-l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoro methoxy)phenyl]-7, 8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazin-l-yl]amino]-l- pyridyl]butanamide; N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]phthalazin-l-yl]amino]- pyridyl]butanamide;

N-methyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6 ,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanamide;

N,N-dimethyl-4-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)pheny l]-6,7-dihydro-5H- cyclopenta[d]pyridazin- 1 -yljamino]- 1 -pyridyl]butanamide;

7-(hydroxymethyl)-4-[(l -methyl -2 -oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin- 1 -one;

and pharmaceutically acceptable salts thereof.

Manufacturing Process General Procedure

(V) (VI) (VII)

Scheme 1. A method for the synthesis of compounds of formula (I) starts from the corresponding phthalazine or pyridazine diones of formula (II). In step 1 of the reaction sequence (scheme 1) the diones are converted into their corresponding monotriflates of formula (III) using methods well known to someone skilled in the art, e.g. reaction with triflic anhydride under basic conditions. Typically used bases are pyridine and triethylamine. The reaction is typically carried out in solvents such as acetonitrile or dichloromethane at temperatures between 0 °C and 100 °C.

In step 2, the obtained compounds of formula (III) are converted with the appropriate aryl boronic acid into the compounds of formula (IV) using methods well known to someone skilled in the art, e.g. with copper (II) acetate under basic conditions. A typically used base is triethylamine and the reaction is carried out in a suitable aprotic solvent such as THF at temperatures between 0 °C and 100 °C.

In step 3, the obtained compounds of formula (IV) are converted with the appropriate aryl amine into the compounds of formula (I) using methods well known to someone skilled in the art, e.g palladium-mediated amination of aryl triflates or aryl bromides or aryl chlorides. The reaction is typically carried out in solvents such as THF, dioxane, DME at temperatures between 40 °C and 110 °C. Typically used bases are caesium carbonate, triethylamine, sodium tert- butoxide and appropriately ligated palladium (0) species can be generated using reagents such as palladium acetate, palladium dichloride, palladium tetrakis-triphenylphosphine,

tris(dibenzylideneacetone)dipalladium, bis-triphenylphosphine palladium dichloride in

conjunction with phosphine based ligands such as 4,5-bis(diphenylphosphino)-9,9- dimethylxanthene (Xantphos), 2,2'-bis(diphenylphosphino)-l, -binaphthyl (BINAP), and 2-(di- tert-butylphosphino)biphenyl.

An alternative method for the synthesis of compounds of formula (I) starts from the corresponding cyclic anhydride of formula (V). In step 4 of scheme 1, the anhydrides are converted with the appropriate hydrazine derivatives, into their corresponding phthalazine or pyridazine diones of formula (VI) using methods well known to someone skilled in the art. The reaction is typically carried out in aprotic solvents such as THF, DMF, NMP or protic solvents such as acetic acid, ethanol, and isopropanol and temperatures between 0 °C and 190 °C. The hydrazine derivative may optionally be a salt, for example a hydrochloride salt. In certain cases the reaction produces a mixture of the corresponding compound of formula (VI) and the corresponding imide which can be converted to the compound of formula (VI) using methods well known to someone skilled in the art, e.g. reaction with a base in a protic solvent. The reaction is typically carried out with bases such as sodium ethoxide in solvents such as ethanol at temperatures between 0 °C and room temperature.

In step 5, the obtained compounds of formula (VI) are converted into the corresponding triflate of formula (IV) using methods well known to someone skilled in the art. Typical reaction conditions are the same as those used for step 2 described above.

An alternative method for the conversion of the diones of formula (VI) into the compounds of formula (I) proceeds via the corresponding bromides or chlorides of formula (VII). In step 6 of scheme 1 the diones are converted into the corresponding bromides or chlorides using methods well known to someone skilled in the art. The reaction is typically carried out with reagents such as phosphorus oxybromide or phosphorus oxychloride in solvents such as dichloromethane or dicholorethane at temperatures between 0 °C and 120 °C. In step 7, the obtained compounds of formula (VII) are converted into the corresponding compounds of formula (I) using methods well known to someone skilled in the art. Typical reaction conditions are the same as those used for step 3 as described above.

A particular embodiment of the invention relates to a process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof as defined herein, comprising a palladium-mediated amination reaction of a compound of formula (IV), wherein X, Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein and wherein TfO represents trifluoromethanesulfonate (triflate, CF 3 SO 3 ). Particularly, the palladium-mediated amination reaction of a compound of formula (IV) is carried out in solvents such as THF, dioxane, DME; at temperatures between 40 °C and 1 10 °C; in the presence of a base such as caesium carbonate, triethylamine, sodium tert-butoxide; and an appropriately ligated palladium (0) species; wherein the ligated palladium (0) species is generated using a palladium reagent such as palladium acetate, palladium dichloride, palladium tetrakis-triphenylphosphine, tris(dibenzylideneacetone)dipalladium, bis-triphenylphosphine palladium dichloride in conjunction with phosphine based ligands such as 4,5- bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), 2,2'-bis(diphenylphosphino)- 1 , Γ- binaphthyl (BINAP), and 2-(di-tert-butylphosphino)biphenyl.

(IV) (I)

Another particular embodiment of the invention relates to a process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof as defined herein, comprising a palladium-mediated amination reaction of a compound of formula (VII), wherein X, Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 4 and R 6 to R 8 are as described herein.

Particularly, the palladium-mediated amination reaction of a compound of formula (VII) is carried out in solvents such as THF, dioxane, DME; at temperatures between 40 °C and 110 °C; in the presence of a base such as caesium carbonate, triethylamine, sodium tert-butoxide; and an appropriately ligated palladium (0) species; wherein the ligated palladium (0) species is generated using a palladium reagent such as palladium acetate, palladium dichloride, palladium tetrakis-triphenylphosphine, tris(dibenzylideneacetone)dipalladium, bis-triphenylphosphine palladium dichloride in conjunction with phosphine based ligands such as 4,5- bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), 2,2'-bis(diphenylphosphino)-l,l'- binaphthyl (BINAP), and 2-(di-tert-butylphosphino)biphenyl.

Pharmaceutical Compositions

Another embodiment provides pharmaceutical compositions or medicaments comprising the compounds of the invention and a therapeutically inert carrier, diluent or pharmaceutically acceptable excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments.

Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.

The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

The compounds of the present invention may be administered in any convenient

administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may comprise

components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents, antioxidants, and further active agents. They can also comprise still other therapeutically valuable substances.

A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel H.C. et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, Philadelphia; Gennaro A.R. et al, Remington: The Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C, Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament). The dosage at which compounds of the invention can be administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.01 to 1000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.

An example of a suitable oral dosage form is a tablet comprising about 100 mg to 500 mg of the compound of the invention compounded with about 30 to 90 mg anhydrous lactose, about 5 to 40 mg sodium croscarmellose, about 5 to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 to 10 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment.

An example of an aerosol formulation can be prepared by dissolving the compound, for example 10 to 100 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such as sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 μιη filter, to remove impurities and contaminants.

Therapeutic Uses

As described above, the compounds of formula (I) and their pharmaceutically acceptable salts possess valuable pharmacological properties and are particularly useful for treating, ameliorating, or preventing viral diseases.

The compounds of the present invention can be used, either alone or in combination with other drugs, for the treatment or prevention of viral diseases. Examples of possible viral diseases include, but are not limited to, viral diseases which are caused by Poxviridae, Herpesviridae, Adenoviridae, Papillomaviridae, Polyomaviridae, Parvoviridae, Hepadnaviridae, Reoviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Orthomyxoviridae, Bunyaviridae, Arenaviridae, Coronaviridae, Picornaviridae, Hepeviridae, Caliciviridae, Astroviridae, Togaviridae,

Flaviviridae, Deltavirus, Bornaviridae, and prions. Preferably viral diseases which are caused by Herpesviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Orthomyxoviridae, Bunyaviridae, Arenaviridae, Coronaviridae, Picornaviridae, Togaviridae, and Flaviviridae. Particularly, the compounds of the present invention can be used, either alone or in combination with other drugs, for the treatment or prevention of viral diseases which are caused by orthomyxoviridae.

Viruses to be treated include, but are not limited to, the viruses given in the Table 1 : Family Viruses (particular examples)

Smallpox virus

Poxviridae

Molluscum contagiosum virus

Herpes simplex virus

Varicella zoster virus

Herpesviridae Cytomegalovirus

Epstein Barr virus

Kaposi's sarcoma-associated herpesvirus

Adenoviridae Human adenovirus A-F

Papillomaviridae Papillomavirus

BK-virus

Polyomaviridae

JC-Virsu

B19 virus

Parvoviridae

Adeno associated virus 2/3/5

Hepadnaviridae Hepatitis B virus

Reovirus 1/2/3

Reoviridae Rotavirus A/B/C

Colorado tick fever virus

Ebola virus

Filoviridae

Marburg virus

Parainfluenza virus 1-4

Mumps virus

Paramyxoviridae Measles virus

Respiratory syncytial virus

Hendravirus

Vesicular stomatitis virus

Rabies virus

Rhabdoviridae Mokola virus

European bat virus

Duvenhage virus

Orthomyxoviridae Influenza virus types A-C

California encephalitis virus

La Crosse virus

Hantaan virus

Puumala virus

Sin Nombre virus

Bunyaviridae Seoul virus

Crimean- Congo hemorrhagic fever virus

Sakhalin virus

Rift valley virus

Sandfly fever virus

Uukuniemi virus

Lassa virus

Arenaviridae

Lymphocytic choriomeningitis virus Family Viruses (particular examples)

Guanarito virus

Junin virus,

Machupo virus

Sabia virus

Coronaviridae Human coronavirus

Human enterovirus types A-D (Poliovirus,

Echovirus, Coxsackie virus A/B)

Pvhino virus types A/B/C

Picornaviridae

Hepatitis A virus

Parechovirus

Food and mouth disease virus

Hepeviridae Hepatitis E virus

Norwalk virus

Caliciviridae

Sapporo virus

Astro viridae Human astrovirus 1

Ross River virus

Chikungunya virus

Togaviridae

O'nyong-nyong virus

Rubella virus

Tick-borne encephalitis virus

Dengue virus

Yellow Fever virus

Japanese encephalitis virus

Murray Valley virus

Flaviviridae

St. Louis encephalitis virus

West Nile virus

Hepatitis C virus

Hepatitis G virus

Hepatitis GB virus

Deltavirus Hepatitis deltavirus

Bornaviridae Bornavirus

Prions

Table 1. Viruses to be treated by the compounds of formula (I).

Preferably, the compounds of the present invention are employed to treat influenza. The present invention covers all virus genera belonging to the family of orthomyxoviridae, specifically influenza virus type A, B, and C, isavirus, and thogotovirus. Within the present invention, the term "influenza" includes influenza caused by any influenza virus such as influenza virus type A, B, and C including their various stains and isolates, and also covers influenza A virus strains commonly referred to as bird flu and swine flu. The subject to be treated is not particularly restricted and can be any wertebrate, such as birds and mammals (including humans). Without wishing to be bound by theory it is assumed that the compounds of the present invention are capable of inhibiting pathogens using the cellular endocytic pathway at some point in their life cycle, particularly that of influenza virus. More specifically it is assumed that they directly interfere with the trafficking of the virus in the cellular endosomes, which is essential for influenza virus replication.

The compounds having the general formula (I) can be used in combination with one or more other medicaments. The type of the other medicaments is not particularly limited and will depend on the disorder to be treated. Preferably, the other medicament will be a further medicament which is useful in treating, ameliorating or preventing a viral disease, more preferably a further medicament which is useful in treating, ameliorating or preventing influenza that has been caused by influenza virus infection and conditions associated with this viral infection such as viral pneumonia or secondary bacterial pneumonia and medicaments to treat symptoms such as chills, fever, sore throat, muscle pains, severe headache, coughing, weakness and fatigue. Furthermore, the compounds having the general formula (I) can be used in combination with anti-inflammatories.

Widespread resistance to both classes of licensed influenza antivirals (M2 ion channel inhibitors (adamantanes) and neuraminidase inhibitors (e.g. oseltamivir)) occurs in both pandemic and seasonal emerging influenza strains, rendering these drugs to be of marginal utility in the treatment modality. For M2 ion channel inhibitors, the frequency of viral resistance has been increasing since 2003 and for seasonal influenza A/H3N2, adamantanes are now regarded as ineffective. Virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to adamantanes (rimantadine and amantadine), and for oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI), WHO reported on significant emergence of influenza A/H1N1 resistance starting in the influenza season 2007/2008; and for the second and third quarters of 2008 in the southern hemisphere. Even more serious numbers were published for the fourth quarter of 2008 (northern hemisphere) where 95% of all tested isolates revealed no oseltamivir- susceptibility. Considering the fact that now most national governments have been stockpiling NAIs as part of their influenza pandemic preparedness plan, it is obvious that the demand for new, effective drugs is growing significantly. To address the need for more effective therapy, preliminary studies using double or even triple combinations of antiviral drugs with different mechanisms of action have been undertaken. Adamantanes and neuraminidase inhibitors in combination were analysed in vitro and in vivo and were found to act highly synergistically. However, it is known that for both types of antivirals resistant viruses emerge rather rapidly and this issue is not tackled by combining these established antiviral drugs. In general, compounds targeting a host factor lead to less generation of viral resistance.

Indeed, there is no pressure on cell to mutate its own factor hijacked by the virus and it is unlikely that the virus will mutate to alleviate its need to this required cellular factor. However, combination therapy may still be advantageous by decreasing the dose of each drug taken individually. Combining a drug that target the host (the present compound) and a drug with a different mechanism of action will increase the probablity of synergism. The following medicaments may therefore be considered as potential options for combination therapy with the present compounds:

(i) The combination with direct acting antivirals such as endonuclease or with cap-binding inhibitors (targeting directly influenza). The endonuclease inhibitors are not particularly limited and can be any endonuclease inhibitor, particularly any viral endonuclease inhibitor. Preferred endonuclease inhibitors are those as defined in the US applications with the serial numbers 61/550,045 (filed on October 21, 2011), 61/650,713 (filed on May 23, 2012), 61/650,725 (filed on May 23, 2012) and 61/679,968 (filed on August 6, 2012). The complete disclosure of these applications is incorporated herein by reference. In particular, all descriptions with respect to the general formula of the compounds according to these US applications, the preferred embodiments of the various substituents as well as the medical utility and advantages of the compounds are incorporated herein by reference.

The cap-binding inhibitors are not particularly limited either and can be any cap-binding inhibitor, particularly any viral cap-binding inhibitor. Preferred cap-binding inhibitors are those having the general formula (II) as defined in US application 61/550,057 (filed on October 21, 2011) and/or the compounds disclosed in WO2011/000566, the complete disclosure of which is incorporated by reference. In particular, all descriptions with respect to the general formula of the compounds according to US 61/550,057 or WO2011/000566, the preferred embodiments of the various substituents as well as the medical utility and advantages of the compounds are incorporated herein by reference.

Both active sites are highly conserved among all influenza A strains (e.g., avian and human) and even influenza B viruses, and hence this high degree of sequence conservation underpins the perception that these targets are not likely to trigger rapid resistant virus generation.. Thus, endonuclease and cap-binding inhibitors individually and in

combination are ideal drug candidates to combat both seasonal and pandemic influenza, irrespectively of the virus strain.

(ii) Combinaison with compounds interfering with viral replication:

favipiravir and analogues, epigallocatechin gallate and analogues, as well as nucleoside analogs such as ribavirine.

(iii) The combination with neuraminidase inhibitors:

Based on the fact that the present compound acts on a cellular target and that NAI act on the virus, one can anticipate that their combination will lead to synergistial antiviral activity. This highly efficient drug combination would result in lower substance

concentrations and hence improved dose-response-relationships and better side effect profiles.

The neuraminidase inhibitor (particularly influenza neuramidase inhibitor) is not specifically limited. Examples include zanamivir, oseltamivir, peramivir, KDN DANA, FAN A, and cyclopentane derivatives.

The combination with M2 channel inhibitors:

Based on the fact that the present compound acts on a cellular target and that M2 ion channel blockers act on the virus, one can anticipate that their combination will lead to synergistial antiviral activity.This highly efficient drug combination would result in lower substance concentrations and hence improved dose-response-relationships and better side effect profiles. The M2 channel inhibitor (particularly influenza M2 channel inhibitor) is not specifically limited. Examples include amantadine and rimantadine.

The combination with alpha glucosidase inhibitors:

This highly efficient drug combination would result in lower substance concentrations and hence improved dose-response-relationships and better side effect profiles.

The alpha glucosidase inhibitor is not specifically limited. Examples include the compounds described in Chang et al, Antiviral Research 2011, 89, 26-34.

The combination with ligands of other influenza targets

Based on the fact that the present compound acts on a cellular target and that other compounds act on the virus, one can anticipate that their combination will lead to synergistial antiviral activity.

Examples include compounds acting on the sialidase fusion protein (e.g., Fludase

(DAS 181), siRNAs and phosphorothioate oligonucleotides).

) The combination with a compound used as an adjuvant to minimize the symptoms of the disease (antibiotics, anti-inflammatory agents like COX inhibitors (e.g., COX-l/COX-2 inhibitors, selective COX-2 inhibitors), lipoxygenase inhibitors, EP ligands (particularly EP4 ligands), bradykinin ligands, and/or cannabinoid ligands (e.g., CB2 agonists)). This combination is expected to act synergistically because these different types of drugs exhibit completely different mechanisms of action requiring different pharmacokinetic properties which act advantageously and synergistically on the antiviral efficacy of the combination.

' ) The combination with compounds modulating the cytokine storm triggered by the virus. Viral diseases which are suitable to be treated or prevented by the compounds of present inventioninclude, but are not limited, to the diseases given in the following Table 2:

Type Family Viral Disease

gastroenteritis

keratoconjunctivitis

pharyngitis

Adenovirus Adenoviridae croup

pharyngoconjunctival fever

pneumonia

cystitis

Hand, foot and mouth disease

pleurodynia

Coxsackievirus Picornaviridae aseptic meningitis

pericarditis

myocarditis

infectious mononucleosis

Epstein-Barr Burkitt's lymphoma

Herpesviridae

virus Hodgkin's lymphoma

nasopharyngeal carcinoma

Hepatitis A virus Picornaviridae acute hepatitis

acute hepatitis

chronic hepatitis

Hepatitis B virus Hepadnaviridae

hepatic cirrhosis

hepatocellular carcinoma

acute hepatitis

chronic hepatitis

Hepatitis C virus Flaviviridae

hepatic cirrhosis

hepatocellular carcinoma

herpes labialis, cold sores

Herpes simplex gingivostomatitis in children

Herpesviridae

virus, type 1 tonsillitis & pharyngitis in adults

keratoconjunctivitis

Herpes simplex Skin vesicles, mucosal ulcers

Herpesviridae

virus, type 2 Aseptic meningitis

Cytomegaloviru infectious mononucleosis

Herpesviridae

s Cytomegalic inclusion disease

Human Kaposi sarcoma

herpesvirus, type Herpesviridae multicentric Castleman disease

8 primary effusion lymphoma

HIV Retroviridae AIDS

influenza

Influenza virus Orthomyxoviridae

Reye syndrome

measles

Measles virus Paramyxoviridae

postinfectious encephalomyelitis

Mumps virus Paramyxoviridae mumps Type Family Viral Disease

hyperplastic epithelial lesions such as

plantar and anogenital warts, laryngeal

Human

Papillomaviridae papillomas, andepidermodysplasia verruciformis papillomavirus

Malignancies such as cervical carcinoma and squamous cell carcinomas

croup

Parainfluenza pneumonia

Paramyxoviridae

virus bronchiolitis

common cold

Poliovirus Picornaviridae poliomyelitis

Rabies virus Rhabdoviridae rabies (fatal encephalitis)

bronchiolitis

Respiratory pneumonia

Paramyxoviridae

syncytial virus influenza-like syndrome

severe bronchiolitis with pneumonia

congenital rubella

Rubella virus Togaviridae

German measles

chickenpox

Varicella-zoster

Herpesviridae herpes zoster

virus

Congenital varicella syndrome

Table 2. Viral diseases to be treated by the compounds of formula (I).

A particular embodiment of the invention also relates to a pharmaceutical composition comprising a compound of formula (I) as described herein and at least one pharmaceutically acceptable excipient.

A particular embodiment of the invention also relates to a compound of formula (I) as described herein for use as therapeutically active substances.

A particular embodiment of the invention also relates to a compound of formula (I) as described herein for use in the treatment or prevention of viral diseases, particularly for use in the treatment or prevention of the viral diseases as listed in Table 2, most particularly for use in the treatment or prevention of influenza.

In another embodiment, the invention relates to a method for the treatment or prevention of viral diseases, which method comprises administering a compound of formula (I) as described herein to a human being or animal.

In another embodiment, the invention relates to a method for the treatment or prevention of viral diseases as listed in Table 2, most particularly for treatment or prevention of influenza, which method comprises administering a compound of formula (I) as described herein to a human being or animal.

The invention also embraces the use of a compound of formula (I) as described herein for the treatment or prevention of viral diseases, particularly for the treatment or prevention of viral diseases as listed in Table 2, most particularly for treatment or prevention of influenza. The invention also relates to the use of a compound of formula (I) as described herein for the preparation of medicaments useful for the treatment or prevention of viral diseases, particularly useful for the treatment or prevention of viral diseases as listed in Table 2, most particularly for treatment or prevention of influenza.

Examples

The following examples 1 - 177 are provided for illustration of the invention. They should not be considered as limiting the scope of the invention, but merely as being representative thereof.

Intermediate 1

[4-Oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl] trifluoromethanesulfonate

A solution of (4-oxo-3H-phthalazin-l-yl) trifluoromethanesulfonate (CAS 1781216-89-4, 5.0 g, 17.0 mmol), [4-(trifluoromethoxy)phenyl]boronic acid (CAS 139301-27-2, 3.5 g, 17.0 mmol), Cu(AcO) 2 (6.1 g, 34.0 mmol) and Et 3 N (5.1 g, 51.0 mmol) in THF was stirred at 15 °C for 40 h. The solvents were removed and the residue was purified by silica gel chromatography (petroleum ether: EtOAc =15: 1/5: 1) to give the title compound (3.0 g, 38.9%) as a white solid. MS (m/e): 455.0 (M+H) + . In analogy to Intermediate 1 compounds of the following table were prepared using different boronic acids as reactants:

Intermediate 7: 1H NMR: (CDC1 3 , 400MHz) δ 8.52-8.45 (m, 1H), 7.95-7.82 (m, 3H), 7.52 (d, J=8.4 Hz, 1H), 7.43 (d, J=8.7 Hz, 1H), 1.29 (s, 9H). Intermediate 8: 1H NMR: (CDC1 3 , 400MHz) δ 8.10 (d, J=7.8 Hz, 1 H), 7.79 - 7.70 (m, 3

H), 7.51-7.45 (m, 2 H), 7.44-7.30 (m, 6 H), 7.09 (d, J=8.5 Hz, 1 H), 6.82 (d, J=8.8 Hz, 1 H), 5.43 (s, 2 H).

Intermediate 9

[4-Oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclope nta[d]pyridazin-l-yl] trifluoromethanesulfonate

Step 1: 3-[4-(trifluoromethoxy)phenyl]-2,5, 6, 7-tetrahydrocyclopenta[d]pyridazine-l,4- dione

A mixture of 5,6-dihydro-4H-cyclopenta[c]furan-l,3-dione (CAS 3205-94-5; 276 mg, 2.0 mmol) and [4-(trifluoromethoxy)phenyl]hydrazine hydrochloride (CAS 133115-72-7; 456 mg, 2.0 mmol) was dissolved in MP (5 mL). The mixture was heated to 180 °C and reacted for 20 min. The reaction was cooled to 30 °C and poured onto water (30 mL). The product was precipitated and then filtered. The solid was washed with H 2 0 (10 mL x 3). The solid was dissolved in DCM (50 mL) and dried over Na 2 S0 4 . The solvent was evaporated to give the title compound (500 mg, yield: 80%) as a off-white solid which was used in the next step without further purification.

Step 2: [4-oxo-3-[4-(trifluoromethoxy)phenyl]-6, 7-dihydro-5H-cyclopenta[d]pyridazin-l- ylj trifluoromethanesulfonate

To a solution of 3-[4-(trifluoromethoxy)phenyl]-2,5,6,7- tetrahydrocyclopenta[d]pyridazine-l,4-dione (500 mg, 1.6 mmol) and triethylamine (323 mg, 3.20 mmol) in DCM (10 mL) was added trifluoromethanesulfonic anhydride (542 mg, 1.92 mmol) at 0 °C. After addition, the reaction was warmed to 30 °C and stirred for 1 h. The reaction was quenched with H 2 0 (20 mL) and extracted with DCM (20 mL). The organic phase was evaporated and purified by column chromatography (petroleum ether: EtOAc=10: l) to give the title compound (480 mg, yield: 54%) as a white solid. 1H MR: (DMSO, 400MHz) δ 11.38 (br., s, 1H), 7.73-7.70 (d, J=5.2 H z , 2H), 7.69-7.45 (d, J=3.6 H z , 2H), 2.85-2.76 (t, J=15.2 H z , 4H), 2.13-2.05 (td, J=15.2 H z , 2H). MS (m/e): 444.1 (M+H) + .

In analogy to Intermediate 9 compounds of the following table were prepared using different diones and hydrazine hydrochlorides as reactants:

Intermediate 11 : 1H NMR: (CDC1 3 , 400MHz) δ 7.66 (m, J=9.0 Hz, 2H), 7.22 (d, J=9.0 Hz, 2H), 6.55 (t, J=76 Hz 1H), 2.74-2.58 (m, 4H), 1.91-1.81 (t, J=2.8 Hz, 4H). Intermediate 16: 1H NMR: (CDC1 3 , 400MHz) δ 7.76 - 7.70 (m, 2H), 7.70 - 7.63 (m, 2H),

3.05 - 2.94 (m, 4H), 2.22 (q, J=7.7 Hz, 2H).

Intermediate 23

[4-Oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydrophth alazin-l-yl]

trifluoromethanesulfonate

Step 1: 3-[4-(trifluoromethoxy)phenyl]-5,6, 7 8-tetrahydro-2H-phthalazine-l ,4-dione

To a solution of 4,5,6,7-tetrahydroisobenzofuran-l,3-dione (CAS 2426-02-0, 3.04 g, 2.0 mmol) in AcOH (30 mL) was added [4-(trifluoromethoxy)phenyl]hydrazine hydrochloride (CAS 133115-72-7, 4.57 g, 2.0 mmol) at 15 °C. After addition, the mixture was warmed to 120 °C and stirred for 20 h. The mixture was cooled to rt and poured into water (60 mL) and there was precipitate formed. The mixture was extracted with EtOAc(150 mL x 2), the organic phase was washed with brine (100 mL), dried over Na 2 S0 4 . After filtration, the filtrate was concentrated in vacuo to get a crude product (6.0 g) as a off-white solid. To a solution of the crude product (6.0 g, 18.4mmol) in EtOH (100 mL) was added EtONa (2.50 g, 36.8 mmol) at 15 °C. After addition, the mixture was warmed to 20-25 °C and stirred for 20 h. The mixture was concentrated in vacuo and the residue was poured into water (100 mL). The mixture was acided with 1 N aq. HC1 to pH = 3, extracted with EtOAc (200 mL x 2). The combined organic phase was washed with brine (100 mL), dried over Na 2 S0 4 . After filtration, the filtrate was concentrated in vacuo to get the title compound (6.0 g crude) as a light yellow solid which was used for the next step without purification. Step 2: [4-oxo-3-[4-(trifluoromethoxy)phenyl]-5, 6, 7,8-tetrahydrophthalazin-l-yl] trifluoromethane sulfonate

To a solution of 3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydro-2H-phthala zine-l,4- dione (6.0 g, 18.4 mmol) and Et 3 N (7.43 g, 73.6 mmol) in DCM (100 mL) was added Tf 2 0 (10.4 g, 36.8 mmol) at 0 °C under N 2 . Then the mixture was stirred at 15 °C for 20 h. Solvent was removed in vacuum to give a residue which was purified by column chromatography on silica gel (Petroleum ether/EtOAc from 150/1 to 100/1) to give the title compound (1.6 g, 19 % yield) as yellow solid. 1 HNMR: (CDC1 3 , 400MHz) δ 7.72 (d, J=9.2 Hz, 2H), 7.33 (d, J=8.3 Hz, 2H), 2.74-2.61 (m, 4H), 1.92-1.82 (m, 4H).

In analogy to Intermediate 23 compounds of the following table were prepared using different 1,3-diones and h drazines as reactants:

Intermediate 26

[3-[4-(2-Methoxyethoxy)phenyl]-4-oxo-phthalazin-l-yl] trifluoromethanesulfonate

Step 1: 2-(4-bromoanilino)isoindoline- 1 ,3-dione

To a solution of isobenzofuran-l,3-dione (CAS 85-44-9, 5.0 g, 33.8 mmol) in AcOH (30 mL) was added (4-bromophenyl)hydrazine hydrochloride (CAS 622-88-8, 8.3 g, 37.1 mmol) in one portion. The mixture was stirred overnight at 120 °C. After cooled to rt, the brown solution was poured into water (100 mL) and the mixture was filtered. The solid was washed with water and dried to give the title compound (8 g), which was used in the next step directly. MS (m/e): 317.1 & 319.1 (M+H) + .

Step 2: 3-(4-bromophenyl)-2H-phthalazine- 1 , 4-dione

To a solution of 2-(4-bromoanilino)isoindoline-l,3-dione (8 g, 25.2 mmol) in EtOH (150 mL) was added sodium ethanolate (2.57 g, 37.8 mmol) at rt. The reaction mixture was stirred at rt for 30 min and then concentrated. The residue was poured into water (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic phase was washed with aq. HC1 (IN) and brine, dried over Na 2 S0 4 and concentrated. The residue was purified by flash column chromatography on silica gel with a gradient of 10% ~ 50% EtOAc in DCM to afford the title compound (4.7 g) as white solid. MS (m/e): 317.1 & 319.1 (M+H) + .

Step 3: 3-[ 4-(2-methoxyethoxy)phenyl]-2H-phthalazine-l, 4-dione

A mixture of 3 -(4-bromophenyl)-2H-phthalazine-l, 4-dione (1.0 g, 3.15 mmol), 2- methoxyethanol (4.8 g, 4.97 mL, 63.1 mmol), K 2 C0 3 (1.31 g, 9.46 mmol) and cupric chloride (212 mg, 1.58 mmol) was stirred at 130 °C for 36 h. After cooled to rt, the mixture was diluted with EtOAc (100 mL) and washed with sat. aqueous H 4 C1 and brine. The organic phase was dried over anhydrous Na 2 S0 4 and concentrated. The residue was purified by column

chromatography (eluting with 10% ~ 50% EtOAc in DCM) to afford the title compound (0.65 g) as white powder. MS (m/e): 313.1 (M+H) + . Step 4: [3-[4-(2-Methoxyethoxy)phenyl]-4-oxo-phthalazin-l-yl] trifluoromethane sulfonate

To a mixture of 3-[4-(2-methoxyethoxy)phenyl]-2H-phthalazine-l,4-dione (650 mg, 2.08 mmol), and pyridine (1.68 mL, 20.8 mmol) in DCM (20 mL) was added Tf 2 0 (410 μί, 2.5 mmol) dropwise at 0 °C. The reaction mixture was stirred at rt for 2 h before quenched by sat. aqueous H 4 C1. The mixture was diluted with EtOAc (100 mL) and the organic phase was washed with aq. HCl and brine. The organic phase was dried over Na 2 S0 4 and concentrated to give the title compound (600 mg, crude). MS (m/e): 445.1 (M+H) + .

Intermediate 27

[8-Methoxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl]

trifluoromethanesulfonate

Step 1 : 4-hydroxy-2-[ 4- ( trifluoromethoxy)anilino ]isoindoline- 1, 3-dione

To a solution of 4-hydroxyisobenzofuran-l, 3-dione (CAS 37418-88-5, 1.0 g, 6.09 mmol) in AcOH (10 mL) was added (4-(trifluoromethoxy)phenyl)hydrazine hydrochloride (CAS 133115-72-7, 1.53 g, 6.7 mmol). The reaction mixture was stirred overnight at 120 °C. After cooling, the brown solution was poured into water (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic phase was washed with water and brine, dried over anhydrous Na 2 S0 and concentrated. The residue was purified by column chromatography (eluting with 10%) ~ 40%) EtOAc in petroleum ether) to afford the title compound (1.0 g) as a white solid. MS (m/e): 339.1 (M+H) + . Step 2: 8-hydroxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione

To a solution of 4-hydroxy-2-[4-(trifluoromethoxy)anilino]isoindoline-l,3-dio ne (1 g, 2.96 mmol) in EtOH (100 mL) was added sodium ethanolate (302 mg, 4.43 mmol). The reaction mixture was stirred overnight at rt. After removal of the solvents, the residue was poured into water (100 mL). The mixture was acidified with concentrated HCl to pH 3 and extracted with EtOAc. The organic phase was washed with water and brine, dried over Na 2 S0 4 and

concentrated. The residue was purified by column chromatography (eluting with 10% ~ 50% EtOAc in petroleum ether) to afford the title compound and the isomer 5-hydroxy-3-[4- (trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione (0.9 g in total) as a white solid. MS (m/e): 339.1 (M+H) + .

Step 3: 8-methoxy-3-f 4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione

To a mixture of 8-hydroxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione and 5-hydroxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l,4- dione (140 mg, 397 μπιοΐ) in Et 2 0/MeOH (10 mL, v:v = 4: 1) was added (diazomethyl)trimethylsilane (1.42 mL, 2.84 mmol) at rt. After stirred at rt for 2 h, the reaction mixture was treated with water and the mixture was extracted with EtOAc. The combined organic extract was dried over Na 2 S0 4 and concentrated. The residue was purified by column chromatography (eluting with 10% ~ 50% EtOAc in petroleum ether) to afford a mixture of the title compound and its isomer 5-methoxy-3-[4- (trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione (300 mg in total) as a white solid. MS (m/e): 353.1 (M+H) + .

Step 4: [8-methoxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl]

trifluoromethane sulfonate

To a mixture of 8-methoxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione and 5-methoxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l,4- dione (300 mg, 852 μπιοΐ), and pyridine (337 mg, 4.26 mmol) in DCM (20 mL) was added Tf 2 0 (168 μΐ, 1.02 mmol) dropwise at 0 °C. The mixture was stirred at rt for 2 h. The reaction mixture was treated with saturated aqueous H C1 and extracted with EtOAc (100 mL). The organic phase was washed with aq. HCl and brine, dried over Na 2 S0 and concentrated to afford the title compound and its isomer [5-methoxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l- yl] trifluoromethanesulfonate (400 mg in total) as a solid. MS (m/e): 485.1 (M+H) + . Intermediate 28

[3-(4-Tert-butylphenyl)-6-ethyl-4-oxo-phthalazin-l-yl] trifluoromethanesulfonate

Step 1: (6-bromo-4-oxo-3H-phthalazin-l-yl) trifluoromethanesulfonate and (7-bromo-4- oxo-3H-phthalazin-l-yl) trifluoromethanesulfonate

To a solution of 6-bromo-2,3-dihydrophthalazine-l,4-dione (CAS 76240-49-8, 36.0 g, 150 mmol) and Et 3 N (37.5 g, 375 mmol) in DCM (1.0 L) was added Tf 2 0 (42.3 g, 150 mol) dropwise over 1 h. The mixture was stirred at 0 °C for 2 h and then kept at 15 °C for 16 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by flash column

(petroleum ether: EtOAc from 5: 1 to 3 : 1) to give a mixture of the title compounds (9.0 g, 16% yield) as a white solid.

Step 2: [6-bromo-3-(4-tert-butylphenyl)-4-oxo-phthalazin-l-yl] trifluoromethanesulfonate and [7-bromo-3-(4-tert-butylphenyl)-4-oxo-phthalazin-l-yl] trifluoromethanesulfonate

A solution of (6-bromo-4-oxo-3H-phthalazin-l-yl) trifluoromethanesulfonate and (7- bromo-4-oxo-3H-phthalazin-l-yl) trifluoromethanesulfonate (9.0 g, 24.1 mmol), (4-tert- butylphenyl)boronic acid (CAS 123324-71-0, 4.2 g, 24.1 mmol), Cu(AcO) 2 (8.6 g, 48.2 mmol) and TEA (7.2 g, 72.3 mol) in THF (100 mL) was stirred at 15 °C for 16 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column

chromatography (petroleum ether: EtOAc from 20: 1 to 10: 1) to give [6-bromo-3-(4-tert- butylphenyl)-4-oxo-phthalazin-l-yl] trifluoromethanesulfonate (4.0 g, 33.0% yield) and [7- bromo-3-(4-tert-butylphenyl)-4-oxo-phthalazin-l-yl] trifluoromethanesulfonate (3.0 g, 25% yield) as white solids. MS (m/e): 505.1 and 507.1 (M+H) + .

Step 3: 6-bromo-3-(4-tert-butylphenyl)-2H-phthalazine-l,4-dione

To a solution of [6-bromo-3-(4-tert-butylphenyl)-4-oxo-phthalazin-l-yl]

trifluoromethanesulfonate (4.0 g, 7.93 mmol) in CH 3 OH (40 mL) was added K 2 C0 3 (5.4 g, 39.6 mmol) and the mixture was stirred at 60 °C for 16 h. The reaction mixture was filtered and the filtration was concentrated. The crude product was dissolved with EtOAc (100 mL) and washed with water (50 mL x 2). The organic phase was dried (Na 2 S0 4 ) and concentrated to yield the title compound (2.0 g, 67.7% yield). MS (m/e): 373.0 and 375.0 (M+H) + .

Step 4: 3-(4-tert-butylphenyl)-6-vinyl-2H-phthalazine- 1 , 4-dione

A mixture of 6-bromo-3-(4-tert-butylphenyl)-2H-phthalazine-l, 4-dione (1.0 g, 2.5 mmol), potassium ethenyltrifluoroborate (CAS 13682-77-4, 0.56 g, 3.7 mmol), K 2 C0 3 (0.86 g, 6.2 mmol), water (0.6 mL) and Pd(dppf)Cl 2 .DCM (0.1 g) in DME (15.0 mL) was stirred at 100 °C for 12 h. The mixture was concentrated and the residue was purified by flash chromatography (petroleum ethenEtOAc from 5: 1 to 2: 1) to afford the title compound (0.75 g, 94% yield) as a light yellow solid. MS (m/e): 321.1 (M+H) + . Step 5: 3-(4-tert-butylphenyl)-6-ethyl-2H-phthalazine- 1 , 4-dione

A solution of 3-(4-/er/-butylphenyl)-6-vinyl-2H-phthalazine-l,4-dione (0.75 g, 2.3 mmol) and Pd/C (0.3 g) in MeOH (20.0 mL) was purge with hydrogen by 3 times. Then the reaction mixture was stirred at rt under hydrogen (15 Psi) for 1 h. The reaction mixture was filtered, and the filtrate was concentrated to afford the title compound (0.6 g, 80.0% yield) as a white solid that was used in the next step without purification. MS (m/e): 323.2 (M+H) + .

Step 6: [3-(4-tert-butylphenyl)-4-oxo-6-vinyl-phthalazin-l-yl] trifluoromethane sulfonate

To a solution of 3 -(4-tert-butylphenyl)-6-ethyl-2H-phthalazine-l, 4-dione (0.7 g, 2.1 mol) and Et 3 N (0.52 g, 5.2 mol) in DCM (20.0 mL) was added Tf 2 0 (0.61 g, 2.1 mol) dropwise at 0 °C. The mixture was stirred at 0 °C for 1 h and kept at 15 °C for 16 h. The mixture was filtered. The filtrate was concentrated and the residue was purified by flash chromatography (petroleum ether: EtOAc from 20: 1 to 10: 1) to give the title compound (0.8 g, 84%) as a white solid. MS (m/e): 455.1 (M+H) + .

Intermediate 29

4-Bromo-2-[4-(trifluoromethoxy)phenyl]phthalazin-l-one

Br

Step 1: 3-[ 4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione

To a solution of isobenzofuran-l,3-dione (CAS 85-44-9, 40 g, 270.0 mmol) in AcOH (400 mL) was added [4-(trifluoromethoxy)phenyl]hydrazine hydrochloride (CAS 133115-72-7, 61.77 g, 270 mmol) at 15 °C. After addition, the mixture was warmed to 120 °C and stirred for 20 h. The mixture was cooled to rt and poured into water (700 mL), a white solid was formed. After about 15 min, the solid was filtered, the filter cake was washed with water (100 mL x 2). The solid was dried under vacuo to get the a crude product (73 g, 84% yield) as an off-white solid. The solid (73.0 g, 226.5 mmol) was dissolved into EtOH (1000 mL) and to the mixture was added EtONa (31.0 g, 455.5 mmol) at 15 °C. After addition, the mixture was warmed to 20- 25 °C and stirred for 20 h. The mixture was concentrated in vacuo and the residue was poured into water (400 mL). The mixture was acidified with 1 N HC1 to pH =3, a white precipitate formed. The solid was filtered and the solid was re-dissolved into EtOAc (1500 mL). The water was separated and the organic phase was dried over Na 2 S0 4 . The organic phase was concentrated in vacuo and residue was trituated with EtOAc (300 mL) to get the title crude product (53 g, 73% yield) as an off-white solid which was used for the next step without purification.

Step 2: 4-bromo-2-[ 4-(trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of 3 -[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione (40.0 g, 124.2 mmol) in DCE (40.0 mL) was added POBr 3 (178.6 g, 621.1 mmol) under N 2 . Then the mixture was stirred at 80 °C for 16 h. The reaction mixture was poured into ice/water (1000 mL), extracted by EtOAc (1000 mL), dried and concentrated. The residue was purified by column (petroleum ether/EtOAc from 50/1 to 15/1) to give title compound as light yellow solid which was purified by trituration with petroleum ether/EtOAc (100 mL) to give the title compound (14 g, 29% yield) as an off white solid. MS (m/e): 385.0 and 387.0 (M+H) + .

Intermediate 30

4-Bromo-6-ethyl-2-[4-(trifluoromethoxy)phenyl]phthalazin-l-o ne and 4-bromo-7-ethyl-2-

[4-(trifluoromethoxy)phenyl]phthalazin-l-one

Step 1: 6-bromo-4-hydroxy-2-[4-(trifluoromethoxy)phenyl]phthalazin-l -one and 7-bromo- 4-hydroxy-2-[4-(trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of 5-bromoisobenzofuran-l,3-dione (CAS 86-90-8, 2.27 g, 10.0 mmol) in AcOH (30 mL) was added (4-(trifluoromethoxy)phenyl)hydrazine hydrochloride (CAS 133115- 72-7, 2.29 g, 10.0 mmol) and the reaction mixture was stirred at 80 °C for 2 h. When LC-MS indicated that the starting material was consumed, the mixture was concentrated to afford the crude product. To a solution of the product in EtOH (100 mL) was added sodium ethanolate (1.43 g, 20.9 mmol) at rt. The mixture was stirred at 80 °C for 2 h before concentrated to give the title compound mixture (4.80g). MS (m/e): 401.0 and 403.0(M+H) + . Step 2: 4-hydroxy-2-[4-(trifluoromethoxy)phenyl]-6-vinyl-phthalazin- l-one and 4-hydroxy-

2-[ 4-(trifluoromethoxy)phenyl] - 7-vinyl-phthalazin-l-one

A mixture of 6-bromo-4-hydroxy-2-(4-(trifluoromethoxy)phenyl)phthalazin-l (2H)-one and 7-bromo-4-hydroxy-2-(4-(trifluoromethoxy)phenyl)phthalazin-l (2H)-one (490 mg, 1.22 mmol), potassium ethenyltrifluoroborate (CAS 13682-77-4, 245 mg, 1.83 mmol), K2C03 (422 mg, 3.05 mmol), water (0.3 mL) and Pd(dppf)Cl 2 .DCM (90 mg) in DME (7.0 mL) was stirred at 100 °C for 12 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by flash chromatography to afford the title compound mixture (180mg) as a light yellow solid. MS (m/e): 348.1 (M+H) + .

Step 3: 6-ethyl-4-hydroxy-2-[4-(trifluoromethoxy)phenyl]phthalazin-l -one and 7-ethyl-4- hydroxy-2-f 4-(trifluoromethoxy)phenyl]phthalazin-l-one

A solution of 4-hydroxy-2-[4-(trifluoromethoxy)phenyl]-6-vinyl-phthalazin- l-one and 4- hydroxy-2-[4-(trifluoromethoxy)phenyl]-7-vinyl-phthalazin-l- one (180 mg, 0.52 mmol), and Pd/C (11 mg) in MeOH (10 mL) was purge with hydrogen for 3 times. Then the reaction mixture was stirred under hydrogen (1 atm) at rt overnight. The reaction mixture was filtered, and the filtrate was concentrated to afford the title compound mixture (150 mg, 83% yield) as a white solid. MS (m/e): 350.1 (M+H) + .

Step 4: 4-bromo-6-ethyl-2-[4-(trifluoromethoxy)phenyl]phthalazin- 1 -one & 4-bromo-7- ethyl-2-[4-(trifluoromethoxy)phenyl]phthalazin-l-one

To a stirred suspension of 6-ethyl-4-hydroxy-2-(4-(trifluoromethoxy)phenyl)phthalazin- l(2H)-one and 7-ethyl-4-hydroxy-2-(4-(trifluoromethoxy)phenyl)phthalazin-l (2H)-one (380 mg, 1.08 mmol) in DCE (10 mL) was added phosphorus oxybromide (622 mg, 2.17 mmol). The mixture was stirred at 100 °C for 18 h before it was cooled to rt and poured into water. The aqueous phase was treated with aqueous Na 2 C0 3 (1 M) to pH 8 and extracted with EtOAc. The organic phases were dried and concentrated in vacuo. The residue was purified by flash chromatography to give the title compound mixture as a solid (320 mg, in 71% yield). MS (m/e): 413.0 and 415.0 (M+H) + .

Intermediate 31

4-Bromo-2-[4-(trifluoromethoxy)phenyl]-6-vinyl-phthalazin-l- one and 4-bromo-2-[4- (trifluoromethoxy)phenyl]-7-vinyl-phthalazin-l-one

To a stirred suspension of 4-hydroxy-2-[4-(trifluoromethoxy)phenyl]-6-vinyl-phthalazin- l- one and 4-hydroxy-2-[4-(trifluoromethoxy)phenyl]-7-vinyl-phthalazin- l-one (Intermediate 30, step 2; 348 mg, 1.00 mmol) in DCE (10 mL) was added phosphorus oxybromide (573 mg, 2.00 mmol). The mixture was stirred at 100 °C for 18 h before it was cooled to rt and poured into water. The aqueous phase was treated with aqueous Na 2 C0 3 (1M) to pH 8 and extracted with EtOAc. The organic phase were dried and concentrated in vacuo. The residue was purified by flash chromatography to give the title compound mixture as a solid (330 mg, in 80% yield). MS (m/e): 411.0 and 413.0 (M+H) + .

Intermediate 32

l-Bromo-6-methyl-3-[4-(trifluoromethoxy)phenyl]-7,8-dihyd ro-5H-pyrido[3,4-d]pyridazin- 4-one and 4-bromo-6-methyl-2- [4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido [3,4- d]pyridazin-l-one

Step 1: l-bromo-3H-pyrido[3,4-d]pyridazin-4-one and 4-bromo-2H-pyrido[3,4- djpyridazin- 1-one

To a solution of 2,3-dihydropyrido[3,4-d]pyridazine-l,4-dione (CAS 31384-08-4, 8.0 g, 49.0 mmol) in DCE (4 mL) was added POBr 3 (84.2 g, 294.0 mmol) at 25 °C, and then the mixture was stirred at 110 °C for 16h. The mixture was poured into 30 mL ice-water, and then extracted with EtOAc (30 mL x 3), combined the organic phase and dried over Na 2 S0 4 . The solid was filtered off and filtrate was concentrated to give the crude product, which was purified by chromatography on silica gel (petroleum ether: EtOAc =10: 1) to give the title compound mixture (2.0 g, crude) as a yellow solid. MS (m/e): 226.1 and 228.1 (M+H) + . Step 2: l-bromo-3-[4-(trifluoromethoxy)phenyl]pyrido[3,4-d]pyridazin -4-one and 4- bromo-2-f 4- ( trifluoromethoxyjphenyl Jpyridof 3, 4-dJpyridazin- 1 -one

To a solution of 4-bromo-2H-pyrido[3,4-d]pyridazin- 1-one and 4-bromo-2H-pyrido[3,4- d]pyridazin- 1-one (2.0 g, 8.85 mmol), [4-(trifluoromethoxy)phenyl]boronic acid (CAS 139301- 27-2; 2.18 g, 10.6 mmol) and TEA (2.6 mL, 17.7 mmol) in THF (100 mL) was added Cu(OAc) 2 (3.2 g, 17.7 mmol), and then the mixture was stirred at 25 °C for 16h. The solvent was removed by concentration to give the crude product, which was purified by chromatography on silica gel to give the title compound mixture (2 g, 58.8% yield) as a yellow solid. MS (m/e): 385.9 and 387.9 (M+H) + .

Step 3: l-bromo-6-methyl-3-[4-(trifluoromethoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4- dJpyridazin-4-one and 4-bromo-6-methyl-2-[4-(trifluoromethoxy)phenyl]-7,8-dihydro- 5H- pyrido[ 3, 4-dJpyridazin- 1-one

To a solution of the mixture of l-bromo-3-[4-(trifluoromethoxy)phenyl]pyrido[3,4- d]pyridazin-4-one and 4-bromo-2-[4-(trifluoromethoxy)phenyl]pyrido[3,4-d]pyridazin -l-one (600 mg, 1.6 mmol) in DMF (50 mL) was added Mel (0.68 g, 4.8 mmol), and then the solution was stirred at 60 °C for 16h. The solvent was removed by concentration to give the crude product (0.9 g, crude) as red solid, which was used in the next step without any further purification. To a solution of the crude product (0.9 g, 1.6 mmol) and Ni(N0 3 ) 2 (146.1 mg, 0.8 mmol) in MeOH (100 mL) was added NaBH 3 CN (301.5 mg, 4.8 mmol), and then the mixture was stirred at 25 °C for 16hr. The solvent was removed by concentration to give the crude product, which was purified by chromatography on silica gel to give the title compound mixture (250 mg, 38.6% yield) as a yellow solid. MS (m/e): 401.9 and 413.9 (M+H) + . Intermediate 33 and Intermediate 34

[6-Benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl] trifluoromethanesulfonate and [7-benzyloxy-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl] trifluoromethanesulfonate

Step 1: 6-benzyloxy-S-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione and 7- benzyloxy-3-f 4-(trifluoromethoxy)phenyl ]-2H-phthalazine-l, 4-dione

To a solution of 5-benzyloxyisobenzofuran-l,3-dione (CAS 5840-65-3; 8.5 g, 33.4 mmol) in AcOH (100 mL) was added [4-(trifluoromethoxy)phenyl]hydrazine (CAS 13957-54-5, 7.6 g, 33.4 mmol) at 20 °C. Then the mixture was heated to 120 °C and stirred for 16h. The mixture was poured into water (200 mL), the precipitate was collected by filtration and the solid was washed by water (100 mL), and dried in high vacuum to give a yellow solid. The solid was dissolved in EtOH (100 mL) and SOCl 2 (4.5 g, 37.4 mmol) was added at 20 °C. Then the mixture was heated to 80 °C and stirred for 16h. Solvent was removed in vacuum to dryness to give the title compund mixture (8.0 g, crude) as a yellow solid which was used in next step without further purification. MS (m/e): 429.1 (M+H) + .

Step 2: [ 6-benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l -yl]

trifluoromethanesulfonate and [7-benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l- ylj trifluoromethanesulfonate To a solution of 6-benzyloxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione and 7-benzyloxy-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-l, 4-dione (8.0 g, 18.7 mmol) and TEA (7.6 g, 74.8 mmol) in DCM (100 mL) was added Tf 2 0 (10.5 g, 37.4 mmol) at 0 °C under N 2 . Then the mixture was stirred at 20 °C for 2h. Solvent was removed in vacuum to give a residue which was purified by column chromatography on silica gel (PE/EA from 200/1 to 100/1) to give [6-benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl]

trifluoromethanesulfonate (4.0 g, 38% yield; 1H MR: (CDC1 3 , 400MHz) δ 7.92 (d, J=2.5 Hz, IH), 7.77 (d, J=8.8 Hz, IH), 7.68 (d, J=9.0 Hz, 2H), 7.50 (dd, J=2.5, 8.8 Hz, IH), 7.43-7.38 (m, 2H), 7.38-7.34 (m, 2H), 7.33-7.29 (m, IH), 7.26 (d, J=8.5 Hz, 2H), 5.21 (s, 2H)) and [7- benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-y l] trifluoromethanesulfonate (2.5 g, 23.8% yield; 1H MR: (CDC1 3 , 400MHz) δ 8.38 (d, J=8.8 Hz, IH), 7.67 (d, J=9.0 Hz, 2H), 7.46 (dd, J=2.3, 8.8 Hz, IH), 7.44 - 7.29 (m, 6H), 7.26 (d, J=8.5 Hz, 2H), 5.20 (s, 2H)) as yellow solids. Intermediate 35

(7-Benzyloxy-4-oxo-3H-p fluoromethanesulfonate

Step 1: 5-benzyloxy-2,3-dihydrophthalazine-l,4-dione

To a solution of 4-benzyloxyisobenzofuran-l,3-dione (CAS 63382-37-6; 7.2 g, 28.3 mmol) in EtOH (100 mL) was added AcOH (13.6 g, 141.5 mmol) at 20 °C, and then N 2 H 4 .H 2 0 (11.5 g, 141.5 mmol) was added at 0 °C. Then the mixture was heated to 80 °C and stirred for 16 h. The mixture was cooled to 25 °C, solvent was removed and the residue poured into water (150 mL), filtered, washed with water (150 mL), the solid was collected to give the title compound (6.8 g, crude) as an off-white solid. MS (m/e): 269.1 (M+H) + .

Step 2: (7-benzyloxy-4-oxo-3H-phthalazin-l-yl) trifluoromethane sulfonate

To a solution of 5-benzyloxy-2,3-dihydrophthalazine-l,4-dione (4.5 g, 16.8 mmol) in MeCN (80.0 mL) was added pyridine (40.0 mL) at 0 °C and then Tf 2 0 (5.7 g, 20.1 mmol) was added at 0 °C. Then the mixture was stirred at 20 °C and stirred for 3 h. The reaction was quenched by IN HC1 (40.0 mL), extracted by DCM (50.0 mL), dried and concentrated in vacuum to give crude product which was purified by column chromatography on silica gel (PE/EA from 20/1 to 8/1 to 3/1) to give the title compound (2.5 g, 37.3% yield; 1H NMR:

(DMSO, 400MHz) δ 12.52 (s, 1 H), 8.01 (t, J=8.2 Hz, 1 H), 7.66 (d, J=8.5 Hz, 1 H), 7.61 (d, J=7.3 Hz, 2 H), 7.39-7.45 (m, 2 H), 7.37-7.30 (m, 2 H), 5.37 (s, 2 H)) and (5-benzyloxy-4-oxo- 3H-phthalazin-l-yl) trifluoromethanesulfonate (2.0 g, 29.8% yield; 1H NMR: (DMSO, 400MHz) δ 10.10 (br. s., 1 H), 8.06-7.98 (m, 1 H), 7.72 (t, J=8.2 Hz, 1 H), 7.50-7.44 (m, 2 H), 7.40 (t, J=7.2 Hz, 2 H), 7.38-7.31 (m, 2 H), 5.41 (s, 2 H)) as yellow solids. Intermediate 36

6-Acetyl-l-bromo-3-[4-(trifluoromethoxy)phenyl]-7,8-dihydro- 5H-pyrido[3,4-d]pyridazin-

4-one

Step 1: l-bromo-3-[4-(trifluoromethoxy)phenylJ-5,6, 7,8-tetrahydropyrido[3,4-dJpyridaz

4-one

To a solution of l-bromo-6-[(4-rnethoxyphenyl)methyl]-3-[4-(trifluoromethoxy) phenyl]- 7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one (Intermediate 55, step 1; 0.3 g, 0.59 mmol) and TEA (0.17 mL, 1.18 mmol) in DCM (20 mL) was added ClCOOCHClCH 3 (0.17 g, 1.18 mmol) at 25 °C for 16 h. The solvent was removed by concentration and the residue was dissolved in 10 mL MeOH, and then stirred at 80 °C for 2h. The solvent was removed by concentration to give the crude title compound (0.3 g, crude) as a green solid, which was used in the next step without any further purification. MS (m/e): 391.8 (M+H) + .

Step 2: 6-acetyl-l-bromo-3-[ 4-(trifluoromethoxy)phenyl] - 7, 8-dihydro-5H-pyrido[ 3, 4- d] pyridazin-4-one

To a solution of l-bromo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyr ido[3,4- d]pyridazin-4-one (0.3 g, 0.59 mmol) and TEA (0.17 mL, 1.18 mmol) in DCM (20 mL) was added CH 3 COCI (55.7 mg, 0.71 mmol) at 0 °C and the mixture was stirred for a further 3 h. The solvent was removed by concentration and the crude product was purified by chromatography on silica gel (PE: EA =3 : 1) to give the title compound (0.23 g, 90% yield) as a yellow solid. MS (m/e): 434.0 (M+H) + .

Intermediate 37

7-Benzyloxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of [6-benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl] trifluoromethanesulfonate (Intermediate 33; 500.0 mg, 0.89 mmol), 3 -amino- 1-methyl-pyri din-Zone (CAS 33631-01-5; 229.0 mg, 1.07 mmol), K 2 C0 3 (357.3 mg, 2.67 mmol) and Xantphos (50.0 mg) in dioxane (100 mL) was added Pd 2 (dba) 3 (80.0 mg) at 20 °C under N 2 . Then the mixture was heated to 110 °C and stirred for 16 h. Solvent was removed in vacuum to dryness to give crude product. The crude product was purified by column chromatography on silica gel (petroleum ether/EtOAc from 10/1 to 1/1) to give the title compound (400 mg, crude) as off white solid which was used in next step without further purification.

In analogy to Intermediate 37 compounds of the following table were prepared using different trifluoromethanesulfonates or bromides and amines as reactants:

Intermediate 48

tert-Butyl N-[7-(2-methoxyethoxy)-4-oxo-3-[4-(trifluoromethoxy)phenyl]p hthalazin-l-yl]- -(l-methyl-2-oxo-3-pyridyl)carbamate

Step 1: tert-butyl N-[7-benzyloxy-4-oxo-3-[4-(trifluoromethoxy)phenylJphthalazi n-l-yl]-N- ( I -methyl-2-oxo-3-pyridyl) carbamate

To a solution of 6-benzyloxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one (Intermediate 38; 300.0 mg, 0.56 mmol) and Boc 2 0 (146.1 mg, 0.67 mmol), DMAP (102.5 mg, 0.84 mmol) in DMF (20 mL) was stirred at 90 °C for 16 hr under N 2 atmosphere. The reaction was cooled to 20 °C and filtered, evaporation of solvent to give a residue, the residue was added EtOAc (100 mL) and water (100 mL), the water phase was washed with EtOAc (50 mL x 2), the combined organic phase, dried (Na 2 S0 4 ), filtered and evaporation of solvent to give a crude product. The crude was purified by column

chromatography on silica gel to give the title compound (150.0 mg, yield: 42.24%) as a green solid. MS (m/e): 635.3 (M+H) + .

Step 2: tert-butyl N-[7-hydroxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl]-N- ( I -methyl-2-oxo-3-pyridyl) carbamate

To a solution of tert-butyl N-[7-benzyloxy-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl]-N-(l -methyl -2-oxo-3-pyridyl)carbamate (150 mg, 0.24 mmol) and Pd/C (100 mg), in THF (15 mL) was stirred at 25 °C for 2 hr under hydrogen atmosphere. The mixture was filtered and solvent was evaporated to give the title compound (110.0 mg, yield: 84.6%) as a green solid. MS (m/e): 545.1 (M+H) + .

Step 3: tert-butyl N-[7-(2-methoxyethoxy)-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl]-N-(l-methyl-2-oxo- 3-pyridyl)carbamate To a solution of tert-butyl N-[7-hydroxy-4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl]-N-(l-methyl-2-oxo-3-pyridyl)carbamate (110.0 mg, 0.20 mmol) and l-bromo-2-methoxy- ethane (33.1 mg, 0.24 mmol) in MeCN (10 mL) was added K 2 C0 3 (55.2 mg, 0.40 mmol). The reaction was heated to 80 °C for 4 hr under N 2 atmosphere. The mixture was filtered solvent was evaporated to give the title compound (91.0 mg, 75.7%) as a green solid. MS (m/e): 603.2 (M+H) + .

Intermediate 49

tert-Butyl N-[6-(2-methoxyethoxy)-4-oxo-3-[4-(trifluoromethoxy)phenyl]p hthalazin-l-yl]- -(l-methyl-2-oxo-3-pyridyl)carbamate

The title compound was prepared from [6-benzyloxy-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazin-l-yl] trifiuoromethanesulfonate (Intermediate 33) using an analogous sequence to that used to prepare Intermediate 48 from [7-benzyloxy-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl] trifiuoromethanesulfonate. MS (m/e): 603.2 (M+H) + .

Intermediate 50

tert-Butyl N-[8-(2-methoxyethoxy)-4-oxo-3-[4-(trifluoromethoxy)phenyl]p hthalazin-l-yl]- -(l-methyl-2-oxo-3-pyridyl)carbamate

The title compound was prepared from [8-benzyloxy-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl] trifiuoromethanesulfonate (Intermediate 8) analogous sequence to that used to prepare Intermediate 48 from [7-benzyloxy-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl] trifluoromethanesulfonate. MS (m/e): 603.2 (M+H) + .

Intermediate 51

Ethyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazine-6-carboxylate

Step 1: l,4-dioxo-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-6-ca rboxylic acid and 1, 4-dioxo-2-[ 4-(trifluoromethoxy)phenyl]-3H-phthalazine-6-carboxylic acid To a solution of l,3-dioxoisobenzofuran-5-carboxylic acid (CAS 552-30-7; 30.0 g, 15.61 mmol) in AcOH (400 mL) was added [4-(trifluoromethoxy)phenyl]hydrazine hydrochloride (CAS 133115-72-7; 35.68 g, 15.61 mmol) at 20 °C. After addition, the mixture was warmed to 120 °C and stirred for 18 h. The mixture was cooled to rt and poured into water (600 mL), there is a white solid was formed. After stirring about 15 min, the solid was filtered; the filter cake was washed with water (100 mL x 2). The solid was dried under vacuo to get the crude title product mixture (42.0 g, 73.4% yield) as a gray solid. It was used for the next step without purification.

Step 2: ethyl 1 ,4-dioxo-3- [4-(trifluoromethoxy)phenyl] -2H-phthalazine-6-carboxylate and ethyl 1 ,4-dioxo-2- [4-(trifluoromethoxy)phenyl] -3H-phthalazine-6-carboxylate

To a solution of l,4-dioxo-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-6-ca rboxylic acid and l,4-dioxo-2-[4-(trifluoromethoxy)phenyl]-3H-phthalazine-6-ca rboxylic acid (37.0 g, 0.30 mmol) in EtOH (500 mL) was added SOCl 2 (36.0 g, 0.30 mmol) at 0 °C. After addition, the mixture was heated to reflux (80-90 °C) and stirred for 6 h. The mixture was concentrated in dryness and the residue was triturated with petroleum/EtOAc (350 mL, v/v=5: 1) to get the title compound mixture (35 g, 88% yield) as an off-white solid that was used for the next step without purification. MS (m/e): 395.1 (M+H) + . Step 3: ethyl 4-oxo-3-[4-(trifluoromethoxy)phenyl]-l- (trifluoromethylsulfonyloxy)phthalazine-6-carboxylate

To a solution of ethyl l,4-dioxo-3-[4-(trifluoromethoxy)phenyl]-2H-phthalazine-6- carboxylate and ethyl l,4-dioxo-2-[4-(trifluoromethoxy)phenyl]-3H-phthalazine-6-ca rboxylate (35.0 g, 88.8 mmol) and Et 3 N (35.6 g, 352 mmol) in DCM (500 mL) was added Tf 2 0 (5.01 g, 17.76 mmol) at -10 °C. After addition, the mixture was warmed to 25 °C and stirred for 20 h. The reaction mixture was mixed with silica gel (150 g) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (petroleum ether:EtOAc=30: 1) to get the title compound (12.5 g, 27% yield) as an off-white solid. 1H NMR: (DMSO, 400MHz) δ 9.17 (d, J=1.5 Hz, IH), 8.62 (dd, J=1.5, 8.4 Hz, IH), 7.99 (d, J=8.4 Hz, IH), 7.77 (d, J=8.9 Hz, 2H), 7.37 (d, J=8.8 Hz, 2H), 4.51 (q, J=7.1 Hz, 2H), 1.47 (t, J=7.2 Hz, 3H).

Step 4: ethyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4- ( (rifluoromethoxy)phenyl Jphthalazine-6-car boxy late

A mixture of ethyl 4-oxo-3-[4-(trifluoromethoxy)phenyl]-l- (trifluoromethylsulfonyloxy)phthalazine-6-carboxylate (1.0 g, 1.89 mmol), 3 -amino- 1-m ethyl - pyridin-2-one (CAS 33631-01-5; 0.28 g, 2.26 mmol), Pd 2 (dba) 3 (0.1 g), Xantphos (0.1 g) and K 2 C0 3 (0.79 g, 5.67 mmol) in dioxane (100 mL) was stirred at 100 °C for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the crude product (1.1 g). The crude product was purified by recrystallized from CH 3 OH (10 mL x 2) to give the title compound (0.66 g, 70.2%) as a white solid. MS (m/e): 501.1 (M+H) + .

Intermediate 52

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromet hoxy)phenyl]phthalazine-6- carbaldehyde

A mixture of 7-(hydroxymethyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one (example 141; 0.4 g, 0.88 mmol), Mn0 2 (0.76 g, 8.8 mmol) in DCM (40 mL) was stirred at 25 °C for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the crude product (0.6 g). The crude product was purified by recrystallization from CH 3 OH (20 mL x 2) to give the title compound (0.3 g, 75.0%) as a white solid. MS (m/e): 457.0 (M+H) + .

Intermediate 53

4- [(l-Methyl-2-oxo-3-pyridyl)amino] -7-nitro-2- [4-(trifluoromethoxy)phenyl] phthalazin-1- one

The title compound was prepared from 5-nitroisobenzofuran-l,3-dione (CAS 5466-84-2), [4-(trifluoromethoxy)phenyl]hydrazine (CAS 13957-54-5) and 3-amino-l-methyl-pyridin-2-one

(CAS 33631-01-5) using a sequence analogous to that used to prepare example 64. MS (m/e): 474.1 (M+H) + .

Intermediate 54

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromet hoxy)phenyl]phthalazine-6- carbaldehyde oxime

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazine-6-carbaldehyde (Intermediate 52; 0.1 g, 0.22 mmol) in THF (2.0 mL) was added hydroxylamine hydrochloride (30.2 mg, 0.44 mmol) portion-wise over 1 min. After the addition was over, the mixture was stirred at 25 °C for 2 h. The sediment was filtered and dried under vacuum to give the title compound (80.0 mg, 80.0%) as a white solid. MS (m/e): 472.0 (M+H) + .

Intermediate 55

4- [(1 -Methyl-2-oxo-3-pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl] -5,6,7,8- tetrahydropyrido [3,4-d] pyridazin- 1-one

Step 1 : 4-bromo-6-[ ( 4-methoxyphenyl )methyl J-2-f 4-(trifluoromethoxy)phenyl /- 7, 8- dihydro-5H-pyrido[ 3,4-d] pyridazin- 1-one and l-bromo-6-[(4-methoxyphenyl)methyl]-3-[4- ( trifluoromethoxyjphenyl /- 7, 8-dihydro-5H-pyrido[ 3, 4-d]pyridazin-4-one To a solution of l-bromo-3-[4-(trifluoromethoxy)phenyl]pyrido[3,4-d]pyridazin -4-one and 4-bromo-2-[4-(trifluoromethoxy)phenyl]pyrido[3,4-d]pyridazin -l-one (Intermediate 32, step 2; 0.2 g, 0.52 mmol) in MeCN (20 mL) was added l-(chloromethyl)-4-methoxy-benzene (97 mg, 0.62 mmol) and Nal (93 mg, 0.62 mmol), and then the mixture was stirred at 60 °C for 16h. The solvent was removed to give the crude product (0.4 g, crude), and to a solution of this mixture in MeOH (20 mL) was added NaBH 3 CN (98 mg, 1.56 mmol) and Ni(N0 3 ) 2 at 25 °C, and the solution was stirred for further 16h. The solution was poured into 30 mL ice-water, and extracted with DCM (30 mL x 3), the combined organic phase was dried over Na 2 S0 4 . The solid was filtered off and the filtrate was concentrated to give the crude product, which was purified by chromatography on silica gel (petroleum ether: EtOAc=10: 1) to give the title 4-bromo-6-[(4- methoxyphenyl)methyl]-2-[4-(trifluoromethoxy)phenyl]-7,8-dih ydro-5H-pyrido[3,4-d]pyridazin- 1-one (0.1 g) as a yellow solid and l-bromo-6-[(4-methoxyphenyl)methyl]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-4-one (0.1 g) as a yellow solid. Step 2: 6-[(4-methoxyphenyl)methyl]-4-[(l-methyl-2-oxo-3-pyridyl)ami no]-2-[4-

(trifluoromethoxy)phenyl /- 7, 8-dihydro-5H-pyrido[ 3, 4-dJpyridazin-l-one

To a solution of 4-bromo-6-[(4-methoxyphenyl)methyl]-2-[4-(trifluoromethoxy)p henyl]- 7,8-dihydro-5H-pyrido[3,4-d]pyridazin-l-one (110.0 mg, 0.22 mmol), K 2 C0 3 (91 mg, 0.66 mmol) and 3-amino-l-methyl-pyridin-2-one hydrochloride (CAS 1523570-95-7; 43.4 mg, 0.27 mmol) in dioxane (10 mL) was added Xantphos (20 mg) and Pd 2 (dba) 3 (10 mg) under N 2 atmosphere, and then the mixture was stirred at 110 °C for another 16hr. The solvent was removed by concentration to give the crude product, which was purified by chromatography on silica gel (petroleum ether: EtOAc= 1 : 1) to give the title compound (60 mg, 49.6% yield) as a yellow solid. 1H MR: (CDC1 3 , 400MHz) δ 8.12 (dd, J=1.5, 7.5 Hz, 1H), 7.81 (d, J=9.0 Hz, 2H), 7.68 (s, 1H), 7.33 (dd, J=5.3, 8.3 Hz, 4H), 6.99-6.87 (m, 3H), 6.24 (t, J=7.2 Hz, 1H), 3.84 (s, 3H), 3.76 (s, 2H), 3.66 (s, 3H), 3.63 (s, 2H), 2.75 (d, J=3.8 Hz, 4H).

Step 3: 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)p henyl]-5,6, 7,8- tetrahydropyridof 3, 4-dJpyridazm-l-une

To a solution of 6-[(4-methoxyphenyl)methyl]-4-[(l-methyl-2-oxo-3-pyridyl)ami no]-2-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-l-one (50 mg, 0.09 mmol) and TEA (0.04 mL) in DCM (10 mL) was added 1-chloroethyl carbonochloridate (CAS 50893- 53-3; 38.6 mg, 0.27 mmol) at 25°C, and then stirred for further 2h. The solvent was removed by concentration and the residue was dissolved in 10 mL MeOH, then the solution was heated to reflux for 2h. The solvent was removed by concentration to give the crude title product (60 mg, crude), which was used in the next step without any further purification. MS (m/e): 434.1 (M+H) + . Intermediate 56

4-[6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydr o- cyclopenta[d]pyridazin-l-yl]amino]pyrimidin-l-yl]butanoate

The title compound was prepared from [4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-l-yl] tnfluoromethanesulfonate (Intermediate 9), 5-bromo- lH-pyrimidin-6-one (CAS 19808-30-1) and ethyl 4-bromobutanoate (CAS 2969-81-5) using a sequence analogous to that used to prepare example 3. MS (m/e): 520.3 (M+H) + .

Intermediate 57

1- [[1- [(4-Benzylmorpholin-3-yl)methyl]-2-oxo-3-pyridyl] amino]-3- [4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one

Step 1: l-[(4-benzylmorpholin-3-yl)methyl]-3-nitro-pyridin A solution of (4-benzylmorpholin-3-yl)methyl methanesulfonate (CAS 1823508-49-1; 340.0 mg, 2.43 mmol), 3-nitro-lH-pyridin-2-one (CAS 6332-56-5; 692.5 mg, 2.43 mmol) and K 2 C0 3 (670.8 mg, 4.85 mmol) in DMF (10 mL) was stirred at 70 °C for 12 hr. The reaction mixture was concentrated in vacuum to give the crude product. The crude product was purified by column chromatography (Si0 2 , petroleum ether/EtOAc 10: 1 to DCM/MeOH 10: 1) to give the title compound (700 mg, yield 66.9%) as a yellow solid. MS (m/e): 352.1 (M+Na) + .

Step 2: 3-amino- 1 -[(4-benzylmorpholin-3-yl)methyl]pyridin-2-one

A solution of l-[(4-benzylmo holin-3-yl)methyl]-3-nitro-pyridin-2-one (315.0 mg, 0.96 mmol), Zn (255.8 mg, 4.78 mmol) and H 4 C1 (312.7 mg, 4.78 mmol) in THF (5 mL) and MeOH (5 mL) was stirred at 15 °C for 2 hr. The crude product was purified by prep-HPLC (NH 4 OH) to give the title compound (120.0 mg, 41.91%) as a white oil. MS (m/e): 300.0 (M+H) + .

Step 3: 1 -ffl - [( 4-benzylmorpholin-3-yl )methyl ] -2-oxo-3-pyridyl ] amino J-3-f 4- (trifluoromethoxy)phenyl]-6, 7-dihydro-5H-cyclopenta[d]pyridazin-4-one

A mixture of [4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H- cyclopenta[d]pyridazin-l-yl] trifluoromethanesulfonate (Intermediate 9; 0.15 g, 0.34 mmol), 3- amino-l-[(4-benzylmorpholin-3-yl)methyl]pyridin-2-one (0.11 g, 0.34 mmol), Pd 2 (dba) 3 (40 mg), Xantphos (40 mg) and K 2 C0 3 (93.4 mg, 0.68 mmol) in dioxane (18.0 mL) was charged with N 2 , and the mixture was stirred at 100 °C for 16 hr. The reaction mixture was cooled;

solvent was removed in vacuum to dryness to give a residue which was purified by column chromatography on silica gel (petroleum ether/EtOAc from 10/1 to EtOAc) to give the title compound (0.2 g, crude) as a yellow solid. MS (m/e): 594.3 (M+H) + .

Intermediate 58

1- [[1- [[(2S)-4- [(4-Methoxyphenyl)methyl] morpholin-2-yl] methyl]-2-oxo-3-pyridyl] amino]-

3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[ d]pyridazin-4-one

The title compound was prepared from [(2,5)-4-[(4-methoxyphenyl)methyl]morpholin-2- yljmethyl methanesulfonate using a method analogous to that used to prepare Intermediate 57. MS (m/e): 624.1 (M+H) + .

The [(2 ) S)-4-[(4-methoxyphenyl)methyl]mo holin-2-yl]methyl methanesulfonate used as a starting material was prepared as follows:

Step 1: [ (2S)-4-[(4-methoxyphenyl)methyl]morpholin-2-yl] methanol

A mixture of [(25)-morpholin-2-yl]methanol (CAS 132073-83-7; 1.0 g, 6.5 mmol), p- methoxybenzyl chloride (1.24 g, 7.8 mmol) and K 2 C0 3 (2.69 g, 19.5 mmol) in THF (20 mL) was stirred under nitrogen at 15 °C for 16 h. The reaction mixture was filtered and the filtration was concentrated under reduced pressure to remove solvent. The residue was diluted with water (10 mL) and extracted with EA (20 mL x 3). The combined organic layers was washed with brine (20 mL x 2), dried over Na 2 S0 4 , filtered and concentrated under reduced pressure to give a residue (2.1 g). The crude product was purified by column chromatography (Si0 2 , PE/EA=1/1 to DCM: CH 3 OH = 10/1) to give the title compound (1.2 g, yield: 80.0%) as a white solid. MS (m/e): 238.1 (M+H) + .

Step 2: [(2S)-4-[(4-methoxyphenyl)methyl]morpholin-2-yl]methyl methanesulfonate

To a solution of [(2,5)-4-[(4-methoxyphenyl)methyl]morpholin-2-yl]methanol (1.2 g, 5.0 mmol) in DCM (20 mL) was added Et 3 N (0.76 g, 7.5 mmol) at 15 °C under N 2 , then the mixture was treated with MsCl (0.63 g, 5.5 mmol). The reaction mixture was stirred at 15 °C for 3 h. The reaction was partitioned between DCM (30 mL) and H 2 0 (30 mL). The organic layer was dried over Na 2 S0 4 , concentrated under reduce pressure to get the crude title compound (1.4 g, crude). The crude product was used for next reaction directly with no further purification.

Intermediate 59

1- [ [1 - [2- [Benzyl(methyl)amino] ethyl] -6-oxo-pyrimidin-5-yl] amino] -3- [4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one

Step 1: 5-amino-3-[2-[benzyl(methyl)amino]ethyl]pyrimidin-4-one

The title compound was prepared from 5-bromo-lH-pyrimidin-6-one (CAS 19808-30-1) and N-benzyl-2-chloro-N-methyl-ethanamine (CAS 17542-47-1) using a procedure analogous to that used to prepare Intermediate 95.

Step 2: l-[[l-[ 2- [benzyl ( methyljamino ] ethyl ] -6-oxo-pyrimidin-5-yl ] amino J-3-f 4- (trifluoromethoxy)phenyl]-6, 7-dihydro-5H-cyclopenta[d]pyridazin-4-one

The title compound was prepared from 5-amino-3-[2- [benzyl(methyl)amino]ethyl]pyrimidin-4-one and [4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-l-yl] trifluoromethanesulfonate (Intermediate 12) using a procedure analogous to that used to prepare Intermediate 57 (step 3). MS (m/e): 553.1 (M+H) + .

Intermediate 60

1- [ [1 - [ [1 - [(4-Methoxyphenyl)methyl] pyrrolidin-2-yl] methyl] -2-oxo-3-pyridyl] amino]

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one

The title compound was prepared from [l-[(4-methoxyphenyl)methyl]pyrrolidin-2- yljmethyl methanesulfonate, 3-nitro-lH-pyridin-2-one (CAS 6332-56-5) and [4-oxo-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-l-yl]

trifluoromethanesulfonate (Intermediate 9) using a sequence analogous to that used to prepare Intermediate 57. MS (m/e): 608.2 (M+H) + . The [l-[(4-methoxyphenyl)methyl]pyrrolidin-2-yl]methyl methanesulfonate used as a starting material was prepared as follows: To a solution of [l-[(4- methoxyphenyl)methyl]pyrrolidin-2-yl]methanol (CAS 1017413-27-2; 2.90 g, 13.10mmol) and triethylamine (2.65 g, 26.21 mmol) in DCM (30 mL) was added methanesulfonyl chloride (3.50 g, 26.81mmol) at 0 °C. The mixture was stirred at 15 °C for 2 h. The reaction mixture was quenched by addition water 50 mL at 15 °C and extracted with DCM (50 mL x 3). The combined organic phases were washed with brine (20 mL x 2), dried over Na 2 S0 4 , filtered and

concentrated under reduced pressure to give [l-[(4-methoxyphenyl)methyl]pyrrolidin-2- yljmethyl methanesulfonate (4 g, crude) which was used for the next step directly. Intermediate 61

6-[(4-Methoxyphenyl)methyl]-l-[(l-methyl-2-oxo-3-pyridyl)ami no]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-4-one

To a solution of l-bromo-6-[(4-methoxyphenyl)methyl]-3-[4-(trifluoromethoxy)p henyl]-

7,8-dihydro-5H-pyrido[3,4-d]pyridazin-4-one (Intermediate 55, step 1; 400 mg, 0.78 mmol), K 2 C0 3 (162 mg, 1.17 mmol) and 3-amino-l-methyl-pyridin-2-one (CAS 33631-01-5; 116.7 mg, 0.94 mmol) in dioxane (40 mL) was added Xantphos (80 mg) and Pd 2 (dba)3(40 mg) under N 2 atmosphere, and then the mixture was stirred at 110 °C for another 16hr. The solvent was removed by concentration to give the crude product, which was purified by chromatography on silica gel (petroleum ether: EtOAc= 1 : 1) to give the title compound (0.5 g, crude) as yellow solid. MS (m/e): 554.1 (M+H) + .

Intermediate 62

l-[(l-Methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluorometh oxy)phenyl]-5,6,7,8- tetrahydropyrido [3,4-d] pyridazin-4-one

Step 1: 6-[(4-methoxyphenyl)methyl]-l-[(l-methyl-6-oxo-pyrimidin-5-y l)amino]-3-[4- ( trifluoromethoxyjphenyl /- 7, 8-dihydro-5H-pyrido[ 3, 4-d]pyridazin-4-one

The title compound was prepared from l-bromo-6-[(4-methoxyphenyl)methyl]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-4-one (Intermediate 55, step 1) and 5-amino-3-methyl-pyrimidin-4-one (CAS 73922-41-5) using a procedure analogous to that used to prepare Intermediate 61. MS (m/e): 555.3 (M+H) + .

Step 2: l-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trifluorometh oxy)phenyl]-5,6, 7,8- tetrahydropyridof 3, 4-d]pyridazin-4-one

The title compound was prepared from 6-[(4-methoxyphenyl)methyl]-l-[(l-methyl-6-oxo- pyrimidin-5-yl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-dih ydro-5H-pyrido[3,4-d]pyridazin- 4-one using a procedure analogous to that used to prepare example 131. MS (m/e): 435.1 (M+H) + .

Intermediate 63

4-[(l-Methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trifluorometh oxy)phenyl]-5,6,7,8- tetrahydropyrido [3,4-d] pyridazin- 1-one

Step 1: 6-[(4-methoxyphenyl)methyl]-4-[(l-methyl-6-oxo^yrimidin-5-yl )amino]-2-[4- (trifluoromethoxy)phenyl ]- 7, 8-dihydro-5H-pyrido[ 3, 4-d] pyridazin- 1 -one The title compound was prepared from 4-bromo-6-[(4-methoxyphenyl)methyl]-2-[4-

(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyr idazin-l-one (Intermediate 55, step 1) and 5-amino-3-methyl-pyrimidin-4-one (CAS 73922-41-5) using a procedure analogous to that used to prepare Intermediate 61. MS (m/e): 555.3 (M+H) + . Step 2: 4-[(l-methyl-6-oxo^yrimidin-5-yl)amino]-2-[4-(trifluorometho xy)phenyl]-5,6, 7,8- tetrahydropyridof 3, 4-dJpyridazin-l-one

The title compound was prepared from 6-[(4-methoxyphenyl)methyl]-4-[(l-methyl-6-oxo- pyrimidin-5-yl)amino]-2-[4-(trifluoromethoxy)phenyl]-7,8-dih ydro-5H-pyrido[3,4-d]pyridazin- 1-one using a procedure analogous to that used to prepare example 131. MS (m/e): 435.1 (M+H) + .

Intermediate 64

tert-Butyl 4- [2- [2-oxo-3- [ [4-oxo-3- [4-(trifluoromethoxy)phenyl] -6,7-dihydro-5H- cyclopenta[d]pyridazin-l-yl]amino]-l-pyridyl]acetyl]piperazi ne-l-carboxylate

The title compound was prepared from tert-butyl 4-(2-chloroacetyl)piperazine-l- carboxylate (CAS 190001-40-2), 3-nitro-lH-pyridin-2-one (CAS 6332-56-5) and [4-oxo-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-l-yl]

trifluoromethanesulfonate (Intermediate 9) using a sequence analagous to that used to prepare Intermediate 57. MS (m/e): 631.2 (M+H) + .

Intermediate 65

Ethyl 4-[l-oxo-4-[(2-oxo-lH-pyridin-3-yl)amino]phthalazin-2-yl]ben zoate

Step 1: 4-[(l,3-dioxoisoindolin-2-yl)amino]benzoic acid To a solution of isobenzofuran-l,3-dione (CAS 85-44-9, 5.0 g, 33.8 mmol) in AcOH (30 mL) was added 4-hydrazinylbenzoic acid hydrochloride (CAS 24589-77-3, 7.0 g, 37.1 mmol). The reaction mixture was stirred at 120 °C overnight. After cooled to rt, the brown solution was poured into water (100 mL) and the mixture was extracted with EtOAc (100 mL x 2). The combined organic phase was washed with water and brine, dried over Na 2 S0 4 , and concentrated to give the title compound (8 g, crude) as a brown solid that was used in the next reaction directly. MS (m/e): 283.1 (M+H) + .

Step 2: methyl 4-[(l,3-dioxoisoindolin-2-yl)amino]benzoate

To a mixture of 4-[(l,3-dioxoisoindolin-2-yl)amino]benzoic acid (3 g, 10.6 mmol) in MeOH (100 mL) was added SOCl 2 (13.1 g, 8 mL, 110 mmol) at 0 °C. The mixture was stirred at 70 °C for 2 h. After removal of the solvents, the residue was dissolved in EtOAc (100 mL) and washed with aqueous NaHC0 3 and brine. The organic phase was dried over anhydrous Na 2 S0 4 and concentrated. The residue was purified by column chromatography (eluting with 10% ~ 50% EtOAc in DCM) to afford the title compound (3 g) as a brown solid. MS (m/e): 297.1 (M+H) + .

Step 3: ethyl 4-(l,4-dioxo-3H-phthalazin-2-yl)benzoate To a mixture of methyl 4-[(l,3-dioxoisoindolin-2-yl)amino]benzoate (1.0 g, 3.38 mmol) in

EtOH (20 mL) was added sodium ethanolate (345 mg, 5.06 mmol) at 25 °C. After stirred at rt for 10 h, the reaction mixture was concentrated in vacuo. The resulting mixture was poured into water and acidified with concentrated HC1 to pH 3. The resulting solid was collected, washed with aq. HC1 and dried to give the title compound (600 mg) as a light yellow solid that was used in the next step directly. MS (m/e): 311.1 (M+H) + . Step 4: ethyl 4-[l-oxo-4-(trifluoromethylsulfonyloxy)phthalazin-2-yl]benzo ate

To a mixture of ethyl 4-(l,4-dioxo-3H-phthalazin-2-yl)benzoate (600 mg, 1.93 mmol), and pyridine (1.64 mL, 20.3 mmol) in DCM (20 mL) was added Tf 2 0 (399 μΐ, 2.43 mmol) dropwise at 0 °C. The mixture was stirred at rt for 2 h before quenched with sat. NH 4 C1. The mixture was extracted with EtOAc (80 mL), and the organic phase was washed with aq. HC1 and brine, dried over Na 2 S0 4 and concentrated to give the title compound (800 mg, crude). MS (m/e): 443.1 (M+H) + .

Step 5: ethyl 4-[l-oxo-4-[(2-oxo-lH-pyridin-3-yl)amino]phthalazin-2-yl]ben zoate

A mixture of ethyl 4-[l-oxo-4-(trifluoromethylsulfonyloxy)phthalazin-2-yl]benzo ate (300 mg, 678 μπιοΐ), 3-amino-l-methylpyridin-2(lH)-one (126.5 mg, 1.02 mmol), Pd 2 (dba) 3 (124 mg, 136 μηιοΐ), Xantphos (157 mg, 271 μηιοΐ) and Cs 2 C0 3 (442 mg, 1.36 mmol) in toluene (10 mL) was stirred at 100 °C for 2 h in a microwave reactor. After cooled to rt, the mixture was diluted with EtOAc (100 mL) and the organic phase was washed with water and brine. The organic phase was dried over anhydrous Na 2 S0 4 and concentrated. The residue was purified by column chromatography (eluting with 10% ~ 40% EtOAc in petroleum ether) to afford the title compound (50 mg) as a white solid. MS (m/e): 417.2 (M+H) + .

Intermediate 66

4- [(l-Methyl-2-oxo-3-pyridyl)amino] -2- [4-(trifluoromethoxy)phi

dihydrophthalazin-l-one

Step 1: dimethyl cyclohexa-1 ,4-diene-l ,2-dicarboxylate

To a solution of 2,5-dihydrothiophene 1, 1 -dioxide (CAS 77-79-2, 19.3 g, 163 mmol) in xylene (150 mL) was added dimethyl but-2-ynedioate (CAS 762-42-5, 46.4 g, 32.1 mL, 327 mmol) at rt. After refluxed under argon for 2.5 h, the reaction mixture was concentrated in vacuo. The residue was purified by column chromatography (eluting with 10% ~ 40% EtOAc in petroleum ether) to afford the title compound (28 g) as a light yellow oil . MS (m/e): 197.0 (M+H) + .

Step 2: 4, 7-dihydroisobenzofuran-l , 3-dione To a solution of dimethyl cyclohexa-l,4-diene-l,2-dicarboxylate (22 g, 112 mmol) in THF

(100 mL) was added Li OH (2 M, 112 mL, 224 mmol) at 0 °C. After stirred at rt for 56 h, the reaction mixture was neutralized with aq. HCl to pH 7. The resulting mixture was extracted with EtOAc (100 mL x 3). The combined organic phase was washed with brine, dried over Na 2 S0 4 and concentrated. The residue was treated with trifluoroacetic anhydride (78 mL, 561 mmol) and stirred at rt overnight. The mixture was concentrated under reduced pressure and the crude product was recrystallized from methanol to give the title compound (6.8 g). MS (m/e): 151.0 (M+H) + .

Step 3: 3-[4-(trifluoromethoxy)phenyl]-5,8-dihydro-2H-phthalazine-l, 4-dione

To a solution of 4,7-dihydroisobenzofuran-l, 3-dione (3.4 g, 22.6 mmol) in AcOH (40 mL) was added (4-(trifluoromethoxy)phenyl)hydrazine hydrochloride (CAS 133115-72-7, 5.69 g, 24.9 mmol) in one portion. The reaction mixture was stirred at 120 °C overnight. After cooled to rt, the brown solution was poured into water and the mixture was extracted with EtOAc (100 mL x 2). The combined organic phase was washed with water and brine, dried over anhydrous Na 2 S0 and concentrated. The crude product was recrystallized from ethyl ether to afford the title compound (3 g). MS (m/e): 325.1 (M+H) + .

Step 4: [ 4-υχυ-3-[ 4-(trifluoromethoxy)phenyl ]-5, 8-dihydrophthalazin-l-yl /

trifluoromethane sulfonate

To a mixture of 3-[4-(trifluoromethoxy)phenyl]-5,8-dihydro-2H-phthalazine-l, 4-dione (1.0 g, 3.08 mmol) and pyridine (2.5 mL, 30.8 mmol) in DCM (20 mL) was added Tf 2 0 (607 μΐ, 3.7 mmol) dropwise at 0 °C. After stirred at rt for 2 h, the reaction mixture was treated with sat. H C1 and diluted with EtOAc (100 mL). The organic phase was washed with aq. HCl and brine, dried over Na 2 S0 and concentrated to give the title compound (1.4 g, crude). MS (m/e): 457.1 (M+H) + .

Step 5: 4-[(l-methyl-2-uxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)p henyl]-5,8- dihydrophthalazin-l-one

A mixture of [4-oxo-3-[4-(trifluoromethoxy)phenyl]-5, 8-dihydrophthalazin-l-yl] trifluoromethanesulfonate (600 mg, 1.31 mmol), 3-amino-l-methylpyridin-2(lH)-one (CAS 33631-01-5, 245 mg, 1.97 mmol), Pd 2 (dba) 3 (241 mg, 263 μιηοΐ), Xantphos (304 mg, 526 μιηοΐ) and CS 2 CO 3 (857 mg, 2.63 mmol) in toluene (10 mL) was stirred at 100 °C for 2 h in a microwave reactor. After cooled to rt, the mixture was diluted with EtOAc (100 mL) and the organic phase was washed with water and brine, dried over anhydrous Na 2 S0 4 and concentrated. The crude product was recrystallized from methanol to afford the title compound (300 mg). MS (m/e): 431.1 (M+H) + .

Intermediate 67

2-[2-Oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl]amino]-l-pyridyl]acetic acid

This was prepared from methyl 2-[2-oxo-3-[[4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl]amino]-l-pyridyl]ac etate (Intermediate 44) procedure analogous to that used to prepare example 109. MS (m/e): 473.2 (M+H) + .

Intermediate 68

2-[2-Oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-te trahydrophthalazin-l- yl]amino]-l-pyridyl]acetic acid

The title compound was prepared from methyl 2-[2-oxo-3-[[4-oxo-3-[4-

(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin- 1 -yljamino]- 1 -pyridyl] acetate (Intermediate 45) using a procedure analogous to that used to prepare example 109. MS (m/e): 477.0 (M+H) + .

Intermediate 69

irans-2-[2-[[2-Oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]- 6,7-dihydro-5H- cyclopenta[d]pyridazin-l-yl]amino]-l-pyridyl]methyl]-l,3-dio xan-5-yl]isoindoline-l,3- dione

To a solution of l-[[l-(2,2-diethoxyethyl)-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one (Intermediate 47; 300 mg, 0.57 mmol) and 2-[2-hydroxy-l-(hydroxymethyl)ethyl]isoindoline-l,3-dione (127 mg, 0.57 mmol) in anhydrous toluene (10 mL) was added TsOH (20 mg, 0.11 mmol). The reaction was heated to 110 °C and stirred for 12 hr. The reaction was evaporated and the residue was dissolved in EtOAc (20 mL) and washed with aqueous NaHC0 3 (10 mL). The organic layer was evaporated and purified by column chromatography (PE:EA=3 : 1) to give the title product (200 mg, yield 54.0%) as a grey solid. MS (m/e): 649.9 (M+H) + .

Intermediate 70

Methyl 2-(3-amino-2-oxo-l-pyridyl)acetate hydrochloride salt

Step 1: methyl 2-(3-nitro-2-oxo-l-pyridyl)acetate

To a suspension of NaH (600 mg, 15 mmol) in DMF (30 mL) was added 3-nitropyridin- 2(lH)-one (CAS 6332-56-5, 2.1 g, 15 mmol) portionwise and the mixture was stirred at 0 °C for 30 min and then at rt for 30 min. Methyl 2-bromoacetate (CAS 96-32-2, 2.29 g, 15 mmol) was added into the flask. The reaction mixture was stirred for 2 h before concentrated in vacuo. The residue was dissolved in EtOAc (100 mL) and washed with water (30 mL x 2) and brine. The organic phase was dried over anhydrous Na2S04 and concentrated. The residue was purified by flash chromatography (eluting with a gradient of petroleun ether : EtOAc) to afford the title compound as a yellow solid (2.2 g, 68% yield). MS (m/e): 213 (M+H) + . Step 2: methyl 2-(3-amino-2-oxo-l-pyridyl)acetate hydrochloride

To a solution of methyl 2-(3-nitro-2-oxopyridin-l(2H)-yl)acetate (2.1 g, 9.9 mmol) in MeOH (30 mL) and THF (10 mL) was added Pd/C (105 mg), and the mixture was charged with a hydrogen balloon and stirred at rt overnight. After filtration to remove the catalyst, the filtrate was treated with concentrated HC1 (2 mL) and concentrated. The solid residue was washed with Et20 (10 mL x 2) and dried under vacuum to give the title compound as a light grey product, which was used in the next step without purification (2.0 g, 92% yield). MS (m/e): 183.0 (M+H) + .

In analogy to Intermediate 70 compounds of the following table were prepared using 3- nitro ridin-2(lH)-one (CAS 6332-56-5) and different halides as reactants:

Intermediate 74: 1H NMR: (CDC1 3 , 400MHz) δ 6.85 (dd, J=1.8, 6.8 Hz, IH), 6.41 (dd, J=1.8, 7.2 Hz, IH), 6.01 (t, J=6.9 Hz, IH), 5.06 (s, 2H), 3.87 (t, J=7.2 Hz, 2H), 2.40 (br. s., 3H), 2.26 (t, J=7.0 Hz, 2H), 2.21 (s, 3H), 1.77 (quin, J=7.1 Hz, 2H). Intermediate 75: 1H MR: (CDC1 3 , 400MHz) δ 6.82 (dd, J=1.8, 6.8 Hz, 1H), 6.39 (dd, J=1.8, 7.0 Hz, 1H), 6.00 (t, J=6.9 Hz, 1H), 5.04 (br. s., 2H), 4.55 (br. s., 1H), 3.88 (t, J=7.0 Hz, 2H), 3.40-3.32 (m, 2H), 1.73 (quin, J=6.6 Hz, 2H).

Intermediate 81

Methyl (2R)-l-[2-(3-amino-2-oxo-l-pyridyl)ethyl]pyrrolidine-2-carbo xylate

Step 1: l-(2-bromoethyl)-3-nitro-pyridin-2-one

To a suspension solution of NaH (400 mg, 9.99 mmol) in DMF (10 mL) was added 3- nitropyridin-2(lH)-one (CAS 6332-56-5, 1.4 g, 9.99 mmol) and the mixture was stirred at rt for 1 h. Then the mixture was added dropwise to a preheated solution of 1,2-dibromoethane (5.63 g, 30 mmol) in DMF (5 mL) at 80 °C. The mixture was stirred at 80 °C for 1 h and cooled to rt. After removal of the solvent, the residue was dissolved in EtOAc (60 mL) and the organic phase was washed with water (20 mL), dried and concentrated. The residue was purified by silica gel chromatography (eluting with a gradient of petroleum ether : EtOAc) to afford 1 -(2-bromoethyl)- 3-nitro-pyridin-2-one as a light yellow oil (1.42 g, 58% yield). MS (m/e): 247.0 and 249.0 (M+H) + .

Step 2: methyl (2R)-l-[2-(3-nitro-2-oxo-l-pyridyl)ethyl]pyrrolidine-2-carbo xylate

A mixture of l-(2-bromoethyl)-3-nitropyridin-2(lH)-one (300 mg, 1.21 mmol), (R)-methyl pyrrolidine-2-carboxylate hydrochloride (CAS 65365-28-8, 201 mg, 1.21 mmol) and DIPEA (785 mg, 1.06 mL, 6.07 mmol) in DMF (5 mL) was stirred at 100 °C for 6 h. After removal of the solvent, the residue was purified by flash chromatography (eluting with a gradient of petroleum ether : EtOAc) to the title compound as a yellowish viscous oil (110 mg,: 31% yield). MS (m/e): 296.1 (M+H) + . Step 3: methyl (2R)-l-[2-(3-amino-2-oxo-l-pyridyl)ethyl]pyrrolidine-2-carbo xylate

To a solution of (R)-m ethyl l-(2-(3-nitro-2-oxopyridin-l(2H)-yl)ethyl)pyrrolidine-2- carboxylate (110 mg, 373 μπιοΐ) in MeOH (10 mL) was added Pd/C (7 mg, 65.8 μπιοΐ) and the mixture was charged with a hydrogen balloon and stirred at rt for 3 h. The mixture was filtered and the filtrate was concentrated under vacuum to afford the title compound as light brown viscous oil (87 mg, 88% yield). MS (m/e): 266.1 (M+H) + .

In analogy to Intermediate 81 compounds of the following table were prepared using l-(2- bromoeth l)-3-nitropyridin-2(lH)-one and different amines as reactants:

Intermediate 86: 1H MR: (CDC1 3 , 400MHz) δ 6.81 (dd, J=1.7, 6.8 Hz, 1H), 6.41 (dd, J=1.7, 7.2 Hz, 1H), 5.99 (t, J=7.0 Hz, 1H), 5.26 (br. s., 1H), 5.04 (s, 2H), 4.11 (br. s., 1H), 3.79 (t, J=6.3 Hz, 2H), 3.53-3.42 (m, 2H), 2.76-2.57 (m, 4H).

Intermediate 95

5-Amino-3-[2-(dimethylamino)ethyl]pyrimidin-4-one hydrochloride

Step 1: 5-bromo-3-[2-(dimethylamino)ethyl]pyrimidin-4-one To a solution of 5-bromo-lH-pyrimidin-6-one (CAS 19808-30-1; 3.0 g, 17.1 mmol) in

DMF (50.0 mL) was added Cs 2 C0 3 (8.4 g, 25.65 mmol) at 20 °C under N 2 . Then 2-chloro-N,N- dimethyl -ethanamine hydrochloride (CAS 4584-46-7; 3.0 g, 20.6 mmol) was added. Then the reaction mixture was heated to 60 °C and stirred for 16h. Solvent was removed in vacuum to dryness to give a residue which was diluted with EtOAc (100.0 mL), washed with water (50.0 mL), dried and concentrated to give crude product which was purified by column

chromatography on silica gel (DCM/MeOH from 300: 1 to 80: 1) to give the title compound (1.6 g, 38.1% yield) as a yellow solid. 1H MR: (400MHz, CDC1 3 ) δ 8.20 (s, 1H), 8.07 (s, 1H), 4.04- 4.01 (t, J=5.6 Hz 2H), 2.64-2.61 (t, J=5.8 Hz, 2H), 2.26 (s, 6H).

Step 2: tert-butyl N-[l-[2-(dimethylamino)ethyl]-6-oxo-pyrimidin-5-yl) 'carbamate A mixture of 5-bromo-3-[2-(dimethylamino)ethyl]pyrimidin-4-one (0.5 g, 2.03 mmol), H 2 Boc (0.35 g, 3.04 mmol), Pd 2 (dba) 3 (100 mg), xantphos (100 mg) and K 2 C0 3 (0.56 g, 4.06 mmol) in dioxane (8.0 mL) was charged with N 2 and the mixture was stirred at 100 °C for 16 hr. After cooling, solvent was removed in vacuum to dryness to give a residue which was purified by column chromatography on silica gel (from DCM to DCM/MeOH=80/l) to give the title compound (0.4 g, 71.2% yield) as a yellow solid. MS (m/e): 283.0 (M+H) + .

Step 3: 5-amino-3-[2-(dimethylamino)ethyl]pyrimidin-4-one hydrochloride

To the solution of tert-butyl N-[l-[2-(dimethylamino)ethyl]-6-oxo-pyrimidin-5- yl]carbamate (0.4 g, 1.42 mmol) in MeOH (4.0 mL) was added HCl/MeOH (4.0 mL) at 0 °C. The reaction mixture was heated to 40 °C and stirred for 2h. Solvent was removed in vacuum to dryness to give the title compound (0.3 g, crude) as yellow solid which was used in the next step without further purification. MS (m/e): 183.0 (M+H) + .

In analogy to Intermediate 95 compounds of the following table were prepared using 5- bromo-lH- rimidin-6-one (CAS 19808-30-1) and different halides as reactants:

Intermediate 101

Methyl 3-(3-amino-2-o -l-pyridyl)-2,2-dimethyl-propanoate

Step 1: methyl 3-bromo-2,2-dimethyl-propanoate

To a solution of 3-bromo-2,2-dimethylpropanoic acid (CAS 2843-17-6, 2.7 g, 14.9 mmol) in MeOH (30 mL) was added SOCl 2 (3.55 g, 2.18 mL, 29.8 mmol) dropwise. The mixture was stirred at refluxing conditions overnight. After cooled to rt, the mixture was concentrated and the residue was redisssolved in ether (50 mL). The organic phase was washed with aqueous NaHC0 3 , dried over anhydrous Na 2 S0 4 and concentrated under vacuum to afford a colorless oil that was used in the next step without further purification. (1.5 g, 52% yield).

Step 2: methyl 2,2-dimethyl-3-(3-nitro-2-oxo-l-pyridyl)propanoate

To a stirring mixture of 3-nitropyridin-2(lH)-one (CAS 6332-56-5, 420mg, 3 mmol) and K 2 C0 3 (621 mg, 4.5 mmol) in DMF (5 mL) was added methyl 3-bromo-2,2-dimethylpropanoate (643 mg, 3.3 mmol) and the mixture was stirred at 130 °C overnight in a sealed tube. After removal of DMF in vacuo, the residue was dissolved in EtOAc (50 mL) and filtered to remove solid particles. The fitrate was concentrated and the residue was purified by flash

chromatography (eluting with a gradient of petroleum ether : EtOAc) to afford the title compound as a light yellow oil (300 mg, yield of 39%). MS (m/e): 255 (M+H) + .

Step 3: methyl 3-(3-amino-2-oxo-l-pyridyl)-2,2-dimethyl-propanoate

A mixture of methyl 2,2-dimethyl-3-(3-nitro-2-oxopyridin-l(2H)-yl)propanoate (300 mg, 1.18 mmol) and Pd/C (12.6 mg, 118 μπιοΐ) in MeOH (20 mL) was charged with a hydrogen balloon, and the mixture was stirred at rt overnight. After filtration to remove the catalyst, the filtrate was concentrated under vacuum to afford the title compound as light yellow oil that was used in the next step without purification (263 mg, 99% yield). MS (m/e): 225.1 (M+H) + .

Intermediate 102

Methyl 5-amino-l-methyl-6-oxo-pyridine-3-carboxylate

To a solution of methyl l-methyl-5-nitro-6-oxo-l,6-dihydropyridine-3-carboxylate (CAS 153888-41-6, 0.95 g, 4.48 mmol) in MeOH (15 mL) and THF (10 mL) was added Pd/C (47.7 mg, 448 μπιοΐ), and the mixture was charged with a hydrogen balloon and stirred at rt for 4 h. The mixture was filtered and the filtrate was concentrated under vacuum to give a light brown solid, which was washed with EtOAc (10 mL). The powder was collected and dried to give the title compound as a light grey solid (620 mg, 75% yield). MS (m/e): 183.0 (M+H) + .

Intermediate 103

3-Amino-5-ethyl-l-methyl-pyridin-2-one Step 1: 5-ethyl-3-nitro-lH-pyridin-2-one

To a solution of 5-ethyl-lH-pyridin-2-one (CAS 53428-03-8; 3.0 g, 24 mmol) in cone. H 2 S0 4 (20 mL) was added cone. HNO3 (6 mL) dropwise at 0-5 °C. After addition, the reaction was warmed to 25 °C and stirred for 12 hr. The reaction was poured onto ice/water (100 g). The mixture was basified to pH at 7-8 and then extracted with DCM (50 mL x 3). The organic phase was evaporated to give the crude product, the crude product was added to petroleum

ether/EtOAc (20 mL/3 mL) and stirred for 2 hr. The mixture was then filtered to give the title compound (2.5 g) as a yellow solid. 1H NMR: (DMSO, 400MHz) δ 8.37 (d, J=2.6 Hz, 1H), 7.74 (d, J=2.5 Hz, 1H), 2.45 (q, J=7.5 Hz, 2H), 1.12 (t, J=7.5 Hz, 3H). Step 2: 5-ethyl-l-methyl-3-nitro-pyridin-2-one

To a solution of 5-ethyl-3-nitro-lH-pyridin-2-one (3.0 g, 17.8 mmol) and K 2 C0 3 (4.9 g, 35.6 mmol) in DMF (20 mL) was added CH 3 I (42.45 g, 300 mmol). The reaction was heated to 60-70 °C and stirred for 4 hr. The reaction was poured onto H 2 0 (100 mL) and the pH adjusted to 7-8. The mixture was extracted with EtOAc (150 mL). The organic phase was washed with brine (30 mL x 3). The organic phase was evaporated to give the title compound (2.8 g, yield 85%) as a yellow solid. 1H NMR: (DMSO, 400MHz) δ 8.35 (d, J=2.5 Hz, 1H), 8.12 (d, J=2.5 Hz, 1H), 3.55 (s, 3H), 2.46 (q, J=7.6 Hz, 2H), 1.14 (t, J=7.5 Hz, 3H).

Step 3: 3-amino-5-ethyl-l-methyl-pyridin-2-one

To a solution of 5-ethyl-l-methyl-3-nitro-pyridin-2-one (1.0 g, 5.5 mmol) in MeOH (14 mL) and EtOAc (6 mL) was added Pd/C (0.5 g). The mixture was degassed 3 times and then refilled with hydrogen (50 PSI). The reaction was stirred for 2 hr at 25 °C. The reaction was filtered through celite and the filtrate was evaporated to give the title compound (0.66 g, yield 79%) as a black oil, which was used directly for the next step. 1H NMR: (DMSO, 400MHz) δ 6.71-6.66 (m, 1H), 6.36 (d, J=2.3 Hz, 1H), 5.04 (s, 2H), 3.39 (s, 3H), 2.26 (q, J=7.5 Hz, 2H), 1.07 (t, J=7.5 Hz, 3H).

Intermediate 104

3-Amino-5-isopropyl-l-methyl-pyridin-2-one

This was prepared from 5-isopropyl-lH-pyridin-2-one (CAS 137013-12-8) using an analogous procedure to that used to prepare Intermediate 103.

Intermediate 105

Methyl 4-(3-amino- l-pyridyl)butanoate

Step 1: methyl 4-(5-chloro-3-nitro-2-oxo-l-pyridyl)butanoate

To a stirring mixture of 5-chloro-3-nitropyridin-2(lH)-one (CAS 21427-61-2, 698 mg, 4 mmol) and K 2 C0 3 (829 mg, 6 mmol) in DMF (5 mL) preheated to 120 °C was added methyl 4- bromobutanoate (CAS 4897-84-1, 797 mg, 4.4 mmol) dropwise. The mixture was stirred at 120 °C for 2 h and concentrated in vacuo. The residue was dissolved in EtOAc(50 mL) and filtered to remove solid particles. The filtrate was concentrated and the residue was purified by flash chromatography (eluting with a gradient of petroleum ether : EtOAc) to afford the title compound as a light yellow oil (570 mg, yield of 52%). MS (m/e): 275 (M+H) + . Step 2: methyl 4-(3-amino-5-chloro-2-oxo-l-pyridyl)butanoate

A mixture of methyl 4-(5-chloro-3-nitro-2-oxopyridin-l(2H)-yl)butanoate (200 mg, 728 μιηοΐ, Eq: 1) and Pd/C (7.75 mg, 72.8 μιηοΐ, Eq: 0.1) in MeOH (10 mL) and CH 2 C1 2 (1 mL) was charged with a hydrogen balloon and stirred at rt for 40 min. After removal of the catalyst, the filtrate was concentrated under vacuum and the residue was purified by flash chromatography (eluting with a gradient of petroleum ether. EtOAc) to afford the title compound as light brown oil (40 mg, yield of 22%). MS (m/e): 245.0 (M+H) + . Intermediate 106

tert-Butyl N- [2-(3-amino-2-oxo- l-pyridyl)ethyl] carbamate

Step 1: tert-butyl N-[2-(3-nitro-2-oxo-l-pyridyl)ethyl) J carbamate To a mixture of l-(2-bromoethyl)-3-nitropyridin-2(lH)-one (350 mg, 1.42 mmol) and tert- butyl carbamate (CAS 4248-19-5, 332 mg, 2.83 mmol) in DMF (5 mL) was added sodium tert- butoxide (136 mg, 1.42 mmol), and the mixture was stirred at rt overnight. After removal of the solvent under vacuum, the residue was dissolved in EtOAc (30 mL) and the organic phase was washed with water, dried and concentrated. The residue was purified by silica gel

chromatography (eluting with a gradient of petroleum ether : EtOAc) to afford the title compound as a light yellow solid (120 mg, 30% yield). MS (m/e): 284 (M+H) + .

Step 2: tert-butyl N- [2-(3-amino-2-uxu- 1 -pyr idyl) ethyl) 'carbamate

A mixture of tert-butyl (2-(3-nitro-2-oxopyridin-l(2H)-yl)ethyl)carbamate (100 mg, 353 μπιοΐ) and Pd/C (7 mg, 65.8 μπιοΐ) in MeOH (10 mL) was charged with a hydrogen balloon and stirred at rt for 3 h. After filtration, the filtrate was concentrated under vacuum to give the title compound as light brown viscous oil that was used in the next step directly (90 mg with 40% purity from LC-MS, yield of 40%). MS (m/e): 254 (M+H) + .

Intermediate 107

3-(3-Amino-2-oxo-l-pyridyl)propane-l-sulfonamide

Step 1: 3-(3-nitro-2-oxo-l-pyridyl)propane-l-sulfonic acid

A solution of 3-nitropyridin-2(lH)-one (CAS 6332-56-5, 560 mg, 4 mmol), 1,2- oxathiolane 2,2-dioxide (CAS 1120-71-4, 635 mg, 5.2 mmol) and NaOH (208 mg, 5.2 mmol) in dry EtOH (30 mL) was stirred at 70 °C for 1 h. After the reaction was completed, the mixture was cooled to rt and filtered to afford the title compound (800 mg, 76% yield). MS (m/e): 263.0 (M+H) + .

Step 2: 3-(3-nitro-2-oxo- 1 -pyridyl)propane- 1 -sulfonyl chloride

To a solution of 3 -(3 -nitro-2-oxopyridin-l(2H)-yl)propane-l -sulfonic acid (1.05 g, 4 mmol) in dry THF (30 mL) was added SOCl 2 (4.76 g, 2.92 mL, 40 mmol) and the mixture was stirred at 70 °C for 1 h. The solvent was removed in vacuo to afford the title compound as a crude product (1.1 g). MS (m/e): 281.0 (M+H) + .

Step 3: 3-(3-nitro-2-oxo- 1 -pyridyljpropane- 1 -sulfonamide

To a solution of 3 -(3 -nitro-2-oxopyridin-l(2H)-yl)propane-l -sulfonyl chloride (200 mg, 713 μπιοΐ) in THF (10 mL) was added ammonia (14.3 mmol) at 0 °C, and the mixture was stirred at rt overnight. The solvents were removed under reduced pressure to afford the title compound as a crude prouct (180 mg). MS (m/e): 262.0 (M+H) + .

Step 4: 3-(3-amino-2-oxo-l-pyridyl)propane-l-sulfonamide

A solution of 3 -(3 -nitro-2-oxopyri din- l(2H)-yl)propane-l -sulfonamide (180 mg, 689 μπιοΐ) and Pd/C (14.7 mg, 138 μπιοΐ) in MeOH (10 mL) was charged with 1 atm of hydrogen and stirred at rt overnight. After filtration to remove the catalyst, the filtrate was concentrated under vacuum to give the title compound (84 mg, yield of 60%). MS (m/e): 232.0 (M+H) + .

Intermediate 108

3-(3-Amino-2-oxo-l-pyridyl)-N,N-dimethyl-propane-l-sulfonami de

The title compound was prepared from 3-(3-nitro-2-oxo-l-pyridyl)propane-l-sulfonyl chloride and dimethylamine hydrochloride using an analogous procedure to that used in the preparation of Intermediate 107.

Intermediate 109

tert-Butyl N- [2-hydroxy-2-methyl-3- [2-oxo-3-[[4-oxo-3- [4-(trifluoromethoxy)phenyl] -6,7- dihydro-5H-cyclopenta [d] pyridazin-1 -yl] amino] - 1-pyridyl] propyl] carbamate

Step 1: l-azido-3-chloro-2-methyl-propan-2-ol To a solution of l-azido-3-chloro-2-methyl-propan-2-ol (CAS 1029615-90-4; 1.2 g, 8.7 mmol) in DMF (20.0 mL) was added Cs 2 C0 3 (4.25 g, 13.0 mmol) at 20 °C under N 2 . Then 3- nitro-lH-pyridin-2-one (CAS 6332-56-5; 1.3 g, 8.7 mmol) was added and the reaction mixture heated to 60 °C and stirred for 16h. Solvent was removed in vacuum to dryness to give a residue which was diluted with EtOAc (50.0 mL), washed with water (50.0 mL), dried and concentrated to give a residue which was purified by column chromatography on silica gel (petroleum ether/EtOAc from 10/1 to 5/1) to give the title compound (0.7 g, 32% yield) as a colorless oil. 1H MR: (CDC1 3 , 400MHz) δ 8.39-8.37 (m, 1 H), 7.82-7.79 (m, 1 H), 6.39-6.35 (t, J=7.2 Hz, 1 H), 4.27-4.12 (m, 2 H), 3.44-3.31 (m, 2 H), 1.31 (s, 3 H).

Step 2: tert-butyl N-[2-hydroxy-2-methyl-3-(3-nitro-2-oxo-l-pyridyl)propyl]carb amate

To a solution of l-azido-3-chloro-2-methyl-propan-2-ol (0.7 g, 2.37 mmol) in THF/H 2 0 (6/1.5 mL) was added PPh 3 (0.9 g, 3.56 mmol) at 5 °C under N 2 . Then the reaction mixture was warmed to 20 °C and stirred for 16h. To the reaction mixture was added Boc 2 0 (1.12 g, 4.74 mmol) and TEA (0.48 g, 4.74 mmol). The reaction was stirred at 20 °C for another 16h. Solvent was removed in vacuum to dryness to give a residue which was purified by column

chromatography in silica gel (petroleum ether/EtOAc from 10/1 to EtOAc) to give the title compound (0.27 g, 34.6% yield) as a yellow solid. MS (m/e): 350.1 (M+Na) + . Step 3: tert-butyl N-[3-(3-amino-2-oxo-l-pyridyl)-2-hydroxy-2-methyl-propyl) J carbamate

To a solution of tert-butyl N-[2-hydroxy-2-methyl-3-(3-nitro-2-oxo-l- pyridyl)propyl]carbamate (250.0 mg, 0.764 mmol) in MeOH (10.0 mL) was added Pd/C (200.0 mg) at 20 °C. Then the reaction mixture was stirred at 20 °C under hydrogen (balloon) and stirred for 16h. The mixture was filtered and concentrated to give the title compound (0.18 g, crude) as yellow solid which was used in next step without further purification. MS (m/e): 198.0 (M+H-Boc) + .

Step 4: tert-butyl N-[2-hydroxy-2-methyl-3-[2-oxo-3-[[4-oxo-3-[4- (trifluoromethoxy)phenyl]-6, 7-dihydro-5H-cyclopenta[d]pyridazin-l-yl] amino] -1- pyridyl ] propyl ] carbamate

A mixture of tert-butyl N-[3-(3-amino-2-oxo-l-pyridyl)-2-hydroxy-2-methyl- propyl]carbamate (166.0 mg, 0.375 mmol), [4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro- 5H-cyclopenta[d]pyridazin-l-yl] trifluoromethanesulfonate (Intermediate 12; 150.0 mg, 0.375 mmol), Pd2(dba)3 (50 mg), Xantphos (50 mg) and K 2 C0 3 (103.5 mg, 0.75 mmol) in dioxane (15.0 mL) was charged with N 2 , and the mixture was stirred at 100 °C for 16 hr. The mixture was concentrated and the residue was purified by column chromatography on silica gel (petroleum ether/EtOAc from 10/1 to EtOAc) to give the title compound (0.15 g, crude) as yellow solid. MS (m/e): 492.2 (M+H-Boc) + .

Intermediate 110

(4-tert-Butyl-2-fluoro-phenyl)hydrazine hydrochloride

A solution of 4-tert-butyl-2-fluoro-aniline (CAS 129373-04-2; 1.2 g, 7.18 mmol) in 6N HCl (12 mL) was cooled to 0 °C. NaN0 2 (0.59 g, 8.62 mmol) in water (5 mL) was added dropwise to a solution at 0 °C for 0.5h. Then SnC1.2H 2 0 (4.1 g, 17.95 mmol) in 6N HCl (12 mL) was added dropwise to the solution at 0 °C for 3hr, then the reaction was stirred and allowed to warm to 25 °C for lhr. The mixture was filtered to give the title compound (1.3 g, yield: 83.6%) as a white solid. 1 HNMR: (DMSO, 400MHz) δ 10.32 (br. s., 3H), 7.23-7.14 (m, 3H), 1.29-1.20 (m, 9H). Intermediate 111

(6-Ethoxy-3-pyridyl)hydrazine hydrochloride The title compound was prepared from 6-ethoxypyridin-3 -amine (CAS 52025-34-0) using a procedure analogous to that used to prepare Intermediate 110.

Intermediate 112

6,7-Dihydro-4H-furo[3,4-c]pyran-l,3-dione

Step 1: 5-ethoxycarbonyl-3,6-dihydro-2H-pyran-4-carboxylic acid

A mixture of HC0 2 Na (6.7 g, 98.6 mmol), Ac 2 0 (6.4 g, 63.6 mmol), and z-Pr 2 Et (8.0 g, 63.6 mmol) was stirred at 15 °C for 1 h. To this mixture were added ethyl 4- (trifluoromethylsulfonyloxy)-3,6-dihydro-2H-pyran-5-carboxyl ate (CAS 1068523-55-6, 10.0 g, 32.8 mmol) in DMF (100 mL), Pd(OAc) 2 (0.37 g, 1.64 mmol), and LiCl (4.1 g, 98.6 mmol) sequentially, and the stirring was continued for another 1 h. The mixture was poured into a separatory funnel where it was partitioned between 2 NHC1 and EtOAc. Then the organic extracts were combined, dried over Na 2 S0 4 , filtered, and concentrated to give the crude product (11.0 g, crude). Step 2: 6, 7-dihydro-4H-furo[3,4-c]pyran-l,3-dione

To a solution of 5-ethoxycarbonyl-3,6-dihydro-2H-pyran-4-carboxylic acid (10.0 g, 50.0 mmol) in CH 3 OH (50.0 mL) and H 2 0 (50.0 mL) was added Li OH (6.7 g g, 150.0 mmol) at 15 °C under N 2 . The reaction mixture was stirred at 15 °C for 3 h. The reaction mixture was concentrated, then added H 2 0 (100 mL) and adjust PH of the mixture to 3-5. The aqueous phase was extracted with EtOAc (100 mL x 3). The combine organic phases were concentrated to give a white solid (11.0 g). The white solid (11.0 g, 63.9 mmol) in Ac 2 0 (110 mL) was stirred at 130 °C for 3 h. The mixture was concentrated to give the crude title product (5.0 g).

Intermediate 113

[3-[2-Methyl-4-(trifluoromethoxy)phenyl]-4-oxo-6,7-dihydr o-5H-cyclopenta[d]pyridazin-l- yl] trifluoromethanesulfonate

The title compound was prepared from [2-methyl-4-(trifluoromethoxy)phenyl]hydrazine (CAS 1801321-38-9) and 5,6-dihydro-4H-cyclopenta[c]furan-l,3-dione (CAS 3205-94-5) using a procedure analogous to that used to prepare intermediate 9. MS (m/e): 459.0 (M+H) + .

Intermediate 114

The title compound was prepared from (3,4-dimethoxyphenyl)hydrazine (CAS 63756-98- 9) and 5,6-dihydro-4H-cyclopenta[c]furan-l,3-dione (CAS 3205-94-5) using a procedure analogous to that used to prepare intermediate 9. MS (m/e): 421.0 (M+H) + . Intermediate 115

[3-[3-Methoxy-4-(trifluoromethyl)phenyl]-4-oxo-6,7-dihydro-5 H-cyclopenta[d]pyridazin-l- yl] trifluoromethanesulfonate

The title compound was prepared from [3-methoxy-4-(trifluoromethyl)phenyl]hydrazine

(CAS 1388058-17-0) and 5,6-dihydro-4H-cyclopenta[c]furan-l,3-dione (CAS 3205-94-5) using a procedure analogous to that used to prepare intermediate 9. MS (m/e): 459.0 (M+H) + .

Intermediate 116

l-Methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5,6, 7,8-tetrahydrophthalazin-l- yl] amino] pyridine-3-carboxylic acid

To a solution of methyl l-methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5, 6,7,8- tetrahydrophthalazin-l-yl]amino]pyridine-3-carboxylate (Example 23; 70 mg, 143 μιηοΐ) in water (5 mL) and THF (5 mL) was added lithium hydroxide monohydrate (59.9 mg, 1.43 mmol), and the mixture was heated to reflux for 4 hr. The mixture was evaporated, the remaining aqueous solution was acidified by HCl to pH~2 to precipitate a solid. The mixture was filtered, and the solid residue was washed with water. The solid was collected and dried to give the title compound (67 mg, 97.5%). MS (m/e): 477.2 (M+H) + . Intermediate 117

l-Methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]ph thalazin-l-yl]amino]pyridine-3- carboxylic acid

The title compound was prepared from methyl 1 -methyl -6-oxo-5-[[4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl]amino]pyridine-3-ca rboxylate (Intermediate 118) using a procedure analogous to that used to prepare intermediate 116. MS (m/e): 473.1 (M+H) + .

Intermediate 118

Methyl l-methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phtha lazin-l- yl] amino] pyridine-3-carboxylate

The title compound was prepared from [4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- 1-yl] trifluoromethanesulfonate (Intermediate 1) and methyl 5-amino-l-methyl-6-oxo-pyridine- 3-carboxylate (Intermediate 103) using a method analogous to that used to prepare Example 23. MS (m/e): 487.3 (M+H) + . Example 1

4- [(l-methyl-2-oxo-3-pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl] phthalazin-l-one

A mixture of [4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin-l-yl]

trifluoromethanesulfonate (Intermediate 1; 0.3 g, 0.66 mmol), 3-amino-l-methyl-pyridin-2-one (CAS 33631-01-5; 0.16 g, 1.32 mmol), Pd 2 (dba) 3 (0.11 g, 0.13 mmol), Xantphos (70.0 mg, 0.13 mmol) and K 2 C0 3 (0.27 g, 1.98 mmol) in dioxane (30 mL) was stirred at 100 °C for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the crude product (0.5 g). The crude product was purified by silica gel (PE: EA =3 : 1/1 : 1) and recrystallized from CH 3 OH (10 mL) to give the title compound (96.0 mg, 34.2%) as a white solid. MS (m/e): 429.1 (M+H) + .

In analogy to Example 1 compounds of the following table were prepared using different amines and trifluoromethanesulfonates or bromides as reactants:

Example 88

4- [[l-(2-Morpholino-2-oxo-ethyl)-2-oxo-3-pyridyl] amino]

(trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of 2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l- yl]amino]-l-pyridyl]acetic acid (Intermediate 67; 35 mg, 74.1 μιηοΐ), morpholine (19.4 mg, 222 μπιοΐ) and Et3N (37.5 mg, 51.6 μΐ, 370 μπιοΐ) in DMF (3 mL) was added HATU (42.3 mg, 111 μιηοΐ) and the mixture was stirred at rt for 4 h. After removal of the solvent, the residue was mixed with 0.5 N HCl (10 mL) and ultrasonicated for 5 min. The solid was collected and washed with water (5 mL twice). The solid was dried to afford Example 88 as a light grey solid (32 mg, yield:78%). MS (m/e): 542.2 (M+H) + .

In analogy to Example 88 compounds of the following table were prepared using different carboxylic acids and amines as reactants: mass

Example Starting found

Structure Systematic Name

No. materials (M+H)

+

N,N-dimethyl-2-[2-oxo-

3-[[4-oxo-3-[4- Intermediate

89 HN (trifluoromethoxy)phenyl 67 and CAS 500.2

] phthal azin- 1 -yl ] amino] - 124-40-3

l-pyridyl]acetamide

N-i sopropyl-2- [2-0X0-3 -

[[4-oxo-3-[4- Intermediate

90 (trifluoromethoxy)phenyl 67 and CAS 514.1

] phthal azin- 1 -yl ] amino] - 75-31-0

l-pyridyl]acetamide

N-methyl-2-[2-oxo-3- [[4-oxo-3-[4- Intermediate

91 „ N XJ (trifluoromethoxy)phenyl 67 and CAS 486.2

] phthal azin- 1 -yl ] amino] - 74-89-5

l-pyridyl]acetamide

N,N-dimethyl-3-[2-oxo-

3-[[4-oxo-3-[4- Example 109

HN (trifluoromethoxy)phenyl and CAS 514.1

] phthal azin- 1 -yl ] amino] - 124-40-3

1 -pyridyl]propanamide

N-methyl-4-[2-oxo-3- [[4-oxo-3-[4- Example 110

N X (trifluoromethoxy)phenyl and CAS 74- 514.2

] phthal azin- 1 -yl ] amino] - 89-5

1 -pyridyl]butanamide

N,N-dimethyl-4-[2-oxo-

3-[[4-oxo-3-[4- Example 110

(trifluoromethoxy)phenyl and CAS 528.2 ] phthal azin- 1 -yl ] amino] - 124-40-3

1 -pyridyl]butanamide

N,2,2-trimethyl-3-[2- oxo-3-[[4-oxo-3-[4- Example 111

(trifluoromethoxy)phenyl and CAS 74- 528.2 ] phthal azin- 1 -yl ] amino] - 89-5

1 -pyridyl]propanamide

Example 109

3-[2-Oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l-yl]amino]-l- pyridyl] propanoic acid

To a solution of methyl 3-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]phthalazin- l- yl]amino]-l-pyridyl]propanoate (Example 69; 116 mg, 0.232 mmol) in THF (5 mL) and water (5 mL) was added lithium hydroxide monohydrate (29.4 mg, 0.7 mmol), and the mixture was stirred for 3 h. After removal of THF, the remained aqueous solution was acidified by HCl to pH 3 and extracted by EtOAc. The organic phase was washed with brine, dried over anhydrous Na 2 S0 4 and concentrated to afford a light grey solid (112 mg, yield: 94%). MS (m/e): 587.1 (M+H)+. In analogy to Example 109 compounds of the following table were prepared using different esters and LiOH as reactants:

mass

Example Starting found

Structure Systematic Name

No. materials (M+H)

+ o

4-[6-oxo-5-[[4-oxo-3- [4-

(trifluoromethoxy)phen

Intermediate

124 yl]-6,7-dihydro-5H- 492.1

56

cyclopenta[d]pyridazin- 1 -yl]amino]pyrimidin- l-yl]butanoic acid

Example 125

7-Hydroxy-4- [(1 -methyl-2-oxo-3-pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl] phthalazin- -one

To a solution of 7-benzyloxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one (Intermediate 37; 180.0 mg, 0.34 mmol) in THF (5.0 mL) was added Pd/C (100 mg) at 20 °C. Then the mixture was stirred for 3 h at 20 °C under H 2 balloon. Solvent was removed in vacuum to dryness to give crude product which was purified by prep-HPLC (base) to give the title compound (25.5 mg, 16.8% yield) as white solid. MS (m/e): 445.1 (M+H) + . Example 126

6-Hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluor omethoxy)phenyl]phthalazin- -one

A mixture of compound 6-benzyloxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-

(trifluoromethoxy)phenyl]phthalazin-l-one (Intermediate 38; 0.15 g, 0.28 mmol) and Pd/C (30.0 mg) in THF (10 mL) was stirred under H 2 (balloon, 15 psi) at 25 °C for 2 h. The reaction mixture was filtered and the filtration was concentrated to give the crude product (0.18 g). The crude product was firstly purified recrystallized from EA (10 mL x 2) to give the title product (35.8 mg, 29.8%) as a white solid. MS (m/e): 445.2 (M+H) + .

Example 127

l-[[l-(morpholin-3-ylmethyl)-2-oxo-3-pyridyl]amino]-3-[4-(tr ifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one

To a solution of l-[[l-[(4-benzylmo holin-3-yl)methyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one (Intermediate 57; 150 mg, 0.162 mmol) and TEA (135 mg, 1.35 mmol) in DCM (5.0 mL) was added 1-chloroethyl carbonochloridate (195 mg, 1.35 mmol) at 0 °C under N 2 . Then the reaction was stirred at 20 °C for 16 hr. The mixture was concentrated to give a residue which was redissolved in MeOH (5.0 mL) and the mixture was heated to reflux and stirred for another 3 h. The mixture was concentrated, dissolved with DCM (10.0 mL), washed with water (5.0 mL), dried and concentrated to give a residue which was purified by prep-HPLC (formic acid) to give the title compound as its formate salt (47.5 mg, 27% yield) as a yellow solid. MS (m/e): 504.1 (M+H) + .

Example 128

l-[[l-[2-(Methylamino)ethyl]-6-oxo-pyrimidin-5-yl]amino]- 3-[4-(trifluoromethoxy)phenyl]-

6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one

This was prepared as its formate salt from l-[[l-[2-[benzyl(methyl)amino]ethyl]-6-oxo- pyrimidin-5-yl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H-cyclopenta[d]pyridazin- 4-one (Intermediate 59) using a procedure analogous to that used to prepare example 127. MS (m/e): 463.0 (M+H) + .

Example 129

2-[2-[2-Oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7-dih ydro-5H- cyclopenta[d]pyridazin-l-yl]amino]-l-pyridyl]ethylamino]acet ic acid

To a solution of 2-[tert-butoxycarbonyl-[2-[2-oxo-3-[[4-oxo-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyr idazin- 1 -yljamino]- 1 - pyridyl] ethyl] amino] acetic acid (Example 43; 35 mg, 58.4 μιηοΐ, Eq: 1) in DCM (3 mL) was added TFA (740 mg, 0.5 mL, 6.49 mmol), and the mixture was stirred at rt overnight. After removal of DCM and excess TFA, the residue was purified by RP-HPLC to give the title compound as a solid (27 mg, yield of 90%). MS (m/e): 506.2 (M+H) + .

Example 130

l-[[l-(2-Aminoethyl)-2-oxo-3-pyridyl]amino]-3-[4-(trifluorom ethoxy)phenyl]-6,7-dihydro-

5H-cyclopenta [d] pyridazin-4-one

The title compound was prepared from Example 45 using an analogous method to that to prepare example 129. MS (m/e): 448.2 (M+H) + .

Example 131

l-[[2-Oxo-l-(pyrrolidin-2-ylmethyl)-3-pyridyl]amino]-3-[4-(t rifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one

A mixture of l-[[l-[[l-[(4-methoxyphenyl)methyl]pyrrolidin-2-yl]methyl]-2 -oxo-3- pyridyl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H -cyclopenta[d]pyridazin-4-one (Intermediate 60; 0.15 g, 0.24 mmol), CF 3 COOH (1.0 mL) in DCM (10 mL) was stirred under nitrogen at 15 °C for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the crude product (0.21 g). The crude product was purified by prep-HPLC to give the title compound (33.8 mg, 23.4%) as a white solid. MS (m/e): 488.3 (M+H) + .

Example 132 and Example 133

6-Methyl- 1- [(1 -methyl -2-oxo-3-pyridyl)amino] -3- [4-(trifluoromethoxy)phenyl] -7,8-dihydro- 5H-pyrido [3,4-d] pyr idazin-4-one and 6-Methyl-4- [(l-methyl-2-oxo-3-pyridyl)amino] -2- [4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-l-one

To a solution of a 1 : 1 mixture of l-bromo-6-methyl-3-[4-(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-4-one and 4-bromo-6-methyl-2-[4-

(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyr idazin-l-one (Intermediate 32; 150.0 mg, 0.37 mmol), K 2 C0 3 (153 mg, 1.11 mmol) and 3-amino-l-methyl-pyridin-2-one

hydrochloride (CAS 1523570-95-7, 72.3 mg, 0.45 mmol) in dioxane (20 mL) was added

Xantphos (30 mg) and Pd 2 (dba) 3 (20 mg) under N 2 atmosphere, and then the mixture was stirred at 110 °C for another 16 h. The solvent was removed by concentration to give the crude product, which was purified by chromatography on silica gel (DCM: MeOH= 2: 1) to give a mixture of mixture compound (100 mg) as green solid, which was separated by chiral SFC to give 6- methyl-l-[(l -methyl -2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-7,8-d ihydro-5H- pyrido[3,4-d]pyridazin-4-one (61.3 mg) as a green solid and 6-methyl-4-[(l-methyl-2-oxo-3- pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl]-7,8-dihydro-5H -pyrido[3,4-d]pyridazin-l-one (11.6 mg) as a green solid. MS (m/e): 448.1 (M+H) + . Example 134

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)p henyl]-5,6,7,8- tetrahydropyrido [3,4-d] pyridazin-4-one

To a solution of 6-[(4-methoxyphenyl)methyl]-l-[(l-methyl-2-oxo-3-pyridyl)ami no]-3-[4-

(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyr idazin-4-one (Intermediate 61; 300 mg, 0.54 mmol) and TEA (0.16 mL, 1.08 mmol) in DCM (20 mL) was added 1-chloroethyl carbonochloridate (154 mg, 1.08 mmol) at 25 °C, and the mixture stirred for 2h. The solvent was removed by concentration and the residue was dissolved in 10 mL MeOH, then the solution was heated to reflux for 2h. The solvent was removed by concentration to give the crude product (0.4 g, crude) as a brown solid, which was purified by prep-HPLC (TFA) separation to give the title compound as its trifluoroacetate salt (23.8 mg, 10.2% yield). MS (m/e): 434.1 (M+H) + .

Example 135

1- [[1- [[(2A> Morpholin-2-yl] methyl] -2-oxo-3-pyridyl] amino]-3- [4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-

The title compound was prepared from 1-[[1-[[(2Λ τ )-4-[(4- methoxyphenyl)methyl]mo holin-2-yl]methyl]-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one (Intermediate 58) using an analagous method to that used to prepare example 134. MS (m/e): 488.3 (M+H) + .

Example 136

6-(2-Methoxyethoxy)-4- [(l-methyl-2-oxo-3-pyridyl)amino] -2- [4- (trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of tert-butyl N-[7-(2-methoxyethoxy)-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazin-l-yl]-N-(l -methyl -2-oxo-3-pyridyl)carbamate

(Intermediate 48; 91.0 mg, 0.15 mmol) in DCM (5 mL) was added TFA (1 mL), the reaction was stirred at 25 °C for 2 h. The solvent was evaporated to give a crude product, the crude product was purified by silica chromatography column to give the title compound (75.4 mg, yield:

99.3%) as a green solid. MS (m/e): 503.1 (M+H) + .

Example 137

7-(2-Methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]

(trifluoromethoxy)phenyl]phthalazin-l-one

The title compound was prepared from tert-butyl N-[6-(2-methoxyethoxy)-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl]-N-(l -methyl -2-oxo-3-pyridyl)carbamate

(Intermediate 49) using an analogous method to that used to prepare example 136. MS (m/e): 503.1 (M+H) + .

Example 138

5-(2-Methoxyethoxy)-4-[(l-methyl-2-oxo-3-pyridyl)amino]

(trifluoromethoxy)phenyl]phthalazin-l-one

The title compound was prepared from tert-butyl N-[8-(2-methoxyethoxy)-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazin-l-yl]-N-(l -methyl -2-oxo-3-pyridyl)carbamate

(Intermediate 50) using an analogous method to that used to prepare example 136. MS (m/e): 503.1 (M+H) + .

Example 139

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromet hoxy)phenyl]phthalazine-6- carboxamide

A mixture of ethyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazine-6-carboxylate (Intermediate 51; 0.2 g, 0.4 mmol), H 3 (30 mL of ethanol saturation solution) in THF (30 mL) under autoclave was stirred at 100 °C for 40 h. The mixture was evaporated to dryness. The residue was purified by recrystallized from DCM

(10 mL x 2) to give the title compound (40.3 mg, 21.4%) as a light white solid. MS (m/e): 501. (M+H) + .

Example 140

7-(l-Hydroxyethyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]

(trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazine-6-carbaldehyde (Intermediate 52; 0.15 g, 0.33 mmol) in THF (15.0 mL) was added MeMgBr (0.22 mL, 3 M) dropwise over 1 min. After the addition was over, the mixture was stirred at -78 °C for 2 h. The crude product was firstly purified by preparative-TLC and then recrystallized from CH 3 OH (10 mL x 2) to give the title compound (26.5 mg, 17.0%) as a white solid. MS (m/e): 473.1 (M+H) + .

Example 141

7-(Hydroxy methyl)-4- [(1 -methyl -2-oxo-3-pyridyl)amino]

(trifluoromethoxy)phenyl]phthalazin-l-one

A mixture of ethyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazine-6-carboxylate (Intermediate 51; 0.2 g, 0.4 mmol), LiAlH 4 (31.0 mg, 0.8 mmol) in THF (20 mL) was stirred at 0 °C for 2 h. The mixture was diluted with EA (20 mL), washed with saturated aqueous sodium bicarbonate and brine, dried with anhydrous Na 2 S0 , filtered and concentrated in vacuum. The crude product was purified by recrystallized from CH 3 OH (10 mL x 2) to give the title compound (140.0 mg, 76.5%) as a white solid. MS (m/e): 459.0 (M+H) + .

Example 142

7-Amino-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluorom ethoxy)phenyl]phthalazin-l- one

To a solution of 4-[(l-methyl-2-oxo-3-pyridyl)amino]-7-nitro-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one (Intermediate 53; 180.0 mg, 0.38 mmol) in EtOH (20 mL) and H 2 0 (1 mL) was added Na 2 S 2 0 (330.8 mg, 1.9 mmol) at 15 °C, and then the solution was stirred at 80 °C for lhr. The solvent was removed by concentration to give the crude product, which was purified by prep-HPLC to give the the trifluoroacetate salt of the title compound (14.6 mg, 8.8% yield) as a brown solid. MS (m/e): 444.2 (M+H) + .

Example 143

7-(Aminomethyl)-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazine-6-carbaldehyde oxime (Intermediate 54; 75.0 mg, 0.16 mmol) in AcOH (2.0 mL) was added Zn (30.0 mg, 0.48 mmol), the mixture was stirred at 80 °C for 2 h. The reaction mixture was filtered and the filtrate was concentrated to give the crude product (0.1 g). The crude product was purified by prep-HPLC to give the trifluoroacetate salt of the title compound (44.6 mg, 61.0%) as a yellow solid. MS (m/e): 458.2 (M+H) + .

Example 144

7- [(Dimethylamino)methyl] -4- [(1 -methyl -2-oxo-3-pyridyl)amino]-2- [4- (trifluoromethoxy)phenyl]phthalazin-l-one

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-

(trifluoromethoxy)phenyl]phthalazine-6-carbaldehyde (Intermediate 52; 0.2 g, 0.44 mmol) in 1 : 1 THF: CH3OH (8.0 mL) was added dimethylamine (0.44 mL, 0.88 mmol). The mixture was stirred at 25 °C for 1 h. After 1 h, NaBH 3 CN (81.6 mg, 1.32 mmol) was added to the mixture, then the reaction was stirred at 25 °C for 15 h. The reaction mixture was filtered and the filtrate was concentrated to give the crude product (0.3 g). The crude product was purified by prep- HPLC to give the title compound (62.9 mg, 29.5%) as a yellow solid. MS (m/e): 486.1 (M+H) + .

Example 145

6-(2-Hydroxypropyl)- 1- [(1 -methyl-2-oxo-3-pyridyl)amino] -3- [4-(trifluoromethoxy)phenyl] - -dihydro-5H-pyrido [3,4-d] pyridazin-4-one

A solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-one (example 134; 100 mg, 0.23 mmol) and 2- methyloxirane (CAS 75-56-9; 26.7 mg) in EtOH (10 mL) was then stirred at 80 °C for 16h. The solvent was removed by concentration to give the crude product, which was purified by prep- HPLC (TFA) separation to give the title compound as its trifluoroacetate salt (41 mg, 36% yield) as a brown oil. MS (m/e): 492.3 (M+H) + .

Example 146

6-(2-Hydroxy-2-methyl-propyl)-l-[(l-methyl-2-oxo-3-pyridyl)a mino]-3-[4- (trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[3,4-d]pyrida zin-4-one

This was prepared as its trifluoroacetate salt from l-[(l-methyl-2-oxo-3-pyridyl)amino]-3- [4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d] pyridazin-4-one (example 134) and 2,2-dimethyloxirane (CAS 558-30-5 ) using a procedure analogous to that used to prepare example 145. MS (m/e): 506.3 (M+H) + .

Example 147

6-(2-Hydroxyethyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4- (trifluoromethoxy)phenyl]- -dihydro-5H-pyrido [3,4-d] pyridazin-4-one

A solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-one (example 134; 100 mg, 0.23 mrnol), 2- bromoethanol (CAS 540-51-2; 57.4 mg, 0.46 mrnol) and K 2 C0 3 (63.4 mg, 0.46 mrnol) in acetonitrile (10 mL) was stirred at 80 °C for 16h. The solid was filtered off and the filtrate was concentrated to give the crude product, which was purified by prep-HPLC (TFA) separation to give compound the title compound as its trifluoroacetate salt (46.5 mg, 42% yield) as a brown oil. MS (m/e): 478.1 (M+H) + .

Example 148

6- Acetyl- 1- [(1 -methyl-2-oxo-3-pyridyl)amino] -3- [4-(trifluoromethoxy)phenyl] -7,8-dihydro-

5H-pyrido [3,4-d] pyridazin-4-one

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-one (example 134; 30 mg, 0.05 mrnol) and TEA (10.1 mg, 0.1 mrnol) in DCM (10 mL) was added CH 3 COCl (7.9 mg, 0.1 mrnol) at 25 °C, and then the solution was stirred for further lh. The solvent was removed by concentration to give the crude product, which was purified by prep-HPLC separation to give the title compound (19 mg, 81.2% yield) as a yellow solid. MS (m/e): 476.2 (M+H) + .

Example 149

6- Acetyl-4- [(1 -methyl-2-oxo-3-pyridyl)amino] -2- [4-(trifluoromethoxy)phenyl] -7,8-dihydro- -pyrido [3,4-d] pyridazin- 1-one

The title compound was prepared from 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-l-one (Intermediate 55) using an analogous method to that used to prepare example 148. MS (m/e): 476.2 (M+H) + .

Example 150

6-Acetyl-l-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4-(trif luoromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3,4-d] pyr idazin-4-one

The title compound was prepared from l-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-3-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-4-one (Intermediate 62) using an analogous method to that used to prepare example 148. MS (m/e): 476.2 (M+H) + . Example 151

6-Acetyl-4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-(trif luoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-l-one

The title compound was prepared from 4-[(l-methyl-6-oxo-pyrimidin-5-yl)amino]-2-[4-

(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d] pyridazin-l-one (Intermediate 63) using an analogous method to that used to prepare example 148. MS (m/e): 476.2 (M+H) + .

Example 152

Methyl 4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-(trifluoromet hoxy)phenyl]-7,8- dihydro-5H- rido 3 4-d ridazine-6-carbox late

To a solution of 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-l-one (Intermediate 55, step 3; 0.1 g, 0.23 mmol) and triethylamine (46.5 mg, 0.46 mmol) in DCM (10 mL) was added methylchloroformate (26.5 mg, 0.28 mmol) at 0 °C, and the solution was stirred for further 2h. 10 mL MeOH was added and the solvent was removed by concentration to give the crude product, which was purified by prep- HPLC (TFA) separation to give the title compound (16.9 mg, 15% yield) as a yellow solid. MS (m/e): 492.3 (M+H) + . Example 153

Methyl l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromet hoxy)phenyl]-7,8- dihydro-5H-pyrido [3,4-d] pyridazine-6-carboxylate

The title compound was prepared from l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-4-one (example 134) using a procedure analogous to that used to prepare example 152. MS (m/e): 492.1 (M+H) + .

Example 154

4- [(1 -Methyl-2-oxo-3-pyridyl)amino] - l-oxo-2- [4-(trifluoromethoxy)phenyl] -7,8-dihydro-

5H-pyrido [3,4-d] pyr idazine-6-carbaldehyde

A solution of compound 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-l-one (Intermediate 55, step 3; 0.2 g, 0.46 mmol) in HCOOH (10 mL) was stirred at 60 °C for 72 h. The solvent was removed by concentration to give the crude product, which was purified by prep-HPLC (formic acid) separation to give the formate salt of the title compound (30.2 mg, 15% yield) as a white solid. MS (m/e): 462.2 (M+H) + .

Example 155

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(trifluoromet hoxy)phenyl]-7,8-dihydro-

5H-pyrido [3,4-d] pyr idazine-6-carbaldehyde

The title compound was prepared from l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-4-one (example 134) using a procedure analogous to that used to prepare example 150. MS (m/e): 462.1 (M+H) + .

Example 156

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-6-methylsulfonyl-3-[4 -(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3,4-d] pyr idazin-4-one

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-one (example 134; 100 mg, 0.23 mmol) and TEA (46.5 mg, 0.46 mmol) in DCM (10 mL) was added MsCl (40 mg, 0.35 mmol) at 0 °C, and then stirred for further 2 h at 25 °C The solvent was removed by concentration to give the crude product, which purified by prep-HPLC (TFA) separation to give the title compound (22.8 mg, 19% yield) as a yellow solid. MS (m/e): 512.1 (M+H) + .

Example 157

4-[(l-Methyl-2-oxo-3-pyridyl)amino]-6-methylsulfonyl-2-[4 -(trifluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido[3,4-d]pyridazin-l-one

The title compound was prepared from 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-l-one (Intermediate 55, step 3) using a procedure analogous to that used to prepare example 156. MS (m/e): 512.1 (M+H) + .

Example 158

6-Ethyl- 1- [(1 -methyl -2-oxo-3-pyridyl)amino] -3- [4-(trifluoromethoxy)phenyl] -7,8-dihydro- -pyrido [3,4-d] pyridazin-4-one

To a solution of l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4-one (example 134; 100 mg, 0.23 mmol) and

CH 3 CHO (0.46 mL, 0.46 mmol, 1 M in EtOH) in EtOH (10 mL) was added NaBH 3 CN (28.8 mg, 0.46 mmol) at 25 °C, and then stirred for further 2 h. The solvent was removed by concentration to give the crude product, which was purified by prep-HPLC (TFA) separation to give the trifluoroacetate salt of the title compound (16.7 mg, 15.7% yield) as a white solid. MS (m/e): 462.1 (M+H) + .

Example 159

6-Isopropyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4-(triflu oromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3,4-d] pyr idazin-4-one

The title compound was prepared as its trifluoroacetate salt from l-[(l-methyl-2-oxo-3- pyridyl)amino]-3-[4-(trifluoromethoxy)phenyl]-5,6,7,8-tetrah ydropyrido[3,4-d]pyridazin-4-one (example 134) and acetone using a procedure analogous to that used to prepare example 158. MS (m/e): 476.1 (M+H) + .

Example 160

N-Methyl-4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-2-[4-(tri fluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3,4-d] pyridazine-6-carboxamide

To a solution of 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)p henyl]- 5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-l-one (Intermediate 55, step 3; 0.1 g, 0.23 mmol) and triethylamine (46.5 mg, 0.46 mmol) in DCM (10 mL) was added N-methylcarbamoyl chloride (26.5 mg, 0.28 mmol) at 0 °C, and the solution was stirred for further 2 h. 10 mL MeOH was added and the solvent was removed by concentration to give the crude product, which was purified by prep-HPLC (TFA) separation to give the title compound (12 mg, 10.6% yield) as a yellow solid. MS (m/e): 491.3 (M+H) + .

Example 161

N-Methyl-l-[(l-methyl-2-oxo-3-pyridyl)amino]-4-oxo-3-[4-(tri fluoromethoxy)phenyl]-7,8- dihydro-5H-pyrido [3,4-d] pyridazine-6-carboxamide

The title compound was prepared from l-[(l-methyl-2-oxo-3-pyridyl)amino]-3-[4- (trifluoromethoxy)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyr idazin-4-one (example 134) using a procedure analogous to that used to prepare example 160. MS (m/e): 491.2 (M+H) + .

Example 162

2-[4-(l-Hydroxy-l-methyl-ethyl)phenyl]-4-[(l-methyl-2-oxo-3- pyridyl)amino]phthalazin-l- one

To a mixture of ethyl 4-[4-[(l-methyl-2-oxo-3-pyridyl)amino]-l-oxo-phthalazin-2- yljbenzoate (Intermediate 65; 50 mg, 120 μιηοΐ) in 20 mL ethyl ether was added

methylmagnesium bromide (600 μΐ, 600 μιηοΐ) and the mixture was stirred for 1 h at rt.The reaction was quenched by adding saturated aqueous NH 4 C1 (20 ml), and the mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (50 mL), and dried over anhydrous Na 2 S0 4 and concentrated. The residue was purified by RP-HPLC to afford the title compound as a white solid (2 mg). MS (m/e): 403.0 (M+H) + .

Example 163

4- [ [1 -(2-Hydroxyethyl)-2-oxo-3-pyridyl] amino] -2- [4-(trifluoromethoxy)phenyl] phthalazin- 1-one

To a solution of methyl 2-(2-oxo-3-((4-oxo-3-(4-(trifluoromethoxy)phenyl)-3,4- dihydrophthalazin-l-yl)amino)pyridin-l(2H)-yl)acetate (Example 3; 30 mg, 61.7 μιηοΐ) in THF (3 mL) was added L1AIH 4 (4.68 mg, 123 μιηοΐ) and the mixture was stirred at rt for 10 min. The reaction was quenched by addition of 3 drops of water and the mixture was stirred for 30 min. and dried over anhydrous Na 2 S0 4 . After filtration, the filtrate was concentrated and the residue was purified by flash chromatography to afford the title compound as a light green solid (19 mg, yield: 66%). MS (m/e): 459.1 (M+H) + .

Example 164 and Example 165

7-Hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluor omethoxy)phenyl]-5,6,7,8- tetrahydrophthalazin-l-one and 6-hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4- (trifluoromethoxy)phenyl]-5,6,7 -tetrahydrophthalazin-l-one

To a solution of 4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)p henyl]-5,8- dihydrophthalazin-l-one (Intermediate 66, 120 mg, 279 μιηοΐ) in 10 mL of THF was added borane-tetrahydrofuran (1M, 558 μΐ, 558 μιηοΐ), and the resulting mixture was stirred at rt for 3 h. The mixture was quenched with water and a aqueous solution of NaOH (5%, 33.5 mg, 836 μιηοΐ) and hydrogen peroxide (28.5 μΐ, 836 μιηοΐ) was added. The reaction mixture was stirred at 50 °C for 30 min. before treated with K 2 CO 3 . The crude product was extracted by EtOAc and purified by RP-HPLC to afford 7-Hydroxy-4-[(l-methyl-2-oxo-3-pyridyl)amino]-2-[4-

(trifluoromethoxy)phenyl]-5,6,7,8-tetrahydrophthalazin-l- one (14 mg) and 6-hydroxy-4-[(l- methyl-2-oxo-3-pyridyl)amino]-2-[4-(trifluoromethoxy)phenyl] -5,6,7,8-tetrahydrophthalazin-l- one as white solids. MS (m/e): 449.2 (M+H) + . Example 166

1- [ [1 -(3- Amino-2-hydroxy-2-methyl-propyl)-2-oxo-3-pyridyl] amino]-3- [4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one

A mixture of tert-butyl N-[2-hydroxy-2-methyl-3-[2-oxo-3-[[4-oxo-3-[4-

(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyr idazin-l-yl]amino]-l- pyridyl]propyl]carbamate (Intermediate 109; 150.0 mg, 0.253 mmol) and TFA (1.0 mL) in DCM (2.0 mL) was stirred at 20 °C for 3 hr. Solvent was removed in vacuum to dryness to give a residue which was purified by prep-HPLC (TFA) to give the title compound (50 mg, TFA salt) as yellow solid. The solid was dissolved in DCM (10 mL) and sat NaHC03 solution (10 mL) was added, the organic layer was dried and concentrated to give the title compound (26.2 mg, 21% yield) as a yellow solid. MS (m/e): 492.2 (M+H) + .

Example 167

l-[[2-Oxo-l-(2-oxo-2-piperazin-l-yl-ethyl)-3-pyridyl]amino]- 3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-

To a solution of tert-butyl 4-[2-[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin- 1 -yljamino] - 1 -pyridyl]acetyl]piperazine- 1 -carboxylate (Intermediate 64; 0.14 g, 0.22 mmol) DCM (1.5 mL) was added TFA (0.5 mL), and the mixture was stirred at 20 °C for 3 h. Solvent was removed in vacuum to dryness to give a residue which was purified by prep-HPLC (formic acid) to give the formate salt of the title compound (16.9 mg, 14.5% yield) as a white solid. MS (m/e): 531.2 (M+H) + .

Example 168

l-[[l-[2-(Oxetan-3-ylamino)ethyl]-2-oxo-3-pyridyl]amino]-3-[ 4-(trifluoromethoxy)phenyl]- 6,7-dihydro-5H-cyclopenta[d]pyridazin-4-one

To a solution of l-[[l-(2-hydroxyethyl)-2-oxo-3-pyridyl]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one (Intermediate 46; 200.0 mg, 0.44 mmol) and TEA (53.2 mg, 0.528 mmol) in DCM (5.0 mL) was added MsCl (60.4 mg, 0.528 mmol) at 0 °C under N 2 , then the mixture was stirred at 20 °C for 1 h. The reaction was quenched by water (10.0 mL), extracted with DCM (10.0 mL), dried and concentrated to give a crude product (220 mg) which was used in next step. To this product in MeCN (5.0 mL) was added K 2 C0 3 (121.6 mg, 0.88 mmol) and Nal (13.2 mg, 0.088mmol), then oxetan-3 -amine (CAS 21635-88-1; 64.4 mg, 0.88 mmol) was added 20 °C under N 2 . The reaction was heated to 40 °C and stirred for 7 h. Solvent was removed in vacuum to dryness to give a residue which was purified by column chromatography on silica gel (EAto DCM/MeOH=30/l) to give crude product (100 mg). The crude product was purified by prep-HPLC (HCOOH) to give the title compound as its formate salt (37.6 mg, 14.4% yield) as a white solid. MS (m/e): 504.1 (M+H) + . Example 169

l-[[l-[2-(3-Hydroxyazetidin-l-yl)ethyl]-6-oxo-pyrimidin-5-yl ]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one

The title compound was prepared from l-[[l-(2-hydroxyethyl)-6-oxo-pyrimidin-5- yl]amino]-3-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cycl openta[d]pyridazin-4-one (example 47) and azetidin-3-ol hydrochloride (CAS 18621-18-6) using a method similar to that used to prepare example 168. MS (m/e): 505.2 (M+H) + .

Example 170

irans-l-[[l-[(5-Amino-l,3-dioxan-2-yl)methyl]-2-oxo-3-pyridy l]amino]-3-[4- (trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrida zin-4-one

To a solution of tra«5-2-[2-[[2-oxo-3-[[4-oxo-3-[4-(trifluoromethoxy)phenyl] -6,7-dihydro- 5H-cyclopenta[d]pyridazin-l-yl]amino]-l-pyridyl]methyl]-l,3- dioxan-5-yl]isoindoline-l,3-dione (Intermediate 69; 180 mg, 0.27 mmol) in EtOH (10 mL) was added Η 2 Η 2 ·Η 2 0 (2 mL). The reaction was heated to 70 °C and stirred for 5 hrs. The solvent was evaporated and the residue was purified by Prep-TLC (PE:EA=1 : 1) to give the title product (56.1 mg, yield 39.2%) as a white solid. MS (m/e): 520.0 (M+H) + .

Example 171

l-[(l-Methyl-2-oxo-3-pyridyl)amino]-3-[2-methyl-4-(trifluoro methoxy)phenyl]-6,7- dihydro-5H-cyclopenta[d]pyridazin-4-one

The title compound was prepared from [3-[2-methyl-4-(trifluoromethoxy)phenyl]-4-oxo- 6,7-dihydro-5H-cyclopenta[d]pyridazin-l-yl] trifluoromethanesulfonate (Intermediate 113) and 3-amino-l-methyl-pyridin-2-one (CAS 33631-01-5) using a procedure analogous to that used to prepare example 1. MS (m/e): 433.2 (M+H) + .

Example 172

3-(3,4-Dimethoxyphenyl)-l-[(l-methyl-2-oxo-3-pyridyl)amino]- 6,7-dihydro-5H- cyclopenta[d]pyridazin-4-one

The title compound was prepared from [3-(3,4-dimethoxyphenyl)-4-oxo-6,7-dihydro-5H- cyclopenta[d]pyridazin-l-yl] trifluoromethanesulfonate (Intermediate 114) and 3-amino-l- methyl-pyridin-2-one (CAS 33631-01-5) using a procedure analogous to that used to prepare example 1. MS (m/e): 395.2 (M+H) + .

Example 173

3-[3-Methoxy-4-(trifluoromethyl)phenyl]-l-[(l-methyl-2-oxo-3 -pyridyl)amino]-6,7-dihydro-

5H-cyclopenta [d] pyridazin-4-one

The title compound was prepared from [3-[3-methoxy-4-(trifluoromethyl)phenyl]-4-oxo- 6,7-dihydro-5H-cyclopenta[d]pyridazin-l-yl] trifluoromethanesulfonate (Intermediate 115) and 3-amino-l-methyl-pyridin-2-one (CAS 33631-01-5) using a procedure analogous to that used to prepare example 1. MS (m/e): 459.0 (M+H) + . Example 174

N,l-Di m ethyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5 ,6,7,8- tetrahydrophthalazin-l-yl] amino] pyridine-3-carboxamide

A mixture of l-methyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]-5, 6,7,8- tetrahydrophthalazin-l-yl]amino]pyridine-3-carboxylic acid (Intermediate 116; 25 mg, 52.5 μιηοΐ), HATU (29.9 mg, 78.7 μιηοΐ), TEA (26.6 mg, 36.6 μΐ, 262 μιηοΐ) and methanamine hydrochloride (10.6 mg, 157 μιηοΐ) in acetonitrile (3 mL) and DCM (3 mL) was stirred at room temperature overnight. After evaporation of solvent, to the residue was added EA (5 mL) and water (5 mL), and a white solid was precipitated. The mixture was filtered, the solid residue was washed with a small amount of EA and water. The solid was collected and dried to give the title compound (16 mg, 62% yield). MS (m/e): 490.2 (M+H) + .

Example 175

N,l-Dimethyl-6-oxo-5-[[4-oxo-3-[4-(trifluoromethoxy)phenyl]p hthalazin-l- yl] amino] pyridine-3-carboxamide

The title compound was prepared from l-methyl-6-oxo-5-[[4-oxo-3-[4- (trifluoromethoxy)phenyl]phthalazin-l-yl]amino]pyridine-3-ca rboxylic acid (Intermediate 117) using a procedure analogous to that used to prepare Example 174. MS (m/e): 486.1 (M+H) + .

Example 176

4- [[l-methyl-2-oxo-5-(trifluoromethyl)-3-pyridyl] amino]

(trifluoromethoxy)phenyl]phthalazin-l-one

The title compound was prepared from 4-bromo-2-[4- (trifluoromethoxy)phenyl]phthalazin-l-one (Intermediate 29) and 3 -amino- 1 -methyl -5- (trifluoromethyl)pyridin-2-one (CAS 1553950-73-4) using a procedure analogous to that used to prepare Example 1. MS (m/e): 497.2 (M+H) + .

Example 177

Luciferase reporter assay ("LRA")

The assay used to determine the antiviral activity of the compounds of present invention is a standard in vitro virus reporter assay. Briefly, the inhibitory effect of the molecules tested is detected by measuring luminescence from the conversion of substrate by Nanoluc gene

(NanoLuc ® Luciferase by Promega, Madison/US) in the virus (proportional to virus quantity).

The luciferase reporter A/WSN/33 virus was engineered by the Mehle laboratory (Tran V. et al, J. Virol (2013) 87(24):13321-13329). Despite the insertion of the "extremely bright luciferase variant NanoLuc" at the 3' end of PA (see below for the details of insertion), this system was shown to behave similarly to the Wild type virus and to recapitulate known antiviral treatment. These characteristics made it a valuable tool for our Roche Flu programs and was validated with compounds described as targeting the flu Cap and Endo.

Virus

The reporter Influenza A/WSN/33 -Luciferase virus (from Dr Andrew Mehle, Department of Medical Microbiology and Immunology, University of Wisconsin, USA) was produced in MDBK cells, aliquoted and stored at -80°C. Viral stock titers were determined by plaque assay in-house and the quality of the newly produced stock was confirmed by deep-sequencing in- house as well.

The Nano-Luc cassette was inserted at the 3 ' end of PA with a self-cleaving 2A peptide to generate discrete PA and NLuc proteins. Repeated regions of the PA ORF that contain packaging signal were introduced at the 3 'end of NLuc. Silent mutations were introduced at the 3' end of PA to avoid duplication with the packaging signal at the 3' end of NLuc.

Cells

Madin-Darby bovine kidney cells MDBK (from Roche Non-Clinical Biosample

Repository (RNCB), Basel/CH, number CL002178) were cultivated in MEM/Glutamax I supplemented with heat-inactivated 10%FBS (Gibco, Thermo Fisher, Waltham/US, batch 1420751) and 1% Pen/Strep.

Human lung cells A549 (from RNCB, number CL000104) were cultured in DMEM High Glucose/Glutamax I supplemented with heat-inactivated 10%FBS (Gibco, batch 1420751) and 1% Pen/Strep ("Growth Medium" or "GM"). Compound treatments and infection were performed in DMEM High Glucose/Glutamax I supplemented with 1% Pen/Strep, 0.3% BSA and 25mM HEPES ("Infection Medium" or "FM"). Infection and treatment of A549 cells

Compound plates with compounds diluted in 100%DMSO were kept at -20°C till use.

A549 cells 95% confluent were trypsinized, counted, seeded at 5,000 cells/well in TC- treated optical 384-well plates and incubated for 24h at 37°C 5%C0 2 . Cells were then washed with 25 μΐ PBS IX and infected with 10 μΐ of A/WSN/33-Luc virus at an MOI of 0.1 for lh. 15 μΐ of culture media and 2.7 μΐ of compounds (final concentration of 1% DMSO) were added on top. Three days later, the antiviral activity of compounds was determined by measure of the Luciferase signal using the NanoGlo® Luciferase Assay System (Promega Cat. No 1120). 18 μΐ of NanoGlo Reagent was added on top of cells, incubated for 10 minutes with shaking and the luciferase signal was measured using a Paradigm instrument using 0.14 second reading time

In parallel, a series of uninfected A549 cells were treated similarly with compounds from the same master plate to determine the cytotoxicity of the compounds. No infection was carried out. Cell viability was determined 72h post treatment using 18 μΐ of CellTiter-Glo®

Luminescent Cell Viability Assay (Promega, Cat. no. G7572). The table below provides IC50 values for antiviral activity obtained according to the above

Luciferase reporter assay for the compounds of the present invention. Particular compounds of the present invention exhibit IC50 values < 5000 nM, more particular compounds of the present invention exhibit IC50 values < 500 nM, even more particular compounds of the present invention exhibit IC50 values < 50 nM, most particular compounds of the present invention exhibit IC50 values < 20 nM.

IC50 IC50 IC50 IC50

Ex. Ex. Ex. Ex.

[nM] [nM] [nM] [nM]

1 22 45 286 89 38 133 538

2 54 46 33 90 162 134 521

3 38 47 71 91 41 135 85

4 489 48 18 92 178 136 61

5 485 49 16 93 166 137 136

6 52 50 28 94 45 138 110

7 4340 51 44 95 102 139 62

8 73 52 62 96 42 140 32

9 275 53 24 97 9 141 12

10 259 54 52 98 10 142 46

11 2010 55 303 99 291 143 271

12 407 56 278 100 36 144 625

13 1510 57 352 101 109 145 129

14 109 58 17 102 37 146 167

15 132 59 137 103 38 147 76

16 12 60 11 104 39 148 19

17 100 61 60 105 15 149 71

18 122 62 186 106 14 150 104

19 59500 63 33 107 49 151 372

20 4 64 355 108 29 152 32

21 5 65 405 109 842 153 61

22 16 66 36 110 482 154 144

23 712 67 563 111 1510 155 86

24 22 68 1710 112 2990 156 266

25 14 69 228 113 161 157 167

26 25 70 19 114 110 158 105

27 41 71 54 115 180 159 186

28 8 72 24 116 261 160 86

29 22 73 49 117 114 161 112

30 37 74 34 118 953 162 1400

31 8 75 25 119 3760 163 62

32 12 76 34 120 1125 164 46

33 6 77 108 121 156 165 24

34 195 78 31 122 3710 166 107

35 68 79 32 123 485 167 148

36 579 80 68 124 4930 168 24

37 20 81 465 125 88 169 307

38 23 82 79 126 191 170 83

39 230 83 1490 127 33 171 6830

40 100 84 176 128 92 172 3480

41 60 85 56 129 79 173 74600

42 40 86 34 130 62 174 14600

43 84 87 17 131 30 175 74400

44 28 88 23 132 87 176 80500